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Abstract 
Background:  
Chronic diseases account for a significant portion of the life expectancy disparity between 
Indigenous and non-Indigenous Australians. Indigenous Australians have high rates of 
chronic kidney disease (CKD), cardiovascular disease (CVD) and diabetes, however the long 
term association of many risk factors is yet to be completely understood. Risk markers such 
as birth weight (BW), C-reactive protein (CRP) and glycosylated haemoglobin (HbA1c) play 
a significant role in the chronic disease burden however more evidence is required in 
Indigenous Australian communities to highlight the true impacts of the associations. 
Furthermore, the appropriateness of HbA1c as a marker of diabetes in remote Indigenous 
Australians has not been sufficiently investigated. 
Aims: 
This thesis aims to investigate HbA1c as a marker of risk for diabetes and CVD, and the 
associations between BW and CVD, CRP and CKD in numerous secondary projects for a 
remote Indigenous Australian community. 
Methods:  
The projects investigating BW and CRP, as risk factors, utilised community-wide health 
screening examinations conducted in 1992-1999, while projects that investigated associations 
with HbA1c used data from screening examinations conducted in 2004-2006. Northern 
Territory hospitalisation records between 1992 and 2012 were utilised to follow participants 
for up to 20 years after baseline exams. Cox proportional hazard models were used to 
investigate the long term associations between BW and CVD, and CRP and CKD. Logistic 
regression models were used for analysis between HbA1c and diabetes. 
Results: 
A total of 1187, 852, and 546 participants were included in the HbA1c, LBW and CRP 
projects, respectively. Of the 1187 HbA1c participants, 158 (13 %) had a previous diabetes 
diagnosis, up to 568 (48 %) were at high risk (5.7-6.4 % (39-46 mmol/mol) HbA1c) and 67 
(6 %) potential new cases of diabetes (≥ 6.5 % (48 mmol/mol) HbA1c) were identified. 
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Almost all traditional cardiovascular disease risk factors showed a positive association with 
levels of HbA1c.  
In our study population, there were 236 (28 %) participants who had a low birth weight. The 
LBW group had a higher risk of developing any CVD (HR = 1.43, 95% CI 1.01-2.03), major 
CVD (HR = 1.51, 95% CI 0.93-2.47) and hypertension (HR = 1.83, 95% CI 1.09-2.96) than 
the normal birth weight (NBW) (≥2,500 g) group. Women with LBW had over 2.6 times the 
risk of a hospitalisation associated with hypertension compared to their NBW counterparts 
(HR = 2.61, 95% CI 1.38-4.93), but this relationship was not seen in men. The risk for CVD 
significantly increased for adults with high waist circumference (WC) and low BW more than 
any other group (RR 7.22, 95 % CI 1.96-26.64, p = 0.003).  
Participants in the highest CRP tertile had almost 4 times the risk for CKD hospitalisations 
compared with participants in the lowest tertile (HR=3.91, 95% CI 1.01-15.20, p=0.049) after 
adjustment for potential confounding factors. Participants with CRP concentrations greater 
than 3mg/L had almost 3 times the risk of CKD hospitalisations than those ≤ 3mg/L 
(HR=2.84, 95% CI 1.00-8.00, p=0.049). Furthermore, risk for CKD increased 34% per 
doubled increase in CRP (HR=1.34, 95% CI 1.04-1.74, p=0.024). 
Conclusions: 
This thesis identified that HbA1c, BW and CRP are significant markers of risk for chronic 
disease in this remote Indigenous Australian community. LBW increased the risk of 
cardiovascular disease hospitalisations in adult life and this risk is increased if the LBW 
individual grows to have a large WC in adult life. The glycosylated haemoglobin screening in 
this community highlighted the high proportion of individuals living at high risk for diabetes 
and with an accentuated cardiovascular risk profile. C-reactive protein was found to be an 
independent predictor of CKD hospitalisations almost a decade later in life. Further 
investigations into the biological mechanisms of the associations are necessary, because this 
was not within the scope of this thesis. This thesis provides much needed evidence using 
longitudinal cohort data demonstrating a long term association between these risk factors and 
chronic disease development up to 20 years later in life. 
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Chapter 1 – Introduction  
1.1 Background 
Decades of research have been produced from the extraordinary coordination and cooperation 
between Professor Wendy Hoy’s group and a remote Indigenous Australian community in the 
Northern Territory. This community identified high prevalence and incidence rates of chronic 
diseases, such as cardiovascular disease (CVD) [1], diabetes [2] and renal disease [3], and 
also a high rate of premature natural deaths [4]. The consequence of this partnership was the 
conduct of two community-wide health screens, in 1992-1999 and 2004-2006, to explore the 
associations of chronic disease risk factors and biomarkers which may provide opportunities 
to reduce the burden of the community’s disadvantage.  
The purpose of the following PhD thesis is to further this research and complement the 
research previously conducted by Prof Hoy’s group. This PhD thesis is a part of a large 
investigation into the risk factors and biomarkers of chronic diseases in this remote 
Indigenous Australian community. 
The strength of the data for this thesis presents a significant opportunity for a PhD candidate. 
The health screening examinations represent over 80% of the age-eligible population [2], 
which is largely attributable to the strong relationship between Prof Hoy’s group and the 
participating Indigenous Australian community. There is an established, long-term 
relationship of trust, respect and honesty as well as ongoing communication and information 
sharing between researchers and the community, which is paramount in the collaboration’s 
success [5]. Members of the local land council and Elders of the community have played a 
significant role in the decision-making and engagement of the collaboration with Prof Wendy 
Hoy’s group which largely dictates the success of the research. Inclusion of data from such a 
strong collaboration in this PhD thesis presents a significant opportunity to contribute to 
Indigenous Australian chronic disease research. 
This thesis aims to link up to 20 years of Northern Territory hospitalisation data, attained by 
Associate Professor Zhiqiang Wang, with data from community health screening 
examinations to investigate the longer term association between chronic disease risk markers 
and the development of chronic disease among residents of this remote community. This 
thesis will also utilise a comprehensively updated mortality dataset complete for the duration 
of this study’s follow-up. 
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This thesis on three chronic diseases including, cardiovascular disease, type 2 diabetes and 
chronic kidney disease, and the exploration of long term associations with selected 
independent risk factors. The thesis will investigate the association between birth weight 
(BW) and CVD hospitalisations in adult life. This thesis will also investigate the relationship 
between glycated haemoglobin (HbA1c), as a marker of diabetes, and the subsequent 
association with cardiovascular risk factors in adults with and without diabetes. And lastly, 
this thesis will explore the association between systemic inflammation, as indicated by C-
reactive protein (CRP) concentration, and chronic kidney disease (CKD). 
The thesis will be presented as a collection of manuscripts published in peer-reviewed 
international scientific journals throughout the duration of the candidature. The Author of this 
thesis will also be the First and Corresponding Author of each manuscript included in this 
thesis. Each included manuscript will be preceded by a literature review relevant to the 
particular research agenda items being addressed. This sequence aims to provide a structured 
flow of the thesis due to the challenging variety of risk factors and chronic disease outcomes 
included in this thesis.   
This thesis aims to further our understanding of the health disadvantage of Indigenous 
Australians in remote communities and expose opportunities for reducing the burden of 
chronic diseases in this community. This thesis will aim to present findings which may be 
useful for public health promotion, health services delivery and further research into risk 
factors of chronic diseases in Indigenous populations.  
 
1.2 Research Agenda 
1.2.1 Objectives 
The objectives of the thesis are as follows:  
1. To investigate the association between HbA1c and all-cause mortality in people with 
type 2 diabetes. 
2. To investigate the association between HbA1c, as a risk marker of type 2 diabetes, 
and the prevalence of cardiovascular risk factors in a remote Indigenous Australian 
community 
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3. To examine the association between birth weight and the development of 
cardiovascular disease in adulthood in a remote Indigenous Australian community 
4. To identify if there is any interaction between birth weight and adult body size and if 
this association influences risk for cardiovascular disease in a remote Indigenous 
Australian community 
5. To investigate the long term association between C-reactive protein and future risk for 
chronic kidney disease in a remote Indigenous Australian community 
1.2.2 Research Questions 
The following research question pertains to Objective 1 identified in Chapter 1.2.1.  
1. Is there a non-linear relationship between HbA1c and all-cause mortality in people 
with type 2 diabetes in observational studies? 
The following research questions pertain to Objective 2 identified in Chapter 1.2.1.  
2. What is the health profile of the community who do not have a diagnosis of 
diabetes, but may be at high risk according to their HbA1c level? 
3. Can a particular HbA1c cut-off value be utilised to highlight an Individuals’ high 
risk of chronic disease? 
The following research questions pertain to Objective 3 identified in Chapter 1.2.1. 
4. What is the risk of Indigenous Australians in a remote Northern Territory 
community developing cardiovascular diseases in adult life if they are born of low 
birth weight (< 2,500g) compared to their normal birth weight (≥ 2,500g) 
counterparts? 
5. Is one gender at a higher risk of developing cardiovascular diseases than the other 
if born of low birth weight?  
The following research questions pertain to Objective 4 identified in Chapter 1.2.1. 
6. Is adult body size or birth weight a more accurate predictor of cardiovascular 
disease development in adulthood?  
7. Do birth weight and adult body size interact to increase cardiovascular risk within 
Indigenous Australians? 
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The following research question pertains to Objective 5 identified in Chapter 1.2.1. 
8. Do elevated CRP levels increase the risk of developing CKD in adult life in a 
remote Indigenous Australian community? 
 
1.3 The Tiwi Community 
This thesis utilised health screening examinations which included members of the Tiwi 
Islands. Comprising of Bathurst and Melville islands, the Tiwi Islands are located 60km north 
of Darwin in the Northern Territory of Australia [6]. Figure 1.1 highlights the three main 
communities in Tiwi including, Nguiu on Bathurst Island, and Pirilangimpi and Milikapati on 
Melville Island.  
 
Figure 1.0.1 Location of Bathurst and Melville Islands (Tiwi Islands) in the far north of the 
Northern Territory of Australia 
Creation stories suggest Indigenous Australians have occupied the Tiwi Islands for at least 
7000 years and their first contact with western explorers was with the Dutch in 1705 [7]. The 
Tiwi community describe themselves as island people who have adapted mainland  
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Aboriginal culture for their own Tiwi uniqueness [6]. The Tiwi Island communities are made 
up of 97 families who comprise eight land owning groups and support the growth of the 
sustainable industries on the islands [6]. The Island’s workforce is 900 members strong who 
work in industries such as plantation forestry, transport and maritime infrastructure, tourism, 
fish farming, retailing, building and contracting and hire services [6].  
Census data from 2006 reported 1,945 Aboriginal and Torres Strait Islander people resided in 
Tiwi Islands [8]. The 2006 Census further reported the median age of Aboriginal and Torres 
Strait Islander people was 24 years in the Tiwi Islands. Of the Aboriginal and Torres Strait 
Islander people, 31.7% were children aged 0 to 14 years and 6.6% were people aged 55 years 
and over. [8] 
1.4 Indigenous health disadvantage and chronic diseases 
Indigenous health is a significant focus on Australia’s national health agenda. Since the 
commencement of the ‘Close the Gap’ initiative in 2008, Indigenous Health has been made a 
health priority area and resources directed towards narrowing the disparity between 
Indigenous and non-Indigenous health [9]. ‘Close the Gap’ refers to the gap in life 
expectancy, child mortality, education and employment between Indigenous and non-
Indigenous Australians. In 1996, Indigenous Australians had a life expectancy 17 years lower 
than the non-Indigenous Australian population [10]. Mortality rates are excessive among 
Indigenous people across all age and sex groups: approximately 3 and 5 times greater in 
infants and adults respectively [10]. 
There is some guarded optimism that life expectancy is improving for Indigenous 
Australians. Increased resources, including hard-working personnel in Indigenous 
communities and more research resulting in better understanding of disease risk factors, have 
assisted to narrow the gap in life expectancy. In 2010-12 the gap between NT Indigenous 
Australians and their non-Indigenous counterparts had narrowed to 14 years for men and 
women [11]. The gap between Indigenous and non-Indigenous Australians in 2010 and 2012 
had decreased to 11.2 years and 10.2 years for male and female residents, respectively, in 
remote Australian communities [12]. Evidence suggests death rates have marginally 
increased or fallen for various chronic diseases in Indigenous Australians from the Northern 
Territory [13-17]. However, Indigenous mortality varies by remoteness and in different 
communities [18-20]. Optimistically, there was a 9% significant decline in the all-cause age-
standardised mortality rate for Indigenous Australians between 2001 and 2012 [11]. 
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Furthermore, natural death rates have been decreasing in remote communities between 1996-
2010 [4]. Although rates that attempt to describe the Indigenous population as one 
homogenous group may be helpful in identifying the overall health gap, they do not reveal 
the entire picture.  
Indigenous Australians, particularly in remote Australia, face obstacles in accessing 
appropriate health care [21]. Access to medical services is compromised by a number of 
factors including the significant distances required to travel for residents of some remote and 
very remote communities. Language and communication issues are also created by the 
underrepresentation of Indigenous Australians in the health work force [10, 21]. 
Communication and trust between patient and health professional are vital, yet these are 
obstacles in effective Indigenous health care delivery [22].  
Mortality and morbidity of chronic diseases are the largest causes of the life expectancy gap 
and health disparity between non-Indigenous and Indigenous people in Australia. For the 
period between 1981 and 2000, approximately 77% of the life expectancy gap in NT was 
primarily attributed to non-communicable diseases [23]. Studies have found Indigenous 
Australian communities have some of the highest prevalence of CVD, diabetes and renal 
disease in the world [2, 24, 25]. A recent government report detailed the increased rates and 
earlier onset of CVD, diabetes and CKD for Indigenous Australians [21]. There is much 
overlap between conditions as demonstrated by the high prevalence of people with multiple 
conditions, suggestive of an integrated metabolic/renal/cardiovascular condition which 
sharply increases in prevalence with age [21, 26]. Although disease rates and markers are 
uniformly high in Aboriginal communities compared to the wider Australian population, they 
differ markedly between communities [21, 27, 28].  
There is much needed evidence for the long term associations between novel risk factors and 
chronic diseases in Indigenous Australians. 
 
1.4.1 Cardiovascular Disease 
Hypercholesterolaemia, hypertension and tobacco smoking are common risk factors for 
atherosclerosis, which is the major cause of cardiovascular disease [29]. The pathophysiology 
of CVD indicates these risk factors may combine through underlying mechanisms, involving 
oxidation and inflammation in the artery wall that, with time, gives rise to characteristic fatty-
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fibrous lesions [30-32]. Physical trauma and inflammation produce lesion rupture, which can 
lead to clinical events such as heart attack and stroke, or resolve with plaque growth [30, 33]. 
Disease progression is marked by an indicator of systemic inflammation, C-reactive protein 
(CRP) [34, 35]. Coronary atherosclerosis is the common cause of heart failure (HF), where 
disordered calcium signalling to the myofilaments occurs [36]. Conversely, enhanced calcium 
signalling suppresses HF [37]. Furthermore, neuro-humoral and biomechanical processes, as 
seen in hypertension, produce cardiac hypertrophy, which predisposes to HF through 
apoptosis [30, 32, 37]. 
Cardiovascular disease including coronary heart disease and stroke, is the largest contributor 
to the health gap between Indigenous and non-Indigenous Australians [21, 28]. An estimated 
3.7 million (22%) Australians self-reported as having one or more CVDs in 2011-12 [28]. 
The prevalence for Indigenous adults was higher than non-Indigenous adults (27% and 21%, 
respectively) [28]. Reports show the sex-standardised prevalence was higher for Indigenous 
Australians in all adult age groups (Figure 1.2) [21]. Those aged over 65 years (60%) had a 
significantly higher prevalence of CVD compared to those aged 18-34 years (9%) [21].  
 
Figure 1.0.2. Prevalence of CHD among persons aged 35 and over, by Indigenous status and 
age, 2011-13 [21] 
Reproduced with permission from Australian Institute of Health and Welfare (AIHW) 
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Indigenous Australians had double the incidence of coronary heart disease (CHD) events as 
non-Indigenous Australians between 2012-2013, after adjustment for age and sex (6.3% and 
3.2%, respectively) [21]. Sex-adjusted, age specific rates showed that younger (age group 35-
44 years) Indigenous Australians have 6 times the incidence of CHD of their non-Indigenous 
counterparts [21].  
CVD was the principal diagnosis in 3% of all Indigenous Australian hospitalisations in 2012-
13 [21]. CHD accounted for 2 out of 5 (40%) Indigenous hospitalisations where CVD was 
named as the primary diagnosis [21]. Between 2007–2008, CHD was 3 times that of non-
Indigenous Australians [38]. Furthermore, the rate for CVD as the principal diagnosis among 
Indigenous people increased by 12% between 2004-05 and 2013-14 compared to a 15% 
decreased for non-Indigenous people [21]. Indigenous Australians also had higher 
hospitalisation rates of cardiovascular disease than other Australians across all age groups, 
particularly 3 time higher for those aged 35–44 years and 45–54 years [21, 39].  
Cardiovascular diseases accounted for approximately 26% of all deaths of Indigenous 
Australians between 2008-2012 [11]. Mortality due to circulatory diseases was estimated to 
be 1.5 times higher in Indigenous compared to non-Indigenous Australians between 2008-
2012. However, circulatory diseases claimed younger to middle aged Indigenous males (25-
44 years) at 9-10 times and females (35-55 years) at 12-13 times the rate of their age matched 
non-Indigenous counterparts between 1999-2003 [10]. For the period 1977-1989, Indigenous 
CHD death increased by 5.7% annually [16]. However, improvements have been observed 
more recently with death rates from all circulatory diseases declined by 30% for males and 
29% for females from 2001 to 2012 [11]. 
Between 2011-2013, Indigenous Australians aged between 25-34 years and 35-44 were 1.6 
times more likely to have high blood pressure than their non-Indigenous Australians from the 
same age group [21]. However, like much of the non-communicable and communicable 
disease across Indigenous Australia, the prevalence of hypertension varies by community. A 
study in 2000-2003 found the prevalence of hypertension across 3 communities from the Top 
End of the NT ranged from 34% to 54%, 3-8 times the risk compared to the AusDiab cohort 
with age adjustment [27]. Hypertension was prevalent in just under 30% of those aged 25-34 
years and almost 70% in those aged 55-74 years. Adjusted for age and sex, the prevalence of 
hypertension in adults aged 25-44 years was 7 fold that of the AusDiab cohort [27].  
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1.4.2 Type 2 Diabetes 
Diabetes is responsible for more than one-tenth (12%) of the health gap between Indigenous 
and non-Indigenous people [30]. Indigenous Australians have an earlier onset of diabetes and 
experience higher rates of diabetes complications than non-Indigenous Australians [38, 39]. 
Type 2 diabetes occurs at earlier ages in the Indigenous population and often remains 
undetected and untreated [21]. Results from the 2012-13 National Aboriginal and Torres 
Strait Islander Health Measures Survey (NATSIHMS) showed that Indigenous Australians 
were 3.5 times more likely to have diabetes, compared to their non-Indigenous counterparts 
[21]. Furthermore, Indigenous Australians living remotely, were twice as likely to have 
diabetes than those living in non-remote areas [21]. This disparity can also vary significantly 
among Indigenous communities. Some Indigenous communities are up to 10 times more 
likely to have diabetes than the general population and 2 times more than other remote 
Indigenous communities [27, 40]. Indigenous Australians also showed significantly higher 
rates of diabetes in each adult age group, particularly those aged 45-54 who were almost five 
times higher than non-Indigenous Australians (Figure 1.3) [21].  
 
 
 
Figure 1.0.3. Prevalence of diabetes based on self-reported and measured HbA1c results 
among persons aged 18 and over, by Indigenous status and age, 2011–13 [21] 
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Reproduced with permission from Australian Institute of Health and Welfare (AIHW) 
In Aboriginal Australians, high rates of diabetes have been associated with various co-
morbidities. These include renal disease and albuminuria [26, 27, 41], hypertension [26, 27], 
abnormal lipid profiles [42], increased BMI [43] and C-Reactive protein (CRP) [44]. Insulin 
resistance has also been shown to be positively associated with BMI, WHR, 2 hr fasting 
glucose, triglycerides, SBP & DBP [45-50]. High density lipoprotein (HDL) cholesterol has 
been shown to be negatively associated with insulin resistance in Aborigines [46, 49].  
The incidence of diabetes in Indigenous adults have been estimated as high as 39.9 per 1000 
person-years in members of a remote NT community aged 45-54 years [2]. In 2012-2013, 
diabetes was more common in Indigenous females than males (56% and 44%, respectively) 
[21].  From 2001-2006, childhood (10-18yrs) diabetes incidence rates were estimated at 12.7 
per 100,000 person years, 6 times greater than non-Indigenous children [51].  
Indigenous males and females were hospitalised for type 2 diabetes (as the principal 
diagnosis) at 3 and 6 times the rate of their non-indigenous counterparts after age adjustment 
[21]. Type 2 diabetes was recorded as an additional or principal diagnosis in almost 47,000 
Indigenous Australian hospitalisations between 2013-14 [21]. For bacterial infections, 
metabolic and circulatory conditions, diabetes was considered an additional diagnosis in 
Indigenous hospitalisations at considerably greater rates than for non-Indigenous 
hospitalisations [21, 28, 52].  
For the period 2008-2012, diabetic death as a proportion of all deaths for Indigenous males 
and females was 7% and 9% respectively, and was as high as 13.4% for Indigenous 
Australians between the ages of 55-64 [11]. Estimated Indigenous mortality rates with a 
diabetic cause increased by 0.7% and decreased by 0.8% annually between 2001-2012 for 
males and females, respectively. Overall, the percent average annual improvement was 
almost 5 times lower in Indigenous compared to non-Indigenous between 2001-2012 [11].  
 
1.4.3 Chronic Kidney Disease 
Results from the National Aboriginal and Torres Strait Islander Health Measures Survey 
(NATSIHMS) in 2012-13, showed almost 1 in 5 (17.9%) Indigenous adults had biomedical 
signs of chronic kidney disease [21]. Similarly to diabetes, CKD prevalence was significantly 
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higher in all age groups of Indigenous adults compared to non-Indigenous (Figure1.4) [21]. 
However, this figure is considered to vary by community. McDonald et al reported that 12% 
of adults from a remote community had stage 3-5 CKD, while there was evidence of some 
form of CKD in another 36% of participants [53]. The incidence of end stage renal disease 
(ESRD) in Indigenous Australians living in remote locations has been reported as high as 30 
times that of the national incidence. In urban areas, the incidence of Indigenous ESRD is 
lower but still higher than the national incidence [54, 55]. ESRD typically occurs in older 
age, however for Indigenous Australians it more likely occurs in middle age [21]. 
 
 
Figure 1.0.4. Prevalence of biomedical signs of CKD among persons aged 18 and over, by 
Indigenous status and age, 2011–13 [21] 
Reproduced with permission from Australian Institute of Health and Welfare (AIHW) 
As at 31 December 2013 the prevalence for ESRD was 5 times higher for Indigenous 
Australians than non-Indigenous [21]. In 2013, 88% of Indigenous Australians treated for 
ESRD were receiving some form of dialysis, with only 12% had a functioning kidney 
transplant [21]. This is a significantly different picture for non-Indigenous people with 52% 
receiving dialysis and 48% had a functioning kidney transplant [21]. In addition, McDonald 
and Russ found that between 1991-2000, Indigenous Australians commenced renal 
replacement therapy (RRT) on average 12 years earlier than non-Indigenous end stage renal 
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disease patients [56]. Obstacles for Indigenous Australians from remote communities 
receiving dialysis, include isolation and travel, which may prevent such patients receiving 
adequate dialysis treatment [57] and may result in higher mortality rates [58]. 
Renal transplantation is regarded as the ideal form of RRT as it releases patients from the 
restrictions of dialysis and patients have comparatively better mortality outcomes. However, 
Indigenous Australians are less likely to receive a renal transplant, and only 14% received 
grafts from living donors compared to 36% for non-Indigenous patients [56, 59]. Graft 
survival, be it from living or deceased donors, is low in Indigenous recipients, which may to 
some extent be explained by higher rates of comorbidities (obesity, CVD, type 2 diabetes) in 
Indigenous and non-Indigenous kidney transplant recipients [59].  
Deaths from kidney diseases were higher in the Indigenous population. In 2008–2012, 
Indigenous Australians died from kidney diseases at 2.6 times the rate of non-Indigenous 
Australians and kidney diseases represented almost 5% of the mortality gap [11]. This may 
be an underestimation of true Indigenous renal failure mortality. Where renal failure is listed 
as one of the multiple causes of death, it is less likely to be reported as the underlying cause 
of death compared to diabetes or circulatory disease [21]. Despite an increasing burden of 
comorbid conditions, there has been improved survival for both Indigenous and non-
Indigenous patients receiving kidney replacement therapy. However, the gap in survival 
between Indigenous and non-Indigenous patients has not narrowed [60]. 
In addition to predicting renal failure, albuminuria also predicts a proportion of 
cardiovascular and diabetic mortality and morbidity [61-63]. In Indigenous Australians, 
microalbuminuria (ACR 3.4-33.9mg/mmol) has been independently associated with prevalent 
hypertension and diabetes, while macroalbuminuria (ACR≥34mg/mmol) too has been 
independently associated with hypertension, diabetes and abdominal obesity [41]. In another 
study, more conservative cut offs of 2.5 and 25mg/mmol were used for micro and 
macroalbuminuria, respectively [64, 65]. After adjustment for traditional risk factors, both 
micoalbuminuria and macroalbuminuria were significantly associated with new cases of 
diabetes [65] and incident CHD [64]. In one Aboriginal community, albuminuria was present 
in children. This is consistent with the early appearance of CVD risk and renal disease in a 
high risk population [66]. 
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Chapter 2 – Glycated Haemoglobin Literature Review 
Australia, like many countries, is experiencing the emerging type 2 diabetes (T2D) epidemic. 
T2D significantly contributes to morbidity, premature mortality and places immense 
pressures on the health care system. A recent study in Melbourne hospitals found that the 
prevalence of diabetes in hospitalised patients ranged from 15.7 % to 35.1 %, and over 82 % 
of diabetes patients suffered from microvascular or macrovascular complications [67].  
Indigenous Australians are at a further disadvantage as they are 3 times more likely to have 
diabetes than their non-Indigenous counterparts, have an earlier onset of diabetes and 
experience higher rates of diabetes complications [38, 39]. The disadvantage is significantly 
increased for those living in remote communities [27, 40, 68]. Increased attempts at early 
detection and prevention of T2D are justified in Indigenous Australians due to this significant 
burden and HbA1c is fast becoming an appropriate tool to be utilised in the management and 
screening of diabetes in these communities. 
HbA1c is produced when haemoglobin binds with glucose in the blood, becoming 
‘glycosylated’ or ‘glycated’. Also referred to in the literature as glycated haemoglobin, 
haemoglobin A1c, and A1c, HbA1c was initially proposed as a screening and diagnostic test 
for diabetes by Saudek et al in 2008 [69]. The advocacy from Saudek and colleagues for 
HbA1c was driven by the convenience for patients as there was no necessary fasting period 
and the fact it represented a longer term glycaemia than fasting plasma glucose (FPG) and 
oral glycose tolerance tests (OGTT). HbA1c monitoring provides health practitioners with an 
indication of blood glucose levels over the previous 3-4 months and is not affected by short 
lifestyle changes [69], whereas FPG and OGTT can be affected by a few days or weeks of 
dieting or increased exercise in preparation for a doctor visit [70]. Since Saudek et al’s initial 
advocacy, HbA1c has been utilised as an approved test for diagnosis of and management of 
diabetes in many countries. 
2.1 Diagnosis of Diabetes 
The first HbA1c threshold of ≥ 6.0 % to diagnose diabetes was recommended by Saudek et al 
in 2008 [69]. It was one year later that the International Expert Committee (IEC) used data 
from the National Health and Nutrition Study (NHANES) to recommend a threshold HbA1c 
value of ≥6.5% [71], and this threshold has become the most popularly adopted diabetes 
diagnosis HbA1c cut-off value. This ≥6.5% HbA1c threshold was first adopted by the 
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American Diabetes Association (ADA) [72] and the American College of Endocrinologists 
[73] in 2010. The IEC recommended threshold was then further adopted by the World Health 
Organization (WHO) [74], the Canadian Diabetes Association (CDA) [75] and the Australian 
Diabetes Society (ADS) in 2011. This widely adopted diabetes diagnosis HbA1c threshold of 
≥6.5% is currently used in clinical practice in Australia [76], United Kingdom and United 
States [72, 77] and has been shown to successfully screen for diabetes in remote Indigenous 
Australians [78]. 
In addition to diagnosing diabetes, HbA1c is proposed to also identify individuals at high risk 
of developing diabetes. The IEC recommends a 6.0-6.4 %  HbA1c category to identify those 
at high risk for diabetes [71] , while the ADA recommends a 5.7-6.4 %  HbA1c category 
[72]. Although diabetes risk is a continuum, these categories may be appropriate for 
prevention and early identification of those at high risk for diabetes. Although these high risk 
categories have been recommended for general populations, it is unknown what level of 
HbA1c would be most appropriate in the Indigenous Australian context. 
2.2 HbA1c and All-cause mortality meta-analysis and systematic review 
Whilst reviewing the literature to understand the HbA1c and diabetes-related complications, a 
gap was exposed in the research which needed to be answered. The conflicting findings of 
lower HbA1c levels in clinical trials and observational studies required more investigation. 
There was a significant need for a meta-analysis of observational studies, as the study design 
enabled researchers to detect patterns of mortality over a larger range of HbA1c values than 
existing clinical trial findings. A meta-analysis was conducted utilising linear and non-linear 
statistical techniques to allow a deeper investigation into the HbA1c and all-cause mortality 
relationship. The study explored potential causes of the non-linear relationship based on the 
available data and sample populations. 
As will be discussed in the following chapter, the existence of a U-shape association could 
impact the target HbA1c levels for diabetes management. The purpose of the meta-analysis 
was to inform whether it may be useful to test for a non-linear association between HbA1c 
and diabetes-related complications in Indigenous Australian observational studies. The 
following chapter addresses Research Question 1 as proposed in Chapter 1.2.2 and details a 
meta-analysis study which was published in the Review of Diabetic Studies. 
34 
 
2.2.1 Systematic Review/Meta-analysis article published in the Review of Diabetic 
Studies 
Arnold, L.W. and Wang, Z. The HbA1c and all-cause mortality relationship in patients with 
type 2 diabetes is J-shaped: a meta-analysis of observational studies. Rev Diabet Stud, 2014. 
11(2): p. 138-52. doi: 10.1900/rds.2014.11.138 
The HbA1c and All-Cause Mortality Relationship in Patients with Type 2 diabetes is J-
shaped: A Meta-Analysis of Observational Studies 
Luke W. Arnold and Zhiqiang Wang 
Centre for Chronic Disease, The University of Queensland School of Medicine, Royal 
Brisbane and Women’s Hospital, Herston QLD 4029, Australia 
 
ABSTRACT 
BACKGROUND: Low blood glucose and HbA1c levels are recommended in the literature 
on management of diabetes. However, data have shown that low blood glucose is associated 
with serious adverse effects for the patients and the recommendation has been criticized. 
Therefore, this article revisits the relationship between HbA1c and all-cause mortality by a 
meta-analysis of observational studies. AIM: The aim of this study is to determine whether 
there is a J- or U-shaped non-linear relationship between HbA1c and all-cause mortality in 
type 2 diabetes patients, implying an increased risk to premature all-cause mortality at high 
and low levels of HbA1c. METHODS: A comprehensive literature search was conducted 
using PubMed, Medline, and Cochrane Library databases with strict inclusion/exclusion 
criteria. The published adjusted hazard ratios (HR) with 95% confidence intervals of all-
cause mortality for each HbA1c category and per study were analyzed. Fractional polynomial 
regression was used with random effect modeling to assess the non-linear relationship of the 
HR trends between studies. Seven eligible observational studies with a total of 147,424 
participants were included in the study. RESULTS: A significant J-shaped relationship was 
observed between HbA1c and all-cause mortality. Crude relative risk for all-cause mortality 
identified a decreased risk per 1% increase in HbA1c below 7.5% (58 mmol/mol) (0.90, CI 
0.86-0.94) and an increased risk per 1% increase in HbA1c above 7.5% (58 mmol/mol) (1.04, 
CI 1.01-1.06). Observational studies revealed a J-shaped relationship between HbA1c and all-
cause mortality, equivalent to an increased risk of mortality at high and low HbA1c levels. 
CONCLUSIONS: This increased mortality at high and low HbA1c levels has significant 
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implications on investigating optimum clinical HbA1c targets as it suggests that there are 
upper and lower limits for creating a ‘security zone’ for diabetes management.  
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Introduction 
Type 2 diabetes (T2D) is one of the most serious burdens on public health in terms of 
mortality, morbidity, and cost to the health care system. The increase in prevalence of chronic 
diseases such as cardiovascular disease, hypertension, and obesity in both developed and 
developing nations highlights the increasing global burden, to which T2D is contributing as a 
common comorbidity [79]. The projected financial burden and mortality associated with 
complications of diabetes are evidence enough that early detection and minimization of T2D 
adverse effects are critical measures worldwide [80]. 
Glycosylated hemoglobin (HbA1c) is used as a screening tool of diabetes in clinical practice 
throughout the United Kingdom, United States, and Australia [77, 81]. The World Health 
Organization (WHO) has specified cut-off values for diagnosis of specific stages of diabetes 
[74]; it has not, however, published recommendations on the appropriate target HbA1c values 
for the management of the disease. This is largely due to the unclear and conflicting literature 
reporting about the HbA1c/mortality relationship.  
The research in this area was dominated by clinical trials up to 2008, which gave rise to the 
different and frequently commentated conclusions. Many clinical trials suggest a decrease in 
all-cause mortality as HbA1c values decrease [82-84], while others suggest that there is no 
association [85-87]. The debate has continued because of the early cessation of the Action to 
Control Cardiovascular Risk for Diabetes (ACCORD) trial [88], because there was an 
increased mortality in the treatment group that included patients who were trying to achieve 
low HbA1c levels. Since 2008, a number of meta-analyses have been conducted on these 
clinical studies to highlight further the conflicting results [89-95]. 
Several observational studies have explored the HbA1c and all-cause mortality relationship 
since the publication of prior clinical trials and subsequent meta-analyses; these studies 
present interesting results. All studies show an increase in all-cause mortality with HbA1c 
values, where only the degree and pattern of association differ. Whilst most studies highlight 
a linear relationship [96-105], several studies report a J- or U-shape relationship [106-110], 
indicating an increased all-cause mortality at lower HbA1c levels similar to that seen in the 
ACCORD trial. 
The difference between the conclusions drawn from clinical trials and observational studies 
deserves further investigation. The need for a meta-analysis in observational studies has been 
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long reported [111]. Despite two meta-analyses reporting a linear relationship [112, 113], 
there is no analysis investigating the overall trend and allowing for a non-linear relationship. 
Observational studies have the ability to detect patterns of mortality over a larger range of 
HbA1c values than current clinical trial results. A meta-analysis flexibly utilizing statistical 
methods will allow deeper investigation of the HbA1c and all-cause mortality relationship to 
seek for potential causes of a non-linear relationship based on the available data. 
The objective of this meta-analysis is to determine whether there is a J- or U-shaped 
relationship between HbA1c and all-cause mortality in T2D patients within observational 
studies. 
 
Methods 
This meta-analysis was conducted according to the PRISMA statement [114], and the 
proposed reporting checklist and recommendations of the Observational Studies in 
Epidemiology group [115]. 
 
Study selection 
A systematic literature search was conducted in May 2013 utilizing PubMed, Medline 
(OVID), EMBASE, and Cochrane Library databases. A combination of the following MeSH 
terms were used: ‘diabetes mellitus, type 2’, ‘diabetes complications’, ‘haemoglobin A, 
glycosylated’, ‘mortality’, ‘survival’, ‘aged’, and ‘adult’, using ‘AND’ and ‘OR’ for 
appropriate combinations. 
The contents of 2,255 publications identified by the literature search were reviewed 
independently by each of the authors to determine whether they met the eligibility criteria. 
Studies were eligible for inclusion when they satisfied the following criteria: if HbA1c levels 
were measured at baseline, patients with diagnosed T2D were included, the study population 
consisted of adult or aged patients, hazard ratios (HRs) were recorded for all-cause mortality, 
the study design was classified as an observational study, HRs were available for more than 
two HbA1c categories, ranges, or values, it was a human study and if it was written in the 
English language. 
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Studies were excluded when they fulfilled one or more of the following criteria: if HR or 
relative risk (RR) of all-cause mortality for HbA1c were not exposure variables, not 
conducted on adult patients with diabetes, HbA1c was not measured at baseline, measured 
HR in only two HbA1c categories and if results were presented as HR per 1% increase in 
HbA1c.  
 
If the full-text could not be found through the searched databases, journals were contacted 
directly. Full texts of all necessary articles were acquired and reviewed. 
 The selection was carried out in the following three steps (Figure 2.1): 
1. Each of the titles was screened for relevance using exclusion criteria. 
2. Duplicates were removed and abstracts were reviewed within inclusion and exclusion 
criteria. 
3. A thorough full-text review of the remaining publications was conducted to determine 
whether the studies met the inclusion criteria. 
 
Reference lists, citations, and review articles were manually reviewed for additional studies. 
These titles and abstracts were similarly screened and subsequently included if they satisfied 
the eligibility criteria. Experts were also asked to identify additional studies. See Figure 2.1 
for a summary of the screening and literature review process. 
The correspondent author of one study was contacted to request unpublished information 
necessary for the meta-analysis [116]. However, the information was not supplied and 
therefore the study was excluded.  
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Figure 2.1 Systematic literature search flow chart 
 
Medline/EMBASE = 449 
PubMed = 1545 
Cochrane = 245    Title Review 
Others = 16    Not relevant/ 
Total = 2255    Exclusion criteria = 1809 
     Duplicates = 173 
 
 
 
 
 
 
                     273    Abstract Review 
          Abstracts reviewed   - Not relevant (n=74) 
      - Commentary/review (n=52) 
      - Clinical trial (n=29) 
      - Not reporting HbA1c values (n=3) 
      - Systematic review/meta-analysis (n=18) 
      - Not conducted in type 2 diabetes patients (n=1) 
      - Only reporting prevalence and incidence 
        of complications (n=2) 
      - Study conducted on adolescents and  
  young adults (n=1) 
 
 
 
 
                  93 
Full-text articles    Full-text Screening 
       reviewed    - Not relevant (n=17) 
      - All-cause mortality not reported (n=6) 
      - Clinical trial (n=2) 
      - Diabetes participants excluded from analysis (n=4) 
      - HbA1c used as a confounding variable (n=1) 
      - HR or RR not calculated in results (n=4) 
      - Insufficient comparable HbA1c categories (n=26) 
      - Mean HbA1c measured in two groups (n=10) 
      - Results not reported in a way this meta-analysis 
        can use (n=14) 
      - Review article (n=1) 
      - Full-text not available in English (n=2) 
 
             6 
Studies included in 
   Meta-analysis 
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Quality assessment 
To determine the methodological quality of the studies included in the meta-analysis, we used 
modified criteria recommended by BioMed Central for study evaluation [117]. The following 
criteria were used for evaluating study quality: 
1. Source of information, including the time of data collection. 
2. Study designs, including type of study, appropriateness to answer research questions, 
measurement of exposure, ascertainment of outcomes, statistical techniques, and 
control for confounding factors. 
3. Valid interpretation of results. 
4. Discussion. 
A score was assigned to each study based on our assessment criteria and the quality 
assessment scheme conducted by Phung et al. [118]. Each study could obtain a quality score 
between 5 and 30, whilst a cut-off point of 25 was used to qualify for inclusion in our study. 
This cut-off score corresponded to the minimum required quality. Details of the quality 
assessment template can be found in Supplementary Table 2.3. 
 
Data synthesis and analysis 
Data was analyzed using Stata 12.0 [119]. The analysis was conducted in four steps: 
1. Pooled effect sizing, using a random effects model to ensure the correct adjustment 
and influence over the meta-analytic trend, was assigned to each study using sample 
size. 
2. Fractional polynomial regression was used to assess the non-linear relationship and 
generate coefficients. 
3. Values obtained from the fractional polynomial regression were then used to predict 
the fitted average curve of the studies included in the meta-analysis. 
41 
 
4. Poisson regression was used to calculate crude relative risk (RR) per 1% increase in 
HbA1c in each direction of the non-linear curve to provide further numerical 
evidence. 
The analysis was conducted by treating HbA1c as a continuous variable to fit the appropriate 
fractional polynomial regression model. To convert the HbA1c categorical data obtained 
from each study into a continuous variable, we used the recommendations and methods 
suggested by Berlin et al. [120] and Il’Yasova et al. [121]. The midpoint (arithmetic mean) 
was used in the case of a-b categories, while 0.8*a was used for categories as < a% HbA1c. 
In the case of > a% HbA1c, we utilized the an + (an- an-1) formula [121]. This is true for all 
studies included in the meta-analysis with the exception of both cohorts included from Currie 
et al. where we used the mean HbA1c of each category, as provided by the authors [107].  
Because of the differences in HbA1c categories used in the studies, we needed to adjust the 
HR reference values to ensure that the study trends were better comparable in the fractional 
polynomial analysis [121]. Each of the studies were adjusted so that the reference value (HR 
= 1) was located as near to 7.5% (58 mmol/mol) HbA1c as possible. This arbitrary reference 
value was selected upon observation that each of the included studies produced an HR for an 
HbA1c value of 7.5% (58 mmol/mol) or within 0.05 %. 
To test for heterogeneity between studies we used the coefficient of inconsistency (I2) as 
recommended by Higgins et al. [122]. This measure provides a degree of inconsistency in the 
studies’ findings by describing the percentage of total variation across studies which is due to 
heterogeneity [122]. The heterogeneity degrees ranged from 0 to 100%; we categorized them 
as low (< 25 %), moderate (25 % to 75 %), and high (≥ 75 %). 
 
Results 
Included and excluded studies 
The systematic literature search initially identified 2,255 studies, 1,809 of which were 
excluded because of irrelevance or matching exclusion criteria. Duplicates  
(n = 173) were also excluded at this stage. We reviewed 273 abstracts and excluded studies 
for the following reasons: Non-relevance (n = 73), commentaries or review articles (n = 52), 
reports based on clinical trial data (n = 29) and systematic reviews or meta-analyses (n = 18). 
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In the final screening stage, we reviewed the full text of 93 articles, and excluded a total of 87 
studies. The main reasons for excluding studies at this stage were as follows: Non-relevance 
(n = 17), reported HRs for less than 5 HbA1c categories (n = 26), only mean HbA1c reported 
in two population groups (n = 10) and results reported in such a way that they could not be 
used in this meta-analysis (n = 13). 
Some of the reviewed studies reported results in terms of HR per 1% increase of HbA1c. 
These studies were excluded as their analysis is only suitable to demonstrate a linear 
relationship. Similarly, we excluded studies which had only two comparable HRs of HbA1c 
values because of their inability to demonstrate a non-linear relationship. During the 
statistical analysis process, we further excluded studies with HRs for less than five HbA1c 
categories [96-100, 103, 123, 124]. Evidence of exclusion is highlighted in the results.  
Full texts could not be found in the English language for two articles [125, 126], which were 
subsequently not included in the meta-analysis. The full text of Bramlage et al. was available 
in German and investigated the prevention of cardiovascular disease through various 
biomechanisms, specifically by blocking the endocannabinoid system [126]. HbA1c was 
discussed as a risk factor for cardiovascular disease, but HRs for risk to all-cause mortality 
was not reported. The full text of Kim et al. was published in Korean and reported on HbA1c 
as a summary of diabetes management in a particular population [125]. This form of HbA1c 
values could not be utilized in this meta-analysis. The complete search summary can be seen 
in Figure 2.1.  
Currie et al. reported results on two separate cohorts included in the single publication [107]. 
Both of these retrospective cohorts fitted the inclusion criteria, and were included in the 
meta-analysis individually. Each was named for simplicity and easy reference, Currie et al. 
Cohort 1 and Currie et al. Cohort 2. 
The studies included in the meta-analysis were retrospective cohort studies (n = 4) [106-108], 
prospective studies (n = 2) [102, 109], and a population-based observational study [110]. 
Furthermore, the majority of the studies were conducted in the UK [102, 107], the US [106, 
108], Denmark [110], and the Netherlands [109]. Most of the studies had a median follow-up 
period of 2-4.4 years, with the exception of Stratton et al. (2000) [102] which had a median 
of 10 years’ follow-up. The number of participants in the studies ranged from 1,145 [109] to 
71,092 [108], which combined to a total 147,424 included participants. 
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Of the studies included, the main confounding variables adjusted for in the analysis were age, 
gender, ethnicity/race, smoking status, blood pressure, cholesterol, BMI, and various 
comorbidities associated with the specific area of research. Specific adjustment variables 
used in each study are highlighted in Table 2.1. 
As per our quality assessment outlined in Supplementary Table 2.3 (in Chapter 2.3.2 
Supplementary Material), all of the studies hold a quality score of 80-100%. This translates 
that all included studies achieved a score above the cut-off value of 25 out of 30; they could 
be regarded as high quality research articles. 
 
Table 2.1. Summary of the studies included in meta-analysis 
 
Author Year Location Study design Participants 
(n) 
Follow-
up 
Mean 
age 
(SD) 
% 
Men 
Adjusted variables 
Aguilar et 
al. 
2009 US Retrospective 
Cohort 
5,815 2 Years 69.2 
(9.2) 
94 Age, gender, race, cancer, 
glomerular filtration rate 
(GFR), left ventricular 
ejection fraction, 
hemoglobin, 
hyponatremia, chronic 
obstructive pulmonary 
disease, atrial fibrillation, 
race, cancer, previous 
heart failure 
hospitalization within last 
2 years, angiotensin-
converting enzyme 
inhibitor or angiotensin II 
receptor blocker use, beta-
blocker use, statin use, 
peripheral vascular 
disease, dementia, 
sulfonylurea use, and 
biguanide use 
Currie et al. 
Cohort 1 
2010 UK Retrospective 
Cohort 
27,965 3.9 years 
Median 
64.1 57 Age at index date, sex, 
smoking status, mean 
post-index total 
cholesterol, baseline BMI, 
and general comorbidity. 
The Charlson comorbidity 
index was also used. 
Currie et al. 
Cohort 2 
2010 UK Retrospective 
Cohort 
20,005 4.4 Years 
median 
63.6 
(11) 
53 Age at index date, sex, 
smoking status, mean 
post-index total 
cholesterol, baseline BMI, 
and general comorbidity. 
The Charlson comorbidity 
index was also used. 
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Huang et al.  2011 US Retrospective 
Cohort 
71,092 4 Years 71 
(7.4) 
52.6 Age, gender, race, 
smoking status, duration 
of diabetes, systolic BP, 
GFR, urinary albumin 
excretion, BMI, prevalent 
complications and 
comorbidities (history of 
lower-extremity 
amputation, 
photocoagulation, 
hospitalization for acute 
metabolic event, 
myocardial infarction, 
stroke, congestive heart 
failure, cancer, chronic 
lung disease, and 
depression), number of 
inpatient admissions in 
the previous year, and 
baseline use of glucose-
lowering medications 
Landman et 
al.  
2010 The 
Netherlands 
Prospective 
cohort study 
1145 5.8 years 
median 
68.7 
(11.5) 
45.7 Age, gender, smoking 
status, duration of 
diabetes, creatinine, BMI, 
systolic BP, total 
cholesterol-HDL (high-
density lipoprotein) ratio, 
macrovascular 
complications, use of 
statins, insulin use, and 
albuminuria. 
Skriver et 
al. 
2012 Denmark Population-
based 
observation 
study 
17,760 2 years 
median 
66 47.7 Adjusted for age, sex, 
prior hospital admission 
for cardiovascular 
disease, number of prior 
diagnosed non-
cardiovascular diseases, 
and response status. 
Stratton et 
al. 
2000 UK Observations of 
UKPDS (35) - 
prospective 
observation 
study 
3642 10 Years 
median 
53 (8) 60 Age, sex, race/ethnicity, 
smoking status, baseline 
LDL and HDL 
cholesterol, triglyceride, 
presence of albuminuria, 
and systolic BP. 
 
Table 2.2. Summary of data from studies to include in meta-analysis 
 
Study HbA1c categories as 
presented in publication, 
HbA1c % 
HbA1c used for 
analysis, HbA1c % 
(mmol/mol)a 
Sample 
size (n) 
HR as published 
(95% CI) 
Adjusted HR for 
meta-analysisb 
Aguilar et al. 
[106] 2009  
≤6.4 5.12 (32) 1264 1 1.37 
  6.4-7.1 6.75 (50) 1152 0.96 (0.81-1.13) 1.32 
  7.1-7.8 7.45 (58) 1092 0.73 (0.61-0.88) 1 
  7.8-9 8.40 (68) 1198 0.96 (0.81-1.13) 1.32 
  >9.0 10.20 (88) 1109 1.06 (0.90-1.26) 1.45 
Currie et al. [107] 
2010 Cohort 1 
6.42 6.42 (47) 3513 1.30 (1.07-1.58) 1.30 
  6.94 6.94 (52) 3501 1.07 (0.88-1.31) 1.07 
  7.27 7.27 (56) 3374 1.03 (0.85-1.26) 1.03 
  7.54 7.54 (59) 3136 1 1 
  7.82 7.82 (62) 2884 1.06 (0.86-1.30) 1.06 
  8.11 8.11 (65) 2684 0.99 (0.80-1.23) 0.99 
45 
 
  8.44 8.44 (69) 2437 1.12 (0.90-1.39) 1.12 
  8.85 8.85 (73) 2334 1.09 (0.87-1.37) 1.09 
  9.41 9.41 (79) 2133 1.23 (0.98-1.55) 1.23 
  10.47 10.47 (91) 1969 1.93 (1.55-2.42) 1.93 
Currie et al. [107] 
2010 Cohort 2 
6.42 6.42 (47) 1289 1.79 (1.45-2.22) 1.79 
  6.94 6.94 (52) 1291 1.45 (1.17-1.80) 1.45 
  7.27 7.27 (56) 1424 1.35 (1.09-1.67) 1.35 
  7.54 7.54 (59) 1661 1 1 
  7.82 7.82 (62) 1878 0.98 (0.79-1.21) 0.98 
  8.11 8.11 (65) 2148 1.15 (0.95-1.41) 1.15 
  8.44 8.44 (69) 2354 1.21 (1.00-1.48) 1.21 
  8.85 8.85 (73) 2463 1.21 (0.99-1.47) 1.21 
  9.41 9.41 (79) 2660 1.46 (1.21-1.77) 1.46 
  10.47 10.47 (91) 2837 1.80 (1.49-2.17) 1.80 
Huang et al. 
[108] 2011 
<6 5.50 (37) 10921 1 1.19 
  6.0-6.9 6.50 (48) 32125 0.84 (0.79-0.90) 1 
  7.0-7.9 7.50 (58) 17454 0.83 (0.76-0.90) 0.99 
  8.0-8.9 8.50 (69) 5962 0.90 (0.81-1.00) 1.07 
  9.0-9.9 9.50 (80) 2372 1.02 (0.88-1.17) 1.21 
  10.0-10.9 10.50 (91) 1125 1.21 (1.01-1.45) 1.44 
  >11 11.50 (102) 1133 1.31 (1.19-1.57) 1.56 
Stratton et al. 
[102] 2000 
<6 4.80 (29) 1011 1 0.57 
  6 to <7 6.50 (48) 1314 1.37 0.78 
  7 to <8 7.50 (58) 1005 1.76 1 
  8 to <9 8.50 (69) 660 1.87 1.06 
  9 to <10 9.50 (80) 314 2.18 1.24 
  ≥10 11.00 (97) 154 2.39 1.36 
Landman et al. 
[109] 2010 
<6.5 6.00 (42) 228 1.11 (0.71-1.74) 1 
  6.5-7.0 6.75 (50) 245 1 0.90 
  7.0-8.0 7.50 (58) 318 1.40 (0.99-1.97) 1.26 
  8.0-9.0 8.50 (69) 208 1.43 (0.97-2.10) 1.29 
  >9.0 9.50 (80) 114 2.26 (1.39-3.67) 2.04 
Skriver et al. 
[110] 2012 
<5 4.00 (20) 161 1.75 (1.14-2.69) 1.43 
  5-5.9 5.45 (36) 2295 1.12 (0.97-1.29) 0.92 
  6-6.9 6.45 (47) 5792 1 0.82 
  7-7.9 7.45 (58) 4104 1.22 (1.08-1.38) 1 
  8-8.9 8.45 (69) 2415 1.37 (1.18-1.60) 1.12 
  ≥9 10.00 (86) 2993 1.44 (1.24-1.66) 1.18 
aHbA1c values were converted from categorical into continuous data for analysis 
bHRs were adjusted so the arbitrary reference value (HR=1) was as close to 7.5 % (58 
mmol/mol) HbA1c as possible 
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HbA1c and all-cause mortality 
Preliminary analysis included fourteen studies with more than two HbA1c categories [96-
100, 102, 103, 106-110, 123, 124], which significantly influenced the fractional polynomial 
curve so that a non-linear curve was not evident (Figure 2.2). Since the non-linear 
relationship could be better detected with multiple HbA1c categories, further analysis was 
conducted. We excluded studies with HRs for less than five HbA1c categories and a distinct 
non-linear J-shape curve was observed (Figure 2.3) (p < 0.0001). This means that diabetes 
patients with high HbA1c levels have the highest risk of all-cause mortality, while patients 
with low HbA1c are also exposed to a high risk, albeit less than that associated with high 
HbA1c. By comparing Figures 2.2 and 2.3 the following is apparent: when studies reporting 
HR for less than 5 HbA1c categories were included, the analysis was not detecting a 
significant J-shaped non-linear relationship. This translates to both Figures 2.2 and 2.3, 
demonstrating an increased risk of all-cause mortality at higher HbA1c. However, only 
Figure 2.3, which includes studies with more than 4 HbA1c categories, had the power to 
detect an increased risk at lower HbA1c levels. 
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Figure 2.2. All-cause mortality HR for HbA1c values. Observed studies plotted against the 
predicted curve from regression analysis for studies with HRs reported for greater than two 
HbA1c categories. 
 
To investigate further the trend observed in Figure 2.3 and provide additional numerical 
support, we calculated crude all-cause mortality RR per 1% increase in HbA1c within studies 
for HbA1c values above and below 7.5% (58 mmol/mol). Further data were extracted, and 
person-years for each HbA1c group were estimated from the studies (Supplementary Table 
2.4). Using a Poisson regression model, we conducted further analysis on the trends by 
separating the HbA1c categories into two groups of < 7.5% (58 mmol/mol) and ≥ 7.5 % (58 
mmol/mol) HbA1c. Two studies were excluded from this analysis as they did not report the 
crude number of events (all-cause mortality) [108, 109]. 
 
Figure 2.3 All-cause mortality HR for HbA1c values. Observed studies plotted against the 
predicted curve from regression analysis for studies with HRs reported for greater than four 
HbA1c categories.  
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The equation of the fitted curve is HR = 4.55018 – 1.53970*HbA1c + 0.53225 
(HbA1c*ln(HbA1c)) 
 
Figure 2.4 demonstrates the crude pooled RRs for each group of HbA1c values and 
highlights the significant decreased risk of death as HbA1c % increases below 7.5% HbA1c 
(58 mmol/mol) (RR 0.90; CI 0.86-0.94, per 1% increase HbA1c). The percentages of total 
variation amongst the studies in this group caused by heterogeneity was high (I2 92.1 %, p < 
0.001). 
Furthermore, we observed an increased risk in all-cause mortality for the group of HbA1c 
values above 7.5% (58 mmol/mol) as HbA1c increased. The pooled RR was 1.04 (CI, 1.01-
1.06) per 1% increase in HbA1c. The percentages of total variation amongst the studies in 
this group caused by heterogeneity was also high and significant (I2 92.6 %, p < 0.001). 
 
Figure 2.4. Calculated crude relative risks (RR) per 1 % increase of HbA1c values for ≤ 7.5 
% (≤ 58 mmol/mol) and ≥ 7.5 % (≥ 58 mmol/mol).  
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Figure 2.4 demonstrates that, although there is high heterogeneity amongst the studies, the 
analysis determined a significantly increased risk of all-cause mortality at both high and low 
levels of HbA1c. This provides further evidence for the overall J-shaped trend observed in 
Figure 2.3, suggesting that diabetes patients with low or high HbA1c are at higher risk of all-
cause mortality compared with patients with relatively moderate HbA1c levels. 
 
Discussion 
This meta-analysis highlighted an observed J-shape relationship between HbA1c values and 
all-cause mortality in observational studies. This means an increased risk of all-cause 
mortality in low- and high-HbA1c groups. Also, this J-shaped trend was significant in studies 
which measured all-cause mortality rates and HRs in more than four HbA1c categories. 
Crude RR per 1% increase of HbA1c demonstrated a significantly increased risk of all-cause 
mortality for HbA1c values both above and below 7.5% (58 mmol/mol) HbA1c. 
The J-shape relationship of this meta-analysis supports the results of ACCORD trial that 
showed an increased risk of mortality in T2D patients with <6% (<42 mmol/mol) HbA1c 
compared to those with 7.0-7.9% (53-63 mmol/mol) (RR 1.22) [88]. By locating the HbA1c 
values of the ACCORD trial standard and treatment groups on the fitted curve in Figure 2.3, 
it appears that the ACCORD trial reflects the comparative relationship observed in this meta-
analysis below 7.5% (≤58 mmol/mol) HbA1c. The crude RR obtained in Figure 2.4 within 
the <7.5% (≤58 mmol/mol) HbA1c group showed a 10% increased risk of all-cause mortality 
(RR=0.90), which is slightly less than the 22% risk found in the ACCORD trial (RR=1.22), 
but highlights an increased risk nonetheless. This difference may be attributable to the crude 
mortality rates and estimated person-years which were used and/or the inclusion of the 
Stratton et al. [102] study which negatively influenced the meta-analysis result in this group. 
In contrast, the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE) trial compared HbA1c values of 6.5% (48 
mmol/mol) in the treatment group with 7.3% (56 mmol/mol) in the standard group, and 
obtained a HR of 0.93 for all-cause mortality [85]. By locating these HbA1c values on the 
fitted curve in Figure 2.3, it appears that the given HR would be expected to be indicated by 
the gradient of the curve between these values. It also appears that each of the ACCORD and 
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ADVANCE trials are simply reporting a relationship at a different position along the curve 
predicted by these observational studies. 
The studies included in this meta-analysis were of high quality and justifiably appropriate for 
inclusion. However, there were differences in the study populations resulting in 
heterogeneous HRs. All studies in the final analysis included elderly patients with a mean age 
for each study of over 63.6 years, except for Stratton et al. [102] (53 years). It can be seen in 
Figure 2.4 that Stratton et al. was the only study to report a decreased risk of mortality below 
7.5% (58 mmol/mol), suggesting age may play a role in the elevated risk. 
Skriver et al. had a significantly lower number of participants in their < 5% (< 31 mmo/mol) 
HbA1c group [110], which could have dramatically influenced the reported high risk to all-
cause mortality (HR = 1.43) in low HbA1c levels. Aguilar et al. conducted their study in the 
most noticeably different population within our analysis [106]. This population had a mean 
age of 69.2 years, and all individuals had suffered from heart failure. This places them at high 
risk of mortality irrespective of HbA1c level. After Cox adjustment, we still observed high 
mortality risk in the two lowest HbA1c groups (HR = 1.37, HR = 1.32). The mortality risk in 
this population appears to affect significantly the curve for HbA1c values less than 7.45% (58 
mmol/mol).  
This provides support for Rutter’s hypothesis that patients with high comorbidities are more 
susceptible to an increased risk of all-cause mortality at lower HbA1c [111]. However, the 
exact range of HbA1c values of the association varies between populations. 
The accuracy and reliability of the models used in this meta-analysis and the use of 
observational studies are strongly supported by their appropriateness to fit the relationship 
determined in two of the most cited and highly debated studies in the literature [85, 88]. 
Although the ADVANCE and the ACCORD trials report different relationships between all-
cause mortality and HbA1c, the fractional polynomial regression of the observational studies 
is able to capture the overall trend over a larger range, while still providing support of each 
relationship. 
The two previous meta-analyses of observational studies [112, 113] using RRs of 1% 
increase in HbA1c concluded that all studies highlighted an increased risk to cardiovascular 
mortality when HbA1c is increased. Figure 2.3 implies the following: if you were to 
calculate RRs between 6% (42 mmol/mol) HbA1c and any value above 8.5% (69 mmol/mol) 
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you would expect to achieve an increased relative risk of mortality. However, we have also 
shown that this is an insufficient way of measuring the mortality and HbA1c relationship over 
this complete range of HbA1c values. By analyzing the available observational studies using 
a non-linear fractional polynomial regression technique, we are able to identify the significant 
J-shaped relationship which previous statistical analyses were unable to detect.  
The J-shaped trend conflicts with a recent observational study of a clinical trial conducted by 
Andersson et al. who found no association between low HbA1c and increased mortality in 
overweight and obese patients not experiencing weight loss [84]. This could be caused by the 
difference in population groups between this study and the adjusted variables used in other 
studies. The participants in Andersson et al. were overweight or obese, specifically recruited 
for a weight-loss trial assessing the association between HbA1c and body mass index (BMI). 
However, four out of our seven studies [107-109] included in our analysis have adjusted for 
BMI in their studies.  
The results presented here are also stable and reliable because we excluded those 
observational studies from our analysis with an insufficient number of HbA1c categories (n = 
26). We are unable to determine whether there could have been a J-shaped relationship in 
these studies when their statistical analysis was tested for a non-linear relationship. For 
example, Eeg-Olofsson et al. presented HRs in terms of per 1% increase of HbA1c, and they 
used three HbA1c categories, which led to a linear trend [97]. However, some of the reported 
figures (Figure 3E) presented in [97] showed a U-shaped relationship in our analysis when 
HbA1c was subdivided into deciles. Without complete knowledge of the dataset it is difficult 
to draw a conclusion. However, it may be worth re-analyzing these data to test for a 
statistically significant non-linear trend. 
The J-shape found in our analysis is significant and has major implications for clinical trial 
design and clinical practice in the future. The predicted values obtained from the regression 
model apparently demonstrate a kind of ‘security zone’ of minimal effect on HR for HbA1c 
values approximately between 6% and 7.5% (42-58 mmol/mol). The regression model has 
observed higher HRs for all-cause mortality in HbA1c values below 6% (42 mmol/mol) and 
above 7.5% (58 mmol/mol). 
It was not the aim of the analysis to identify such a ‘security zone’ or to influence directly 
clinical management parameters. Also, the results cannot define the optimal HbA1c range for 
T2D management, but they emphasize the need for more investigation surrounding this 
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HbA1c range in further clinical trials and observational studies. Future clinical trials 
investigating the efficacy of diabetes management regimens should consider the 
consequences of lower HbA1c levels in different populations, as identified in this study, and 
cautiously assign targets accordingly. 
 
Limitations 
This meta-analysis has limitations regarding the systematic literature search which was 
limited to articles published in English. Although we identified two non-relevant articles in 
non-English languages, we are unable to estimate the true representation of the worldwide 
published literature regarding the HbA1c/all-cause mortality relationship. We are confident 
that any publication selection bias would be minimal as we also identified a number of 
studies conducted in non-English speaking countries, which were published in English. 
The findings of the meta-analysis are not generalisable to Indigenous populations of the 
world such as Aboriginal and Torres Strait Islanders in Australia. The included studies 
reported median ages between 63.6 and 69.2 years [102, 106, 107, 110]. These reported ages 
represent the upper anticipations of life expectancy for Indigenous Australian men and 
women (69.1 and 73.7 years, respectively) [11, 12]. Similarly, the studies were conducted in 
cohorts of participants with type 2 diabetes and high comorbid status, such as prior heart 
failure [106], where Indigenous Australians have been identified as a highly comorbid cohort 
[21, 26]. These similarities between the cohorts included in the meta-analysis and Indigenous 
Australian people suggest the association is likely to be consistent, however as there were no 
Indigenous populations included in the analysis, we are unable to generalise the findings to 
Indigenous communities. Future studies in Indigenous populations would need to be 
conducted to investigate the association. 
The meta-analysis may also be limited because of data excluded from studies which reported 
only all-cause mortality HRs in less than five HbA1c categories. These studies may not have 
enough participants or events in the study to warrant so many categories. We cannot conclude 
that they would also have a non-linear relationship if more HbA1c categories were reported; 
they may in fact still report a linear relationship. Although it would be optimal, we did not 
have the resources to obtain all raw data from excluded studies to conduct non-linear tests 
and calculate adjusted HRs in synonymous HbA1c categories. However, our analysis 
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highlights a distinct J-shaped relationship in all-cause mortality for studies that report HRs 
for more than four HbA1c categories.  
We also need to mention that there may be other constraints caused by the inherent 
limitations of the studies included in the analysis. However, we are confident that the quality 
assessment scheme applied ensured that only studies of high-quality research were included. 
 
Conclusion 
This meta-analysis found a J-shaped relationship between HbA1c and all-cause mortality in 
T2D patients in observational studies when mortality rates and hazard ratios were measured 
in more than four HbA1c categories. The J-shaped relationship provides evidence that a 
‘security zone’ exists for clinicians to target optimal HbA1c levels. To provide even stronger 
evidence for clinical practice, the existing data of HbA1c values between 5.5% (37 
mmol/mol) and 9% (75 mmol/mol) should be re-analyzed in more detail, and new data 
should consider HRs to be calculated in more than four HbA1c categories. 
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2.2.2 Supplementary Tables 
 
Supplementary Table 2.3. Quality Assessment template 
Criteria  Question Potential 
Score 
Achieved 
Score 
Source of the  Published in a peer-reviewed journal 5   
Information  Not peer-reviewed but reviewed by some other groups     
   Non-reviewed journal or groups 4   
   Unpublished 3   
   If the study is unpublished, is the investigator willing to give 
an assurance that these are final, clean data?  
    
  Yes/No 2/1   
   Are the investigators and all institutional affiliations 
identified? 
    
  Yes/No 1/0   
   When was information collected     
  - Recent 5 years 3   
  - Recent 10 years 2   
  - More than 10 years 1   
       
Study Design 
(1)  
 Is the design described clearly? Yes/No 1/0   
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   Is the design appropriate to the study questions? Yes/No 1/0   
       
  Are exposure indicators (HbA1c) clearly defined? Yes/No     
  - WHO category 3   
  - Cut-off point of the study population 2   
  - Other 1   
       
   Are there clear inclusion and exclusion criteria? Yes/No 1/0   
   Are there appropriate statistical packages for data analysis?     
  Yes/No 1/0   
   Are there controlling for confounding factors? Yes/No 1/0   
       
Study Design 
(2)  
Are the outcomes (All-Cause Mortality) clearly defined, 
including methods of ascertainment? Yes/No 
    
   - All-cause mortality is the primary outcome in the study 3   
   - All-cause mortality is not the primary outcome in the study 2   
   - All-cause mortality is not measured 1   
       
   Are the HbA1c measurement methods validated?? 1/0   
  Yes/No     
       
Study Results  Are baseline characteristics of subjects well described? 
Yes/No 
1/0   
   Is the main question/hypothesis answered properly? Yes/No 1/0   
   Are HR/RR, 95%CI, p-value presented? Yes/No 2/0   
   Are potential confounding factors controlled or presented?     
  Yes/No 1/0   
   Was analysis sensitive enough? Yes/No 1/0   
       
Study 
Discussion 
 Discussion of the limitations/innovation of the study? Yes/No 1/0   
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   Comparison with previous work? Yes/No 1/0   
   Discussion of plausibility? Yes/No 1/0   
       
  TOTAL SCORE (Max 30; Min 5)     
 
 
Supplementary Table 2.4. Summary of data extracted from studies to calculate crude all-
cause mortality Relative Risk (RR). 
Study HbA1c categories 
as presented in 
publication, 
HbA1c % 
HbA1c used 
for analysis, 
HbA1c % 
(mmol/mol)a 
Sample 
size (n) 
Event 
number 
(n) 
Median 
duration 
(years) 
person
-years 
Incidence 
(1,000 
person-
years) 
HR as 
published 
(95% CI) 
Adjusted HR 
for meta-
analysisb 
Aguilar et al. 
2009  ≤6.4 5.12 (32) 1264 316 2 2528 125.0 1 1.37 
  6.4-7.1 6.75 (50) 1152 265 2 2304 115.0 0.96 (0.81-1.13) 1.32 
  7.1-7.8 7.45 (58) 1092 193 2 2184 88.4 0.73 (0.61-0.88) 1 
  7.8-9 8.40 (68) 1198 269 2 2396 112.3 0.96 (0.81-1.13) 1.32 
  >9.0 10.20 (88) 1109 257 2 2218 115.9 1.06 (0.90-1.26) 1.45 
Currie et al. 
2010 Cohort 1 6.42 6.42 (47) 3513 301 3.9 13701 22.0 1.30 (1.07-1.58) 1.30 
  6.94 6.94 (52) 3501 238 3.9 13654 17.4 1.07 (0.88-1.31) 1.07 
  7.27 7.27 (56) 3374 231 3.9 13159 17.6 1.03 (0.85-1.26) 1.03 
  7.54 7.54 (59) 3136 207 3.9 12230 16.9 1 1 
  7.82 7.82 (62) 2884 190 3.9 11248 16.9 1.06 (0.86-1.30) 1.06 
  8.11 8.11 (65) 2684 179 3.9 10468 17.1 0.99 (0.80-1.23) 0.99 
  8.44 8.44 (69) 2437 175 3.9 9504 18.4 1.12 (0.90-1.39) 1.12 
  8.85 8.85 (73) 2334 168 3.9 9103 18.5 1.09 (0.87-1.37) 1.09 
  9.41 9.41 (79) 2133 161 3.9 8319 19.4 1.23 (0.98-1.55) 1.23 
  10.47 10.47 (91) 1969 185 3.9 7679 24.1 1.93 (1.55-2.42) 1.93 
Currie et al. 
2010 Cohort 2 6.42 6.42 (47) 1289 232 4.4 5672 40.9 1.79 (1.45-2.22) 1.79 
  6.94 6.94 (52) 1291 204 4.4 5680 35.9 1.45 (1.17-1.80) 1.45 
  7.27 7.27 (56) 1424 209 4.4 6266 33.4 1.35 (1.09-1.67) 1.35 
  7.54 7.54 (59) 1661 192 4.4 7308 26.3 1 1 
  7.82 7.82 (62) 1878 211 4.4 8263 25.5 0.98 (0.79-1.21) 0.98 
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  8.11 8.11 (65) 2148 271 4.4 9451 28.7 1.15 (0.95-1.41) 1.15 
  8.44 8.44 (69) 2354 305 4.4 10358 29.4 1.21 (1.00-1.48) 1.21 
  8.85 8.85 (73) 2463 334 4.4 10837 30.8 1.21 (0.99-1.47) 1.21 
  9.41 9.41 (79) 2660 404 4.4 11704 34.5 1.46 (1.21-1.77) 1.46 
  10.47 10.47 (91) 2837 472 4.4 12483 37.8 1.80 (1.49-2.17) 1.80 
Stratton et al. 
2000 <6 4.80 (29) 1011 112 10 10113 11.1 1 0.57 
  6 to <7 6.50 (48) 1314 207 10 13143 15.8 1.37 0.78 
  7 to <8 7.50 (58) 1005 188 10 10054 18.7 1.76 1 
  8 to <9 8.50 (69) 660 123 10 6595 18.7 1.87 1.06 
  9 to <10 9.50 (80) 314 64 10 3137 20.4 2.18 1.24 
  ≥10 11.00 (97) 154 26 10 1537 16.9 2.39 1.36 
Skriver et al. 
2012 <5 4.00 (20) 161 22 2 322 68.3 1.75 (1.14-2.69) 1.43 
  5-5.9 5.45 (36) 2295 275 2 4590 59.9 1.12 (0.97-1.29) 0.92 
  6-6.9 6.45 (47) 5792 638 2 11584 55.1 1 0.82 
  7-7.9 7.45 (58) 4104 428 2 8208 52.1 1.22 (1.08-1.38) 1 
  8-8.9 8.45 (69) 2415 228 2 4830 47.2 1.37 (1.18-1.60) 1.12 
  ≥9 10.00 (86) 2993 268 2 5986 44.8 1.44 (1.24-1.66) 1.18 
aHbA1c values were converted from categorical into continuous data for analysis 
bHRs were adjusted so the arbitrary reference value (HR=1) was as close to 7.5% 
(58mmol/mol) HbA1c as possible 
 
2.3 HbA1c and Indigenous Australians 
The preceding chapters presented literature on the association between HbA1c and type 2 
diabetes complications in general populations, however prior to 2004 there was significantly 
less published data detailing the prevalence of diabetes complications in Indigenous 
Australians [127-130]. Diabetic nephropathy prevalence has been well reported, and evidence 
supports renal disease as a significant cause of premature mortality of Indigenous Australian 
people [131, 132]. Peripheral neuropathy in Indigenous people with diabetes had not been 
well documented prior to 2000, however a study of hospital admissions in Central Australia 
between 1992 and 1997 found a three-fold increase in diabetic foot complications. Aboriginal 
people accounted for ninety percent of these admissions [133]. Further, diabetic retinopathy 
in the Aboriginal population was also not well documented. One study in 1998 found a 
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diabetic retinopathy prevalence of 27% in a group of Aboriginal people with type 2 diabetes 
from five remote communities in the Pilbara region of Western Australia [134]. 
The detail reported for prevalence of type 2 diabetes in Indigenous communities has been 
increasing over the past 2 decades, with a particular focus on complications associated with 
diabetes for the last decade. Some prevalence estimates had been published from the 
Australian Diabetes, Obesity, and Lifestyle (AusDiab) population-based surveys and 
Australian National Diabetes Information Audit & Benchmarking (ANDIAB) reports, 
however Indigenous Australians were inadequately represented in these samples [47, 135]. 
The full extent of the diabetes burden has historically been better understood in the general 
Australian population than in the Indigenous minority.  
Maple-Brown and colleagues were one of the first to publish data showing the prevalence of 
numerous diabetes complications with HbA1c values in a highly representative sample of a 
remote Indigenous Australian community. Mean HbA1c was high (9.0%) in this community 
and there was also high prevalence of hypertension, albuminuria, peripheral neuropathy [47]. 
Maple-Brown et al recognized the excellent progress the primary health care providers had 
made despite the very challenging environment for managing diabetes complications in these 
remote communities.  In an audit of 27 remote Indigenous community clinics, McDermott et 
al also found that diabetes checks are routinely being conducted in remote Indigenous 
Australian communities [136]. The audit found high prevalence of hypertension and 
albuminuria, which were appropriately treated. In the overall sample, glycaemic control was 
poor, highlighted by a mean HbA1c of 8.9% [136].  
Studies comparing the health status of Indigenous and non-Indigenous diabetes patients 
continued to highlight the significant disparity of diabetes and micro/macrovascular 
complications between these populations. In a comparison with non-Indigenous patients 
presenting to the same practitioner, Thomas and colleagues identified Indigenous patients 
were more likely to have poor glycaemic control [137]. This was surprising considering both 
groups had similar frequency use of oral antidiabetic agents and insulin. Positively, Thomas 
et al also found that achievement of LDL and BP targets was the same or better in Indigenous 
patients [137]. Findings from the Darwin Region Urban Indigenous Diabetes (DRUID) study 
were reported by Maple-Brown et al and O’Dea et al in 2008, which detailed the 
characteristics of urban Indigenous type 2 diabetes patients [46, 50]. The DRUID study found 
a high prevalence of albuminuria and peripheral vascular disease among the urban 
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participants. DRUID patients with new diabetes had less difference between diabetes 
complication rates than those with known diabetes, compared with non-Indigenous 
Australians from the AusDiab study [46, 50]. Men and women from the DRUID study aged 
over 35 years had the highest rates of diabetes and albuminuria and also had higher mean 
HbA1c % [50]. The Fremantle Diabetes Study also found a significant disparity in diabetes 
complications between urban Anglo-Celt and Aboriginal type 2 diabetes patients [45]. The 
Aboriginal group had a high prevalence of diabetes complications including up to 33% 
prevalence of retinopathy and 30.7% of peripheral arterial disease.  
In a comparison of the cardiovascular risk profile and microvascular complications of type 2 
diabetes patients from a remote Australian Aboriginal community, DRUID participants and 
an Indigenous Canadian community Maple-Brown et al found similarities yet significant 
differences between Indigenous populations [48, 49]. A more recent study found a high 
proportion of Aboriginal and Torres Strait Island people with type 2 diabetes had poorly 
controlled glycaemia and high rates of albuminuria and other cardiovascular risk factors 
[138]. Johnson et al identified a very high prevalence of albuminuria (77%) even compared 
with other Indigenous communities. Further evidence suggested that majority of this 
population had CKD than normal renal function [138].  
As reported in Chapter 2.2, Rowley et al and Marley et al pioneered the validation and 
efficacy of using HbA1c as a screening tool for diabetes in Indigenous Australians [78, 81, 
139]. There may be more applications for HbA1c testing in the management of and early 
detection or risk for diabetes in these communities.  
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Chapter 3 – HbA1c screening and cardiovascular risk markers 
HbA1c screening in Indigenous Australia is still a relatively new concept. The successful 
screening for diabetes diagnosis using HbA1c in remote and urban Indigenous Australian 
communities has only been recently recognised [78, 81]. The usefulness of HbA1c screening 
for diabetes diagnosis was first studied in Indigenous Australians by Rowley and colleagues 
in a small sample of urban Indigenous Australians [81]. This study provided evidence that the 
concept of HbA1c screening could be applicable and successful in Indigenous Australian 
communities, however the low sample size restricted the finding’s generalisability.  
The successful use of HbA1c for diabetes screening in remote Indigenous communities has 
recently been shown by Marley and colleagues. Marley et al studied participants from remote 
Indigenous communities in the Kimberley region of Western Australia and concluded that a 
point of care (POC) HbA1c level of ≥6.5% can successfully diagnose diabetes in these 
communities [139]. To date, this is the only HbA1c screening evaluation conducted with 
remote Indigenous Australians.  
Our study population did not have fasting plasma glucose or oral glucose tolerance test 
information recorded in their health examinations, so we were unable to conduct screening 
test analysis to provide sensitivity, specificity and receive operating characteristic (ROC) 
curve and predictive values. However, the health status of the community and their risk for 
diabetes was a significantly important research question. There are yet to be any studies 
conducted on the overall health status of any Indigenous community in the world based on 
their HbA1c prior to development of diabetes. Diabetes is a progressive disease on a 
continuum, so the next chapter in this thesis details a study which profiles the community’s 
risk for cardiovascular disease based on their HbA1c level.   
Chapter 2.2.1 presented a systematic literature review and meta-analysis, which identified the 
non-linear relationship between all-cause mortality and HbA1c in people diagnosed with type 
2 diabetes. A limitation for similar analysis in the study community of this thesis, is the large 
number of people who may have diabetes, however may not be diagnosed. The health 
screening examinations conducted between 2004 and 2006 enabled an investigation into the 
distribution of HbA1c, and subsequent risk for diabetes, and cardiovascular disease risk 
profile in the community.   
The following chapter addresses Research Questions 2 and 3 as proposed in Chapter 1.2.2.  
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3.1 Original Research article published in The Journal of Diabetes Research 
Luke W. Arnold, Wendy E. Hoy, Suresh K. Sharma, and Zhiqiang Wang, “The Association 
between HbA1c and Cardiovascular Disease Markers in a Remote Indigenous Australian 
Community with and without Diagnosed Diabetes,” Journal of Diabetes Research, vol. 2016, 
Article ID 5342304, 8 pages, 2016. doi:10.1155/2016/5342304 
 
Abstract 
Objectives: This study investigates the burden of cardiovascular risk markers in people with 
and without diabetes in a remote Indigenous Australian community, based on their HbA1c 
concentration. 
Methods: This study included health screening exams of 1187 remote Indigenous residents 
over 15 years old who represented 70% of the age-eligible community. The participants were 
stratified by HbA1c into 5 groups using cut-off points recommended by international 
organisations. The associations of traditional cardiovascular risk markers with HbA1c groups 
were assessed using logistic and linear regressions, and ANOVA models. 
Results: Of the 1187 participants, 158 (13%) had a previous diabetes diagnosis, up to 568 
(48%) were at high risk (5.7-6.4% (39-46mmol/mol) HbA1c) and 67 (6%) potential new 
cases of diabetes (≥6.5% (48mmol/mol)) were identified. Individuals with higher HbA1c 
levels were more likely to have albuminuria (OR 3.14, 95%CI 1.26-7.82) and dyslipidaemia 
(OR 2.37, 95%CI 1.29-4.34), and visited the clinic more often (OR 2.52, 95%CI 1.26-4.99). 
Almost all traditional CVD risk factors showed a positive association with HbA1c.  
Conclusions: Screening in this remote Indigenous Australian community highlights the high 
proportion of individuals at high risk of diabetes as indicated by HbA1c and who also had an 
accentuated cardiovascular risk profile. 
 
Keywords 
HbA1c; Indigenous Australians; type 2 diabetes; screening; cardiovascular risk; remote 
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Introduction 
The Indigenous population of Australia are 3 times more likely to have type 2 diabetes than 
their non-Indigenous counterparts, have an earlier onset of diabetes and experience higher 
rates of diabetes complications [38, 39]. This disparity can also vary significantly among 
Indigenous communities. Some Indigenous communities are up to 10 times more likely to 
have diabetes than the general population and 2 times more than other remote Indigenous 
communities [27, 40]. This further disadvantage for individuals living in remote communities 
requires continued efforts. 
Many previous studies report the burden of diabetes based on diabetes incidence, prevalence, 
or microvascular and macrovascular complications associated with diabetes [2, 46, 50]. It is 
also important to investigate the burden of this disease in remote Indigenous Australians 
before they are diagnosed with diabetes. The risk for, and progression of, type 2 diabetes is 
on a continuum, so the earliest identification of these high risk individuals would increase the 
chance to delay or prevent diabetes development.  
Use of glycosylated haemoglobin (HbA1c) may be a successful screening option to 
investigate the burden of diabetes in these remote Indigenous Australian communities. 
HbA1c is currently recommended for diabetes diagnosis in clinical practice in United 
Kingdom, New Zealand, United States and Australian [72, 76, 77, 140] general populations. 
HbA1c has also been shown to successfully screen for diabetes in urban Indigenous 
Australians [81] and more recently, in remote Indigenous Australian communities [139].  
In addition to diagnosing diabetes, HbA1c could also identify individuals at high risk of 
developing diabetes. An International Expert Committee recommended a 6.0-6.4% (42-46 
mmol/mol) HbA1c category to identify those at high risk for diabetes [71], while the 
American Diabetes Association (ADA) recommends a 5.7-6.4% (39-46 mmol/mol) HbA1c 
category [72]. Although diabetes risk is a continuum, these categories are a starting point for 
health services to focus on prevention and early identification of those at high risk for 
diabetes. Although high risk categories have been recommended in general populations, it is 
unknown what level of HbA1c would be most appropriate in the Indigenous Australian 
context.  
This study aims to investigate the cardiovascular risk profile of people in a remote Indigenous 
Australian community across a wide range of HbA1c levels. We also compare the difference 
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between groups with and without diabetes to highlight how the burden of cardiovascular risk 
markers changes as risk for diabetes increases based on increased HbA1c. 
 
Methods 
Participants 
Health screening examinations were offered between 2004 and 2006 to every individual of a 
remote Indigenous Australian community in the Northern Territory who were ambulatory. 
People in old age care, in hospital, on dialysis, resident elsewhere or out of community on the 
screening occasion did not participate. All participants provided written informed consent. 
Blood and urine samples were collected, anthropometric measurements and lifestyle 
questions were recorded and medical records were reviewed. Blood samples were only taken 
from participants over 15 years old. There were 1,554 who participated in the health 
screening examinations and 79 percent were aged between 15 and 82 years, which 
represented 70% of the (1,757) total age-eligible population, based on the 2006 Census. 
Participants were excluded from the current analysis if they did not identify themselves as 
Indigenous Australian or did not have a blood sample taken.  
 
Measurements and Identification of Events 
Urine and blood samples collected from participants were sent to Westerns Pathology in 
Darwin. All assays were performed using the Roche Integra I800. HbA1c was measured from 
blood serum samples. Urinary albumin was measured by immunoturbidimetry using the 
Beckmann Array (Beckman Instruments, Brea, CA). Urinary creatinine was measured using 
the kinetic method with an alkaline picrate reagent. Samples were analysed within 48 hours 
of collection, with interim storage at 4⁰C. Microalbuminuria and macroalbuminuria were 
classified by a urinary albumin/creatinine ratio (ACR) of 3.4-33 g/mol and ≥34 g/mol, 
respectively [24]. Blood pressure was measured on the right arm in a seated position after 
participants had rested for at least 5 minutes using an automated BP device (Welch Allyn, 
Skaneateles Falls, NY) and appropriate cuffs for arm size. Hypertension was defined if the 
participant had a previous diagnosis of hypertension in their health records, was taking 
antihypertensive medication or had elevated levels in the baseline examination (≥ 140mmHg 
64 
 
systolic, ≥ 90mmHg diastolic). Estimated glomerular filtration rate (eGFR) was calculated 
using the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) formula as 
validated (without adjustment for African American status) in Indigenous Australian 
populations by Maple-Brown et al [141]. Triglyceride levels were measured using 
lipase/glycerol kinase/ GPO-PAP (glycerol-3-phosphate oxidase; phenol + aminophenazone) 
assays.  Total cholesterol concentration was measured using cholesterol oxidase/peroxidase 
reagents. HDL cholesterol levels were measured using cyclodextrin sulphate/ polyethylene 
glycol (PEG) modified enzymes. Dyslipidaemia was defined by a previous diagnosis of high 
cholesterol, taking cholesterol management medication or had a total cholesterol ≥ 5.5 
mmol/L or HDL < 1.0 mmol/L at the screening examination as per the Australian Diabetes, 
Obesity, and Lifestyle Study (AusDiab) [142]. High sensitivity CRP was analysed using 
immunoturbidimetric CRP assay on a Hitachi 917 analyser (Roche Diagnostics Australia) 
with a detection limit of 0.03 mg/L. The assay’s analytical range was from 0.1 to 20 mg/L. 
CRP concentrations greater than 20 mg/L were measured using diluted samples. The 
imprecision of the assay is less than 5% [44]. Waist circumference (WC) was measured at the 
narrowest point below the ribs or halfway between the lower border of the ribs and the iliac 
crest in centimetres. Participants in the highest quartile for WC based on age and sex-adjusted 
z-scores were defined as having high WC. Body mass index (BMI) was calculated by 
dividing the individual’s weight in kilograms by their height in metres-squared (kg/m2). 
Smoking status was self-reported in the health screening interview. The number of clinic 
visits in the last year was counted through the clinic records for each individual in the past 12 
months prior to their health screening examination. A history of CVD was determined if the 
participant had a hospitalisation associated with CVD in the last 12 years prior to their health 
screening examination. The number of cardiovascular risk factors was the total score of the 
following possible risk factors: micro/macro albuminuria, hypertension, dyslipidaemia, 
current smoker and high WC. 
 
Statistical Analysis 
The study population was stratified by HbA1c into 5 groups of participants, as follows: four 
groups without a prior diagnosis of diabetes (<5.7% (39mmol/mol), 5.7-5.9% (39-41 
mmol/mol), 6.0-6.4% (42-46 mmol/mol), ≥6.5% (48 mmol/mol)) and a single group of 
participants with known diabetes (4.9-15.6% (30-147 mmol/mol)). The HbA1c categories 
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were created according to the recommended definitions of high risk for diabetes and diabetes 
diagnosis from the World Health Organisation (≥6.5% (48 mmol/mol) HbA1c diabetes 
diagnosis), the International Expert Committee (IEC) (6.0-6.4% (42-46 mmol/mol) HbA1c 
for high risk of diabetes) and the American Diabetes Association (ADA) (5.7-6.4% (39-46 
mmol/mol) HbA1c for high risk of diabetes) [71, 72, 74]. The number of clinic visits were 
categorised into low (<5), moderate (5-15) and high (>15) for analysis. Age and sex-adjusted 
means and 95% confidence intervals of traditional chronic disease risk factors were 
calculated for the categories of HbA1c and the differences were tested using linear regression 
and two-way ANOVA. Logistic regression tested the trend and calculated odds ratios among 
HbA1c categories for dichotomous and categorical variables. Logistic regression analysis 
was conducted in a number of models to identify how the following variables such as age, 
sex, systolic blood pressure, waist circumference, total cholesterol, HDL cholesterol, current 
smoking status and hypertensive medication may affect the association. Consistent with 
Maple-Brown and colleagues, the following variables were considered for inclusion in the 
final model: age, diabetes duration, gender, weight, BMI, waist, waist–hip ratio, current 
smoker, systolic blood pressure, HbA1c, total cholesterol, triglycerides, HDL cholesterol, 
urine ACR [46]. Variables with p < 0.05 were included in the final model [46]. This approach 
enables full transparency of potential confounders and ensures the traditional risk factors of 
CVD are tested to better understand the conceptual model of their interactions [143]. All 
analyses were  conducted using STATA 13.0 [144]. 
 
Ethical Approval 
Ethical approval was obtained for this study from the Behavioural and Social Sciences 
Ethical Review Committee on behalf of School of Medicine in The University of Queensland 
(Appendix 1), the Human Research Ethics Committee of the Northern Territory Department 
of Health and Community Services, the Menzies School of Health Research, the community 
Land Council and local council. 
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Table 3.1. Characteristics of the total population over 15 years old of a remote Indigenous 
Australian community 
 Total Population 
n (%) 1187 
Age 33 (24-44) 
Men, % 54 
HbA1c, % 5.8 (5.5-6.1) 
SBP, mmHg 118 (108-129) 
Cholesterol, mmol/L 4.7 (4-5.3) 
HDL chol, mmol/L 1.2 (1.1-1.5) 
LDL chol, mmol/L 2.55 (2.0-3.1) 
BMI, kg/m2 22.7 (19.5-27.2) 
Waist, cm 87 (77-97.5) 
ACR, g/mol b 2.58 (0.95-11.25) 
Triglycerides, mmol/L b 1.5 (1.0-2.4) 
CRP, mg/L b 6 (2-11) 
eGFR, mL/min/1.73m2 b 108.9 (95.5-121.5) 
Current smoker, % 72 
Microalbuminuria, % c 29 
Macroalbuminuria, % d 15 
Hypertension, % e 28 
Dyslipidaemia, % f 45 
Number of clinic visits in 
previous 12 months 
 
High (>15) a 17 (204) 
Moderate (5-15) a 39 (463) 
Low (<5) a 43 (513) 
CVD History a 5.2 (62) 
Median (25th-75th percentiles) unless otherwise stated. SBP, systolic blood pressure; HDL, 
high-density lipoproteins; LDL, low-density lipoproteins; BMI, body mass index; ACR, 
Albumin/creatinine ratio; CRP, C-reactive protein; eGFR, estimated glomerular filtration 
rate.  
a % (n)  
b Geometric mean (95% CI) 
c ACR 3.4-33 g/mol 
d ACR ≥ 34 g/mol 
e Dyslipidaemia was defined by a previous diagnosis of high cholesterol, taking cholesterol 
management medication or had a total cholesterol ≥ 5.5 mmol/L or HDL < 1.0 mmol/L 
f Hypertension was defined if the participant had a previous diagnosis of hypertension in their 
health records, was taking antihypertensive medication or had elevated levels in the baseline 
examination (≥ 140mmHg systolic, ≥ 90mmHg diastolic) 
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Results 
A total of 1187 participants over 15 years old with HbA1c measurements were included in 
the analysis. Sixty seven (6%) had an HbA1c greater than or equal to 6.5% (48 mmol/mol), 
but had no record of diagnosis or management of diabetes, while 158 (13%) participants had 
a prior diagnosis of diabetes. A further 195 participants were identified as high risk for 
developing type 2 diabetes using the IEC (International Expert Committee) 6.0% (42 
mmol/mol) cut-off and up to 568 (48%) participants by the ADA criteria of 5.7-6.4% (39-46 
mmol/mol). Participants with known diabetes had HbA1c levels at time of screening between 
4.9% (30 mmol/mol) and 15.6% (147 mmol/mol). Sixty of the 158 participants with known 
diabetes (38%) had an HbA1c level between 6.5% (48 mmol/mol) and 8.5% (69 mmol/mol), 
and 133 (84%) of known diabetes patients were taking hypoglycaemic medication. Eighty 
seven participants with known diabetes (55%) had an HbA1c level >7.5% (59 mmol/mol). 
Table 3.2. Characteristics of a remote Indigenous Australian community over 15 years old 
stratified by HbA1c categories 
 Without a prior diabetes diagnosis With a prior 
diagnosis of 
diabetes 
  
 < 5.7 % 5.7-5.9 % 6.0-6.4 % ≥ 6.5 % 4.9-15.6 % p-value 
n (%) 420 347 195 67 158  
Age 27 (21-34) 31 (23-39) 39 (29-47) 39 (32-53) 48 (40-55) <0.001 
Men, % 64 59 48 42 34 <0.001 
HbA1c, % 5.5 (5.3-5.6) 5.8 (5.7-5.9) 6.1 (6.0-6.2) 6.9 (6.7-7.8) 8.0 (6.6-9.8) <0.001 
SBP, mmHg 115 (105-125) 118 (107-128) 120 (109-132) 123 (112-133) 123 (112-141) <0.001 
Cholesterol, mmol/L 4.6 (3.9-5.2) 4.7 (4.1-5.4) 4.7 (4.0-5.5) 4.9 (4.1-5.9) 4.7 (4.0-5.4) 0.569 
HDL chol, mmol/L 1.3 (1.1-1.5) 1.3 (1.1-1.5) 1.2 (1.0-1.5) 1.1 (0.9-1.3) 1.2 (1.0-1.3) <0.001 
LDL chol, mmol/L 2.5 (2.0-3.1) 2.6 (2.1-3.2) 2.6 (2.0-3.2) 2.5 (1.8-3.2) 2.2 (1.8-3.0) 0.213 
BMI, kg/m2 20.5 (18.6-24.8) 21.2 (19.0-25.0) 24.2 (21.2-28.6) 27.1 (23.0-31.7) 27.5 (23.0-31.7) <0.001 
Waist, cm 81 (73-90) 83 (74.4-93) 93 (83-102) 99 (92-109) 102 (93-111.3) <0.001 
ACR, g/mol b 1.37 (0.8-5.0) 1.74 (0.8-6.3) 4.50 (1.5-17.7) 11.68 (2.3-48.3) 31.29 (5.8-101.9) <0.001 
Triglycerides, mmol/L b 1.2 (0.9-1.8) 1.3 (0.9-2.0) 1.7 (1.3-2.5) 2.8 (2.0-4.0) 2.5 (1.7-3.3) <0.001 
CRP, mg/L b 4 (2-7) 5 (2-9) 7 (4-13) 10 (5-17) 10 (6-16) <0.001 
eGFR, mL/min/1.73m2 b 114.2 (102-124) 112.5 (100-122) 104.8 (91-118) 105.5 (92-117) 94.3 (82-109) 0.900 
Current smoker, % 74 74 70 70 64 0.140 
Microalbuminuria, % c 23 27 38 40 34 <0.0001 
Macroalbuminuria, % d 6 7 19 27 47 <0.0001 
Hypertension, % e 15 20 34 40 67 <0.0001 
Dyslipidaemia, % f 30 37 57 69 80 <0.0001 
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Number of clinic visits in 
previous 12 months 
      
High (>15) a 10.2 (43) 14.4 (50) 21.5 (42) 20.9 (14) 34.8 (55) <0.0001 
Moderate (5-15) a 35.7 (150) 34.5 (130) 41.5 (81) 52.2 (35) 42.4 (67) <0.0001 
Low (<5) a 54.0 (227) 48.1 (167) 36.9 (72) 26.9 (18) 22.8 (36) <0.0001 
CVD History a 2.9 (12) 2.6 (9) 8.2 (16) 9.0 (6) 12.0 (19) <0.0001 
Median (25th-75th percentiles) unless otherwise stated. SBP, systolic blood pressure; HDL, 
high-density lipoproteins; LDL, low-density lipoproteins; BMI, body mass index; ACR, 
Albumin/creatinine ratio; CRP, C-reactive protein; eGFR, estimated glomerular filtration 
rate.  
a % (n)  
b Geometric mean (95% CI) 
c ACR 3.4-33 g/mol 
d ACR ≥ 34 g/mol 
e Dyslipidaemia was defined by a previous diagnosis of high cholesterol, taking cholesterol 
management medication or had a total cholesterol ≥ 5.5 mmol/L or HDL < 1.0 mmol/L 
f Hypertension was defined if the participant had a previous diagnosis of hypertension in their 
health records, was taking antihypertensive medication or had elevated levels in the baseline 
examination (≥ 140mmHg systolic, ≥ 90mmHg diastolic) 
 
Table 3.1 details the demographics of the total population over 15 years old in this remote 
Indigenous community. About 54% of our study participants were men and there was a high 
prevalence of smoking (72%), microalbuminuria (29%), macroalbuminuria (15%), 
hypertension (28%) and dyslipidaemia (45%) in this community. Sixty-two participants 
(5.2%) had a cardiovascular event prior to their health examination. Table 3.2 shows the 
baseline characteristics by HbA1c categories. As expected, that those at higher risk of 
diabetes tended to be older. Women made up a larger proportion of the higher HbA1c groups 
and a lower proportion of the lower HbA1c groups. There was a direct relationship of 
categories of HbA1c with several cardiovascular risk markers, such as systolic blood 
pressure, body size, triglycerides, C-reactive protein and an inverse association with HDL 
cholesterol levels. The prevalence of microalbuminuria, macroalbuminuria, dyslipidaemia 
and hypertension were also higher in groups with higher HbA1c.  A larger proportion of 
participants from the higher HbA1c categories visited the local clinic a high or moderate 
number of times compared to the lowest HbA1c group. Odds ratios in Table 3.3 also show 
that participants in the higher HbA1c groups were more likely to show indicators of risk than 
those in the lowest HbA1c % group. Figure 3.1 highlights that participants with higher 
HbA1c had higher numbers of cardiovascular disease risk factors. Over 75 % of the 
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participants in the 6.0-6.4% (42-46 mmol/mol) HbA1c group had 2 or more cardiovascular 
risk factors, compared with 90% for participants in the ≥6.5% (48 mmol/mol) HbA1c group. 
Over 95% of participants with known diabetes had 2 or more cardiovascular risk factors, with 
nearly half (49%) having 4 or more risk factors. 
Table 3.3. Odds Ratios (OR) of comorbidities for participants with and without a prior 
diabetes diagnosis stratified by HbA1c % categories 
  Without a prior diabetes diagnosis With a prior diagnosis 
of diabetes 
  <5.7 5.7 - 5.9 6.0-6.4 ≥ 6.5 4.9 - 15.6 
 n OR OR 95% CI OR 95% CI OR 95% CI OR 95% CI 
Microalbuminuria d           
Unadjusted 989 1 1.31 (0.94-1.82) 2.65 (1.80-3.91) 4.28 (2.28-8.03) 5.81 (3.48-9.68) 
Age and sex Adjusted 989 1 1.10 (0.78-1.55) 1.73 (1.14-2.62) 2.28 (1.16-4.47) 2.22 (1.25-3.95) 
Final Model a 981 1 1.06 (0.75-1.51) 1.53 (0.99-2.34) 1.89 (0.94-3.80) 1.76 (0.95-3.26) 
Macroalbuminuria d           
Unadjusted 823 1 1.23 (0.70-2.19) 4.76 (2.74-8.28) 10.25 (4.81-21.81) 28.58 (15.89-51.41) 
Age and sex Adjusted 823 1 0.91 (0.50-1.65) 2.81 (1.55-5.09) 5.07 (2.25-11.41) 10.27 (5.30-19.93) 
Final Model a 814 1 1.01 (0.53-1.90) 1.97 (1.02-3.83) 3.14 (1.26-7.82) 6.05 (2.86-12.77) 
Hypertension e           
Unadjusted 1187 1 1.43 (0.98-2.08) 2.97 (1.99-4.42) 3.83 (2.19-6.68) 11.55 (7.54-17.69) 
Age and sex Adjusted 1187 1 1.14 (0.76-1.71) 1.79 (1.14-2.81) 1.82 (0.96-3.45) 4.84 (2.92-8.03) 
Final Model b 1159 1 1.12 (0.73-1.71) 1.34 (0.82-2.17) 0.97 (0.48-1.95) 2.86 (1.66-4.95) 
Dyslipidaemia f           
Unadjusted 1187 1 1.36 (1.01-1.84) 3.08 (2.17-4.38) 5.11 (2.93-8.92) 9.19 (5.91-14.27) 
Age and sex Adjusted 1187 1 1.22 (0.90-1.67) 2.38 (1.64-3.46) 3.51 (1.95-6.30) 5.27 (3.23-8.58) 
Final Model c 1183 1 1.21 (0.88-1.66) 1.97 (1.34-2.90) 2.37 (1.29-4.34) 3.34 (1.99-5.60) 
Number of clinic visits 
in previous 12 months 
          
High (>15) g           
Unadjusted 717 1 1.58 (1.00-2.48) 3.10 (1.87-5.11) 4.07 (1.88-8.80) 8.72 (5.08-14.98) 
Age and sex Adjusted 717 1 1.35 (0.84-2.17) 1.94 (1.12-3.35) 1.94 (0.84-4.48) 3.48 (1.86-6.49) 
Final Model a 705 1 1.52 (0.94-2.46) 1.83 (1.04-3.24) 2.25 (0.91-5.59) 2.47 (1.25-4.88) 
Moderate (5-15) g           
Unadjusted 976 1 1.17 (0.86-1.60) 1.71 (1.17-2.50) 2.92 (1.59-5.34) 3.05 (1.91-4.85) 
Age and sex Adjusted 976 1 1.10 (0.80-1.50) 1.42 (0.96-2.12) 2.10 (1.11-3.95) 1.95 (1.16-3.30) 
Final Model a 965 1 1.13 (0.82-1.55) 1.42 (0.95-2.13) 2.52 (1.26-4.99) 1.96 (1.12-3.41) 
OR, odds ratio;  
a Age, sex, systolic blood pressure, waist circumference, total cholesterol, HDL cholesterol, 
current smoking status and hypertensive medication were included in the final model 
b Age, sex, waist circumference, total cholesterol, HDL cholesterol and current smoking 
status were included in the final model 
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c Age, sex, systolic blood pressure, waist circumference, current smoking status and 
hypertensive medication were included in the final model 
d Compared with participants with normal ACR levels (< 3.4) 
e Hypertension was defined if the participant had a previous diagnosis of hypertension in their 
health records, was taking antihypertensive medication or had elevated levels in the baseline 
examination (≥ 140mmHg systolic, ≥ 90mmHg diastolic) 
f Dyslipidaemia was defined by a previous diagnosis of high cholesterol, taking high 
cholesterol management medication or had a total cholesterol ≥ 5.5 mmol/L or HDL < 1.0 
mmol/L 
g Compared with participants with low number of clinic visits in previous 12 months (< 5) 
 
 
 
 
Figure 3.0.1.  The number of cardiovascular risk factors identified in participants with and 
without a prior diabetes diagnosis by HbA1c categories. The number of cardiovascular risk 
factors was the sum of the following possible risk factors: micro/macro albuminuria, 
hypertension, dyslipidaemia, current smoker and high WC. 
* Participants without a prior diagnosis of diabetes 
** Participants with a known diabetes diagnosis  
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Discussion 
The screening results of glycosylated haemoglobin levels in this remote Indigenous 
Australian community highlights the significant burden of diabetes, risk for diabetes and 
cardiovascular risk factors force on this population. HbA1c screening of people not 
previously diagnosed with diabetes identified a significant proportion (6%) of people living 
with HbA1c levels over the cut-off recommendations for diabetes diagnosis of ≥6.5% (48 
mmol/mol) recommended by WHO and Marley et al. [74, 139]. Over half of all non-diabetic 
participants were at high risk of developing diabetes according to the ADA specifications 
(5.7-6.4% (39-46 mmol/mol) HbA1c) [72]. Participants in the higher HbA1c categories had 
the highest rates of albuminuria, dyslipidaemia, hypertension and had the highest number of 
cardiovascular risk factors.  
To our knowledge this is the first and largest community-wide HbA1c screen conducted in 
remote Indigenous Australians.  It is also the first demonstration of an association of HbA1c 
with cardiovascular risk factors in non-diabetic Indigenous Australians. We have shown that 
almost half (44 %) of this community over 15 years old, based on the 2006 Census 
population estimate, either had diabetes or was at high risk of developing diabetes, and with a 
significant number of comorbid cardiovascular risk factors. This proportion is similar to that 
observed in high-risk African American and Latino populations in the US [145]. However is 
much higher than the hospital burden, burden of diabetes complications and 
incidence/prevalence of diabetes in Aboriginal Australia indicate [2, 46, 50]. Such a high 
proportion of Indigenous Australians living with a high risk of diabetes and other coexisting 
CVD risk factors presents a substantial challenge. 
This study has identified that a large number of participants in this remote community (29%) 
were only captured as high risk for diabetes using the ADA cut-off point 5.7-5.9%. Over half 
of this group had 2 or more cardiovascular risk factors as shown in Figure 3.1, however the 
odds ratios in Table 3.3 suggest their HbA1c level did not elevate their risk of CVD risk 
markers. The ADA guidelines used the cut-off of 5.7% due to its high positive predictive 
value (equivalent to 100mg/dL fasting glucose) to identify people at high risk for later 
development of diabetes and the effective prevention of diabetes in people targeted between 
5.5-6.0%, according to the Diabetes Prevention Program (DPP) [72]. In the Indigenous 
Australian context, this study confirms there are a significant portion of participants who may 
benefit from diabetes prevention initiatives at this point of the diabetes risk continuum. 
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Interventions to control the limited existing cardiovascular risk markers in this group may 
provide the best opportunity to identify high risk individuals and prevent the development of 
diabetes in remote Indigenous populations such as this.  
The findings of this study also suggest an increased level of systemic inflammation as risk for 
diabetes increases, indicated by higher levels of circulating C-reactive protein in the higher 
HbA1c categories. This is consistent with previous findings suggesting a potential role of 
systemic inflammation in insulin resistance and glucose intolerance [146, 147]. Wu et al 
suspected hyper reaction of the innate immune system as a potential explanation for their 
observed association of elevated CRP with higher HbA1c, however could not confirm this 
mechanism [147]. The present study did not investigate the underlying mechanism of the 
association; however supports further investigation of this potential role within the 
Indigenous Australian population.  
These findings suggest that HbA1c screening might identify those at high risk of diabetes in 
many other urban and remote Indigenous Australian communities. The World Health 
Organisation recognises the strength of HbA1c in screening for diabetes, however it suggests 
a worldwide rollout of the screening is largely limited by the resource difficulties for 
developing nations to establish standardised practice [74]. This study recognises Australia as 
a developed nation with the resources to conduct relative cost-effective and standardised 
HbA1c screening in high risk populations, however a systematic cost-benefit analysis is yet 
to be undertaken [148]. Early detection, delayed progression and prevention of diabetes are 
high priority areas in Australia and this study has identified HbA1c screening as a useful tool 
in this remote Indigenous Australian community. 
The introduction of item 715 (Medicare health assessment for Aboriginal and Torres Strait 
Islander people) into the Medicare Benefits Schedule (MBS) by the Australian government 
was designed to encourage regular repeated testing of Aboriginal adults for the early 
detection and intervention for conditions that cause morbidity and early mortality [149], and 
it is applied with increasing frequency and regularity in many Indigenous health care settings.  
The findings of this study encourage the movement towards incorporating HbA1c screening 
as part of these health assessments [74]. Furthermore, in November 2014, funding for 
laboratory HbA1c testing was included in the MBS for individuals at high-risk of diabetes, 
which significantly increases the opportunity for clinicians to monitor HbA1c in this setting 
[150]. HbA1c can be measured from a standard blood sample without the need for patient 
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fasting or consumption of glucose loads, making it a much more convenient test than oral 
glucose tolerance and fasting plasma glucose tests [77].  
The findings of this study suggest HbA1c may be useful in detecting risk of diabetes and 
cardiovascular risk factors in the primary health care setting. This evidence encourages the 
adoption of HbA1c screening as an effective initiative to monitor risk for diabetes. Further 
research is needed, however, to assess the specific clinical HbA1c cut-off points for diagnosis 
of diabetes in remote Indigenous Australians. This study also confirms the need for repeated 
testing throughout life, to detect cases of diabetes or prediabetes as they emerge with 
increasing age [40].  
The high number of clinic visits in the higher HbA1c groups can be interpreted in two ways. 
It may suggest that those at high risk for diabetes and with a high number of cardiovascular 
risk factors are accessing the medical treatment that they require and are under consistent 
monitoring, which is very positive from a perspective of access to health care for high risk 
populations [47]. The high clinic visits could also be interpreted that individuals with high 
risk for diabetes and cardiovascular disease are a significant burden on the health care system 
in these remote Indigenous communities, which should be addressed. If high numbers of 
clinic visits in these remote communities are related to chronic disease risk factors, there may 
be an opportunity to relieve the primary health care system by targeting health promotion 
initiatives at early prevention of chronic diseases.  
There are limitations of this study which must be acknowledged before generalising these 
findings to other populations. The wide confidence intervals surrounding the odd ratios 
reported in Table 3.3 suggest a high level of uncertainty of the association. There were 
difficulties interpreting the data due to the significant variation of age and gender amongst the 
HbA1c groups and small sample size. We acknowledge that HbA1c may not be suitable to 
independently predict microalbuminuria, macroalbuminuria, dyslipidaemia and hypertension 
and that it has not yet been evaluated for this role.  However, this study’s findings suggest 
utilising HbA1c to screen for diabetes and risk for diabetes is a suitable test which captures a 
high proportion of individuals who have these comorbidities and cardiovascular risk factors. 
This study recognises that diabetes development occurs on a continuum and that categories 
for high risk of diabetes do not necessarily represent an exact point of higher clinical risk to 
diabetes. The HbA1c groups simply allow a more convenient way to categorise the 
population for health promotion interventions. Another limitation of this study is that we did 
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not have information on fasting plasma glucose or 2-h oral glucose tolerance tests to 
determine the sensitivity, specificity and ROC curves of HbA1c screening compared to these 
previous methods. The use of HbA1c is warranted in this setting as a previous study found 
that HbA1c was significantly more likely to determine a diabetes diagnosis than blood 
glucose tests in other remote Indigenous communities [78]. Finally, we had to rely on 
existing literature to guide our HbA1c definitions of diabetes and high-risk of diabetes. 
 
Conclusion 
Glycosylated haemoglobin screening of people not known to have diabetes in this remote 
Indigenous Australian community identified a high proportion of the population at high risk 
of developing or with diabetes using definitions in the literature. HbA1c screening in 
Australian remote communities is a convenient blood test which has the ability to detect 
individuals at high risk of diabetes earlier and who may already be suffering from a 
significant number of comorbid cardiovascular risk factors.  
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Chapter 4 – Birth weight 
4.1 Literature Review 
In addition to HbA1c, many potential chronic disease risk factors have been investigated in 
the existing scientific literature. Some researchers have hypothesised that early life risk 
factors may predispose people to chronic diseases and one such risk factor has been birth 
weight (BW). Birth weight is defined as the first weight of the fetus or newborn obtained 
after birth, usually within the first hour of birth. BW is easy to measure, does not require 
sophisticated equipment or expertise, is reliable and reproducible. There has been a lot of 
focus in general populations investigating the association between BW and an individual’s 
risk of developing chronic diseases. The following chapters will present the prevalence of 
low birth weight babies specifically in Indigenous Australian populations, review existing 
literature assessing the association between BW and CVD and expose opportunities where 
future research is needed.  
4.1.1 Indigenous Australian birth weight 
The World Health Organisation estimates, using epidemiological evidence, a child born of 
low birth weight (LBW) anywhere in the world is 20 times more likely to die prematurely 
than normal birth weight babies [151]. In Australia, Indigenous mothers are over 2.5 times 
more likely to give birth to a LBW baby than non-Indigenous mothers [152]. The Northern 
Territory experiences the worst rates of LBW (15.6%) compared to overall Indigenous 
(10.1%) and non-Indigenous (4.6%) Australians [152]. A greater proportion of NT babies are 
born LBW compared to all other states in Australia [153]. NT also had the lowest mean BW 
in Australia [152, 153]. Studies show LBW incidence in some remote Indigenous Australian 
communities are similar, if not, worse than that of the least developed nations in the world 
[151, 154].  
Figure 4.1 shows a reduction in LBW rates in Indigenous Australians in the last decade. 
Trend data, between 2000 and 2011, shows an average yearly rate decrease of 0.1 LBW 
babies per 100 live births, which equates to a 9 % reduction [152].   
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Figure 4.0.1 Low birthweight among liveborn singleton babies, by Indigenous status of the 
mother, selected jurisdictions (a), 2000 to 2011. [152] 
(a) Excludes data for Tasmania and the Australian Capital Territory as these data are not 
considered stable enough to be included in trend analyses. 
Reproduced with permission from AIHW 
The median birth weights and LBW rates of Indigenous Australian communities have 
undergone dramatic transitions in the past four decades. Previous studies have shown that 
LBW rates have significantly decreased in the Tiwi community from 39% in the 1950s to 
22.5% in the 1980s (Table 4.2) [155]. Data from the second screening examinations of the 
Tiwi community highlight the LBW rate has reduced further to 18% in the 1990 and 2000s 
(unpublished). This is a significant reduction and one that will continue as we observe the 
effects of improved health service delivery and health care.  
Table 4.1. Summary of birthweight data by birth interval for the entire study cohort of 995 
people for whom birthweights were recorded [155] 
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4.1.2 Developmental Origins of Health and Disease (DOHaD) 
The DOHaD paradigm relates to a large body of work from around the world demonstrating 
that adverse events during fetal life have profound effects on the risk of developing certain 
diseases later in life. Furthermore, the poor health and development of one generation may be 
linked to the compromised health and development of earlier generations. 
Epidemiological evidence as early as 1934 describes environmental conditions, infant 
mortality and adult health in Sweden and Britain [156, 157]. The Dutch Hungerwinter of 
1944-45 showed that obesity in young men and rates of high two hour blood glucose were 
higher in those whose mothers experienced rationing during pregnancy [158]. From Norway, 
Forsdahl, in 1977-78, reported a relationship between poor living conditions in childhood and 
adult heart disease and associated risk factors [159, 160]. Research by Barker and his 
colleagues furthered the notion that a poor health in early life is associated with adverse 
health outcomes in later life. Barker’s original observations, based in England and Wales, 
demonstrated that regions with high rates of infant mortality also had high rates of CHD 
mortality in later decades [161-164]. Barker and colleagues have since published widely on 
the inverse association between birth size and later chronic disease development [158, 161-
193].  
Early studies that reported links between intrauterine life and later disease were met with 
criticisms of validity. Inconsistencies related to various exposures, often showing highly 
significant relationships, were a common criticism of Barker’s earlier work [167, 170]. 
Participant loss over many decades has raised concerns of selection bias [194], particularly if 
the association between exposure and outcome was different in those followed up compared 
to those lost [195]. The association between people with LBW and childhood or adult disease 
is also somewhat confounded by socio-economic status (SES) and lifestyle risk factors [196, 
197]. Lower SES and increased lifestyle risk factors are associated with being born of low 
weight, consequently LBW may be simply a surrogate of SES [198]. Controlling for these 
confounders has not necessarily reduced the significance in the association between low birth 
weight children and adults and their subsequent chronic disease risk [199-201].  
Studies have reported contrary evidence to the developmental origins hypothesis [202-206]. 
A population-based survival analysis of people from the 1866-1868 Finnish Famine 
identified no increased mortality in people exposed to the serious and prolonged malnutrition 
period of the Famine [204]. However, there was the potential for selection bias of the control 
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groups. The participants in the control groups were selected from births in a period following 
the Famine, which suggests survival is likely to be related to factors such as fitness, social 
class, and education, in which are likely predictive of longevity [204]. Additionally, the study 
was limited and unable to identify cause-specific mortality. Stanner and colleagues 
investigated the association between in utero malnutrition and diabetes and coronary heart 
disease in adulthood in a smaller sample from the Leningrad siege study [206]. The study 
reported intrauterine malnutrition was not associated with glucose intolerance, dyslipidaemia, 
hypertension, or cardiovascular disease in adulthood, however the sample size may have 
contributed to this finding. Furthermore, this cross-sectional analysis could not obtain reliable 
data on birth weight, thus exposure to siege was used as a surrogate marker of maternal 
nutrient intake, which may limit the generalisability of the findings.  
4.1.3 Birth weight and cardiovascular disease 
Before the DOHaD paradigm however, Barker hypothesized that birth size was associated 
with cardiovascular disease, diabetes and insulin resistance risk in adulthood. Barker et al 
observed that regions of the United Kingdom with high rates of infant mortality also had high 
rates of cardiovascular mortality in later decades [153]. Landmark studies based in Sheffield 
and Hertfordshire showed an association between coronary heart disease mortality and low 
size at birth [154, 161]. Many studies have now demonstrated an association between size at 
birth and various risk factors for cardiovascular disease and the metabolic syndrome in males 
and females, of varying age and ethnicity and socio-economic status [151, 155, 159, 161, 
167, 169, 170, 178, 179]. 
The Fetal Origins hypothesis suggested fetal undernutrition in middle to late gestation, which 
leads to disproportionate fetal growth, programmed coronary heart disease later in life. The 
inverse relationship between BW and CHD in the Hertfordshire cohort provided the basis of 
the Fetal Origins/Barker hypothesis [164, 166, 207]. More recently, several studies have 
confirmed that LBW is associated with greater risk of CHD development in adulthood [175, 
185] independent of parental and adulthood socio-economic status, BMI and traditional 
cardiovascular risk factors [196, 199-201, 208]. A review of 18 previous studies by Huxley et 
al confirmed the association between those born of LBW and CHD for both men and women 
independent of BMI and measures of socio-economic status at either birth or during adult life 
[209]. Common CHD risk factors have been shown to be inversely related to BW in later life.  
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As an indication of cardiovascular disease, early work by Barker and colleagues [167] 
suggested that blood pressure (BP) was inversely related to BW and positively to placental 
weight. Since then, several reviews have described an inverse relationship between BW and 
BP across age [210, 211]. In the most recent review, over 440,000 males and females from 
various ethnicities were considered appropriate for analysis. A 1kg increase in BW was found 
to be associated with a lower SBP by approximately 2mmHg across all participants, but more 
specifically, a reduction of 2-3mmHg and 2-4mmHg in children/adolescents and adults 
respectively [210]. Unlike Barker’s early work, various other birth outcomes showed little or 
no consistency in relation to later blood pressure [210].  
In addition to associations found between BW and BP in adults, the association has been 
popularly studied in children. The use of younger populations to infer adult risk of high BP 
and CVD was justified as childhood blood pressure has been identified as a strong predictor 
of adult BP [212], coronary artery calcifications in young adults [213] and clinically 
significant coronary artery disease in adult life [214]. However recently, studies have been 
reporting conflicting results on the relationship of birth weight and blood pressure in younger 
populations.  
An inverse association between childhood BP and birth weight is the most common 
association reported. Several studies [215-220] suggest there is an increase in blood pressure 
as birth weight decreases, but there are recent studies suggesting there is either a positive or 
no association [221-227]. Several meta-analyses and systematic literature reviews have 
attempted to explain these differences and the three primary trends appear to be due to 
differences in populations, differences of analysis classifications and differences in adjusting 
for confounding variables [210, 228, 229]. 
Many of the populations exhibiting a positive or no association had either a lower number of 
participants [222, 226], conducted in younger children [221], or conducted in post-pubertal 
adolescents [227]. Post-pubertal populations or those close to puberty-age make it difficult 
for analysis and accurate adjustment, due to the inconsistent age and characteristics of 
puberty for each individual. The use of standardization for age, height and gender BP is 
highly recommended due to differences in the populations investigated [229], however many 
studies used absolute BP. This also complicates the ability to compare results among studies.  
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The BW and CVD association has been well established in general populations throughout 
the world, however evidence is scarce for Indigenous Australians. The inverse relationship 
between BW and blood pressure has been described in the Australian Aboriginal setting by 
Singh and Hoy in 2003 [154]. A cross-sectional analysis found a 1kg increase in BW was 
associated with a 2.9mmHg reduction in systolic blood pressure (SBP) while the risk of 
hypertension was elevated in LBW adults. Singh and Hoy found an association between BW 
and BP and BW and albuminuria, which inferred an increased risk for CVD [154]. A further 
investigation by Hoy et al found an inverse association between BW and mortality in this 
same remote Indigenous Australian community [155]. The association between BW and 
CVD deaths was not statistically significant, likely due to small sample size and low number 
of CVD deaths, however a significant association was found when they combined CVD and 
respiratory deaths as a single outcome. While Singh and Hoy were the first to identify this 
association in an Indigenous Australian adult population, the direct relationship with CVD 
development in adult life still requires further investigation [154]. Reported of direct 
relationships rather than relying on inferences, provides stronger evidence for health 
promotion initiatives in the community targeting the prevention of cardiovascular disease.  
4.1.2.1 Adjusting and confounding variables 
There has also been some debate over the use, or lack thereof, adjusting variables. Many 
studies have been criticized for failing to adjust for socio-economic and parental factors 
[229], however the main factor in question is the adjustment of current weight. Many studies 
that did not adjust for current weight failed to show an inverse relationship between birth 
weight and blood pressure [228]. The proposed explanations for these findings have been 
based on the ‘reverse paradox principle’, referring to the potential reversal of an association 
between two variables when the third etiologic variable is introduced into the regression 
model [224].  
A recent publication questioned the appropriateness of adjusting for current weight and the 
units used [230]. Wang suggested a comparison of the magnitude of the association of blood 
pressure with BW and current weight is often misleading due to comparing the risk of 
increased blood pressure per 1 kg increase. A one kilogram increase in BW is much more 
significant than a one kilogram increase in current weight [230]. The study also suggests that 
adjusting for current weight in adulthood makes the mathematical assumption that an increase 
in BW does so, independently without an increase in current weight, which is unlikely. There 
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is significant evidence showing the strong and positive association between BW and current 
weight [183, 231-234]. The association between BW and being overweight has also been 
described as positive for early adolescents, young male adults and older adults [235-237].  
A common phenomenon is the cumulative effect of fetal growth restriction and rapid later 
growth (typically in youth) on subsequent chronic disease risk. The concept of catch up 
growth is used to describe the upward crossing of projected growth centiles such that the 
small for gestational age (SGA) baby grows beyond its set trajectory. In epidemiological 
studies, rapid weight gain has been shown to further increase the subsequent disease of those 
adults born SGA [175, 176]. There is little controversy that catch up growth may influence 
adult disease risk [177], rather, the concept has been comprehensively demonstrated for CVD 
in general populations [168, 173, 174, 196, 210, 238-240]. This phenomenon is yet to be 
understood in Indigenous populations. 
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Chapter 5 – LBW and CVD 
 
The following chapter is a published article in which evidence is provided for the association 
between BW and long term development of cardiovascular disease in this remote Indigenous 
Australian community. Previous research conducted by Wendy Hoy’s team suggested BW is 
associated with CVD risk factors such as albuminuria and elevated blood pressure [66, 154]. 
The following chapter provides evidence for the relationship of BW with the symptomatic 
development and financial burden of cardiovascular disease as indicated by hospitalisations. 
The following chapter addresses Research Questions 4 and 5, as proposed in Chapter 1.2.2. 
 
5.1 Original Research article published in the Australian and New Zealand Journal of 
Public Health 
Arnold, L.W., Hoy, W.E. and Wang, Z. Low birth weight increases risk for cardiovascular 
disease hospitalisations in a remote Indigenous Australian community – A prospective cohort 
study. (2015). Aust N Z J Public Health, doi: 10.1111 /1753-6405.12426 
Low birth weight increases risk for cardiovascular disease hospitalisations in a remote 
Indigenous Australian community – A prospective cohort study 
Luke W Arnold, Wendy E Hoy and Zhiqiang Wang  
Abstract 
Objectives: To investigate the association between low birth weight (LBW; <2,500 grams) 
and cardiovascular disease (CVD) hospitalisations in adult life in a remote Indigenous 
Australian community. 
Methods: This was a prospective cohort of 852 participants with recorded birth weight using 
community-wide health screening examinations conducted between 1992-1999 and 
hospitalisation records up to 2012. Cox proportional hazard models assessed the association 
between LBW and hypertension, major CVD (heart failure, myocardial infarction and stroke) 
and any CVD hospitalisations. 
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Results: There were 236 (28 %) participants who had a low birth weight. The LBW group 
had a higher risk of developing any CVD (HR = 1.43, 95%CI 1.01-2.03), major CVD (HR = 
1.51, 95%CI 0.93-2.47) and hypertension (HR = 1.83, 95%CI 1.09-2.96) than the normal 
birth weight (NBW) (≥2,500 g) group. Women with LBW had over 2.6 times the risk of a 
hospitalisation associated with hypertension compared to their NBW counterparts (HR = 
2.61, 95%CI 1.38-4.93), but this relationship was not seen in men. 
Conclusions and Implications: LBW increased the risk of cardiovascular disease 
hospitalisations in adult life in this group. Further CVD prevention initiatives should continue 
to include LBW as a key predictor of CVD in this community. The mechanisms of gender 
influence on the hypertension relationship are unknown and require further investigation in 
Indigenous populations worldwide. 
 
Keywords 
Birth weight; hypertension; Indigenous Australians; cardiovascular disease; adult 
 
Introduction 
The fetal origins hypothesis suggests there are intrauterine mechanisms influencing fetal 
development which have health consequences later in life [241]. The literature supports 
associating birth weight (BW) with cardiovascular risk factors [173, 242, 243] and renal 
complications [243] throughout their childhood years and onwards to adult life. These risk 
factors lead to some of the major chronic diseases in Australia; cardiovascular disease 
(CVD), chronic kidney disease (CKD) and type 2 diabetes (T2D). The high prevalence of 
these chronic diseases largely attribute to the disparity in life expectancy between Indigenous 
and non-Indigenous Australian men and women [12]. 
This connection between birth weight and chronic disease development is a concern for all 
those interested in improving health equality for Indigenous Australians. Indigenous mothers 
are over 2.5 times more likely to give birth to a low birth weight (LBW; less than 2,500 
grams) baby than non-Indigenous mothers in Australia [152]. The Northern Territory 
experiences the worst rates of LBW (16%) compared to overall Indigenous (10.1%) and non-
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Indigenous (4.6%) Australians. Furthermore, the incidence of LBW infants in some remote 
Indigenous Australian communities are similar, if not, worse than that of the least developed 
nations in the world [151, 154]. The WHO further estimates, using epidemiological evidence, 
a child born of LBW anywhere in the world is 20 times more likely to die prematurely than 
normal birth weight  babies [151]. 
There is a large quantity of literature to suggest LBW increases the risk of developing 
hypertension in adult life as proposed by Barker et al [244] and a further abundance of 
literature supports the importance of LBW for the actual development of cardiovascular 
diseases [209]. Singh and Hoy [154] identified the inverse association between BW and 
blood pressure (BP) in an Indigenous Australian remote community. Although the association 
between BW and CVD risk factors such as albuminuria, lipids and blood pressure has been 
investigated [245],  the relationship between BW and actual CVD development has not been 
investigated in any Indigenous population worldwide. 
This study aims to quantify the risk of a cardiovascular hospitalisation if an infant is born of 
LBW within a remote Indigenous Australian community.  
 
Methods 
This is a prospective cohort study of subjects who participated in baseline examinations 
conducted between 1992 and 1999, where community-wide health screening exams were 
conducted with individuals of a remote Northern Territory Indigenous Australian community. 
The health screening examinations were a part of a broader screen investigating the high rates 
of chronic disease and premature mortality in a remote Indigenous Australian community. 
Standardised screening exams were offered to the entire community and were conducted by 
trained staff. Participants volunteered with written informed consent for clinical examination, 
biological testing and use of their medical records under National Health and Medical 
Research Council (NHMRC) grant 921134 and approval of the Human Research Ethics 
Committee, Menzies School of Health Research, Darwin, Northern Territory (Appendix 1). 
The methods of the health screening exams are detailed elsewhere (Appendix 2) [246]. 
Information on several chronic disease risk factors was collected such as blood pressure, 
anthropometric measurements, triglycerides, cholesterol, use of tobacco and alcohol, and 
their medical records were reviewed. Tobacco and alcohol use at the time of the examination 
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was asked of all participants over 18 years of age as a dichotomous yes/no request. The 
review of medical records enabled identification of diabetes status and birth weight 
measurements.  
Participants were included in the analysis if they fitted the following inclusion criteria; i) 
were over 18 years old at baseline or became over 18 during the follow-up period, ii) were 
born to an aboriginal mother iii) had birth weight data available, iv) participated in the health 
screening examination and v) resided in and was a member of the remote Aboriginal 
community studied.  
Of the 884 participants with birth weight information, 32 participants did not reach adulthood 
(≥18 years of age) during the 20 year follow up period and were hence excluded from the 
analysis. A further 3 participants were excluded from the hypertension analysis because their 
hypertension hospitalisation was pregnancy-related to reduce overrepresentation of women 
and the risk of a gender bias. A total of 852 participants were included in the cardiovascular 
hospitalisations analysis and 849 included in the hypertension hospitalisations analysis.  
All births occurred in a local mission health clinic or in the regional Royal Darwin Hospital. 
Deliveries, the tribal or community assignment of the mother, the mothers name and birth 
weight were recorded in log books. The retrieved birth weights occurred between February 
1956 and December 1998. Further details of obtaining and measuring birth weight 
information are described elsewhere (Appendix 2) [155].  
Hospitalisation data was matched to health screening examinations using participant 
identification numbers. We subsequently identified the first event of each outcome 
(hypertension, any CVD or major CVD) recorded during a hospitalisation in the 20 year 
follow-up period. These hospitalisation records included any admissions and emergency 
department visits for all patients who presented to a public hospital in the Northern Territory 
between 1992 and 2012.   
To identify hypertensive cases, we filtered patient hospitalisation records using English 
Revision International Classification of Diseases (ICD-9 code) codes 401 and International 
Statistical Classification of Diseases, 10th Revision (ICD-10 code) codes I10. A hypertension 
event was defined as the first identified ICD code representing essential hypertension after 
their baseline examination. 
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Analysis of CVD outcomes were conducted separately for any CVD and major CVD events. 
The first case of any CVD outcome is defined as the first occurrence of ICD-9 codes between 
390-459 and ICD-10 codes I00-99 which did not include codes for hypertension or 
hypotension (401-405, I10, 458 or I95). Major CVD outcomes were classified as heart failure 
(HF), myocardial infarction (MI) and stroke, which were identified by patient hospitalisation 
records using ICD-9 codes 410, 411, 413, 414, 428, 434.91 and ICD-10 codes I21, I24, I25, 
I50, I60, I61, I63, I64.  
Follow-up times were calculated from an adult’s health screening examination or from the 
time a participant became an adult (≥ 18 years of age) if aged less than 18 years at their 
health screening exam. For those who were identified by their hospitalisation as a case, their 
follow up time was calculated to their first hospitalisation of the cardiovascular outcome. 
Those who had not reached the endpoint were considered “censored” at the date of 31st May 
2012. Participants who did not have a documented hospitalisation for the cardiovascular 
outcome, but had died before the end of the follow up period were censored at the time of 
death. For participants who died of CVD without a prior CVD hospitalisation the date of their 
first identified event of CVD was the date of CVD death. For death information, we utilised a 
comprehensive and maintained mortality database of the study community. The methods of 
the mortality data have been described in detail elsewhere [155]. 
Low birth weight was defined if their recorded weight at time of birth was < 2,500 g as per 
the recommendations by the World Health Organisation [151]. We separated the population 
into two groups, those with low birth weight (< 2,500 g) and those with normal birth weight 
(≥ 2,500 g). 
We calculated Hazard Ratios (HRs) using the Cox proportional hazard model with 
adjustment for age and diabetes status (yes/no) at time of health screening examinations, as 
well as gender and decade of birth. Support for adjusting for these variables was based on the 
relevant studies in the literature [173, 209, 247-252]. Ethnicity was not applicable as 
participants were all from the same tribal group, and traditional socio-economic 
measurements were not be used in this study population. Study community Elders identified 
traditional socio-economic measurements such as income, education, employment may not be 
appropriately indicative of individual community members due to the collective and 
communal behaviours of the community. All income, food and housing are shared across 
extended family groups. There were insufficient participants with birth length and gestational 
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age information to adjust or categorise the analysis by these variables. Due to the drastic 
changes in mortality rates by birth weight cohorts and reducing incidence of LBW over the 
past 40-50 years in this community the model adjusted for the decade the individual was born 
[155].  
Much of the information on cardiovascular risk factors collected in health screening 
examinations was not routinely collected for children under the age of 18. For this reason, we 
conducted analysis in two ways; the whole population and those who were adults (≥ 18 years) 
at the time of the health screening exam. The subgroup analysis adjusted for age, gender, 
decade of birth, diabetes status and popular cardiovascular risk factors such as smoking 
status, alcohol consumption, triglycerides, systolic blood pressure and cholesterol to test their 
potential confounding influence. 
The results of the health screening examinations were compared between < 2.5 kg and ≥ 2.5 
kg groups for men and women, and boys and girls. Continuous variables were compared 
using a student’s two-tail t-test and dichotomous variables were compared using Chi-squared 
(χ2) tests. Statistical analysis was conducted using STATA 12.0 [253].  
Ethical approval for this study was obtained from the Royal Darwin Hospital and Northern 
Territory Health Services, the community’s Health Board and Land Council, and the Human 
Research Ethics Committee of the Department of Health and Community Services, NT, the 
Menzies School of Health Research, NT and the Behavioural and Social Sciences Ethical 
Review Committee on behalf of School of Medicine in The University of Queensland.  
 
Results 
Eight hundred and fifty-two (852) participants (55% male) were included in the analysis with 
a total follow up of 11,113 person-years. The participants represented 100% of the cohort of 
screened adults and 94 % of the children with recorded birth weight information. Six percent 
of children did not reach 18 years or age before the end of the follow up period. . There were 
236 participants (116 male and 120 female) with recorded low birth weights. Sixty eight (68) 
participants were identified as having a first case of hypertension during the follow up period, 
135 with any CVD and 67 with major CVD outcomes. Forty (40) individuals died from other 
causes before the follow up period ended. These deaths were censored and included in the 
survival analysis, as previously noted.  
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The health screening characteristics in the low birth weight (LBW) and the normal birth 
weight (NBW) groups are shown for adults in Supplementary Table 5.4. Men in the LBW 
group were, on average, 4.6 kg lighter in weight (p = 0.026) and 1.4 kg/m2 lower BMI 
(p=0.032) in the LBW group than the NBW group. Women in the LBW group weighed 5.9 
kg (on average) less than their NBW counterparts (p=0.019). There was also a lower rate of 
tobacco use in the women with LBW (54 %) compared to 68 % in the NBW (p=0.050). Rates 
of tobacco use and alcohol consumption were significantly higher in men than women 
irrespective of birth weight Supplementary Table 5.5 shows that LBW boys under the age 
of 18 were, on average, 4.2 kg lighter (p=0.039) and had a BMI 1.2kg/m2 less (p=0.037) than 
their NBW counterparts after adjustment for age. Supplementary Tables 5.5 and 5.6 also 
show that there were no other significant differences between the LBW and NBW groups for 
boys and girls under the age of 18 in the health screening examinations aside from birth 
weight.  
Table 5.1 demonstrates the increased risk of the LBW group for all cardiovascular outcomes. 
Participants of LBW were over 2 times at risk of a hypertension hospitalisation than their 
NBW counterparts. This risk remained consistent when the Cox proportional hazard model 
was adjusted for age and diabetes status at screening, gender and decade of birth. The LBW 
group also had an increased risk for any CVD and major CVD outcomes. The adjusted model 
shows a 43 % increased risk of any CVD hospitalisations if born of a low weight (p=0.045) 
and showed a 51% increased risk in major CVD hospitalisations; however it failed to achieve 
statistical significance (p=0.097). 
Table 5.1. The risk of cardiovascular hospitalisations in adult life if participants were born of 
low birth weight. 
  
Participants (n) Events (n) 
Incidence 
Density 
(events per 
1,000 
person-
years) 
Mean age at 
hospitalisation, 
years (95%CI) 
Model HR 95% CI p-value 
Hypertension 849 68 10.62 36.5 (34.7-38.3) Unadjusted 2.29 1.42-3.69 0.001 
 849 68   Adjusteda 1.83 1.09-2.96 0.014 
         
Any CVDb 852 135 16.50 38.5 (37.0-39.9) Unadjusted 1.46 1.03-2.06 0.032 
 852 135   Adjusteda 1.43 1.01-2.03 0.045 
         
Major CVDc 852 67 8.86 39.5 (37.9-41.1) Unadjusted 1.71 1.05-2.77 0.031 
  852 67    Adjusteda 1.51 0.93-2.47 0.097 
The corresponding ≥2.5kg group was used as reference for each model 
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aAdjusted for age at health screening exam, gender, decade of birth and diabetes status 
(yes/no) at health screening exam. 
bAny CVD excludes hypertension and hypotension events 
cMajor CVD includes Stroke, Myocardial Infarction and Heart Failure 
 
Table 5.2 demonstrates the sensitivity analysis conducted on participants who were adults at 
time of the health screening examination. Adjusting for age, smoking status, alcohol 
consumption and diabetes status at health screening exam, gender and decade of birth in this 
subgroup produced similar associations seen in the entire population. There was an 83 %, 53 
% and 70 % increased risk of hypertension, any CVD and major CVD, respectively for low 
birth weight participants. Further adjusting for systolic blood pressure, triglycerides and HDL 
cholesterol made little difference to the association of BW and hospitalisations associated 
with hypertension, but reduced the point estimates for any CVD and major CVD and 
statistical significance. 
Table 5.2 Subgroup analysis of participants over 18 years at time of health screening 
examination and their risk of having a cardiovascular hospitalisation in adult life if born of 
low birth weight. 
 
Incidence 
Density 
(events per 
1,000 
person-
years) 
Model n HR 95% CI p-value 
Hypertension 15.94 Unadjusted 406 2.01 1.24-3.24 0.004 
  
Adjusteda 393 1.83 1.12-2.99 0.016 
  
Further adjustedb 342 1.84 1.10-3.09 0.021 
       
Any CVDc 18.85 Unadjusted 408 1.53 1.03-2.29 0.037 
  
Adjusteda 395 1.53 1.01-2.31 0.045 
  
Further adjustedb 343 1.37 0.87-2.14 0.175 
       
Major CVDd 12.12 Unadjusted 408 1.68 1.01-2.81 0.047 
  
Adjusteda 395 1.70 1.01-2.89 0.049 
  Further adjustedb 343 1.36 0.76-2.45 0.305 
The corresponding ≥2.5kg group was used as reference for each model 
aAdjusted for age at health screening exam, gender, decade of birth, smoking status (yes/no), 
alcohol consumption (yes/no) and diabetes status at health screening exam (yes/no) 
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bAdditionally adjusted for other cardiovascular risk factors at health screening examinations, 
including triglycerides, systolic blood pressure and HDL cholesterol 
cAny CVD excludes hypertension and hypotension events 
dMajor CVD includes Stroke, Myocardial Infarction and Heart Failure 
Table 5.3 shows that the risk of LBW participants for hypertension was more marked and 
significant in the female group. The women experienced a crude incidence density nearly 
three-times the amount of the men (women = 15.83 events per 1,000 person-years; men = 
5.66 events per 1,000 person-years). A formal test of statistical interaction was conducted on 
gender with the adjusted Cox proportional hazard model for hypertension hospitalisations, 
however statistical significance was not achieved (p = 0.162). 
This difference in risk by gender was not apparent in the analyses for any CVD and major 
CVD (results not shown). 
Table 5.3. The gender difference of risk for a hospitalisation in which hypertension was 
recorded. 
 
Incidence Density 
(event per 1,000 
person-years) 
Model n HR 95% CI p-value 
Men 5.66 Unadjusted 463 1.38 0.62-3.09 0.426 
 
 
Adjusteda 463 1.25 0.56-2.80 0.589 
 
      
Women 15.83 Unadjusted 385 2.91 1.56-5.41 0.001 
  
 
Adjusteda 385 2.61 1.38-4.93 0.003 
The corresponding ≥2.5kg group was used as reference for each model 
aAdjusted for age at baseline screening, gender, smoking status (yes/no), alcohol 
consumption (yes/no), decade of birth and diabetes status at health screening exam (yes/no) 
 
Discussion 
There is a significant disparity of risk for cardiovascular outcomes based on birth weight in 
this remote Indigenous Australian community. Those with LBW have an increased risk of 
hypertension, any CVD and major CVD hospitalisations in adult life compared to their NBW 
counterparts. When stratified by gender, LBW women were over 2.6 times more likely to 
experience a hospitalisation in which a diagnosis of hypertension was recorded, than women 
who weighed over 2,500 g at birth. This association was not statistically significant in men.  
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These findings support the well-established relationship between LBW and risk of 
hypertension in adult life as first hypothesised by Barker et al [244]. They are consistent with 
the BP and BW relationship first described by Singh and Hoy [154] in this same community. 
They also show that birth weight is associated with the development of cardiovascular 
outcomes and precipitating hospitalisations in adult life of remote Indigenous Australians.  
These findings are consistent with a comprehensive meta-analysis which determined an 
inverse association between BW and subsequent development of CVD in non-Indigenous 
populations [209]. Our findings provide quantifiable evidence for the further extrapolation of 
this relationship between LBW and CVD development in adult Indigenous Australians, 
which translate to the burden of hospitalisations and probably premature death. 
This study also suggests the effect of LBW on increasing incidence of hypertension 
hospitalisations in women was greater than that observed in men, although the mechanisms of 
this gender influence are unknown. This gender difference is contrary to a meta-analysis of 
studies conducted on general non-Indigenous populations worldwide, which concluded there 
was no gender dependence for the association between BW and BP [254]. However, the 
meta-analysis did not include any studies conducted in adult Indigenous Australians. Singh 
and Hoy [154] encountered an inverse relationship between BW and BP in young adults 
which was only significant in women. Moreover, Hoy et al showed a similar inverse 
relationship in this community between BW and albuminuria [255]. Further studies in remote 
and urban Indigenous populations of the world are needed to investigate this gender 
difference and provide more insight into the LBW and CVD association.  
Through effective improvements in health service delivery and an increased focus on birth 
weight by health care providers over the past 40-50 years, mean birth weights in this 
community [155] and across the Northern Territory have been increasing [256]. The 
continued reduction in LBW rates are encouraging, however the remaining high incidence of 
LBW [155] and our observed risk to CVD suggests continued improvements are necessary. 
The mortality trend over the similar time period suggests a reduction in natural cause 
mortality, particularly in women, in this community [4] and aboriginal people in the Northern 
Territory [19]. The increasing mean birth weight may play a significant role in this trend. 
Increasing birth weight may also further reduce the infant mortality rates as experienced in 
other Aboriginal populations [257] and risk to natural deaths later in life [155]. The findings 
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of this study provide further evidence to boost health promotion initiatives targeting birth 
weight due to the large potential benefits to the community.  
Several limitations should be considered when interpreting our findings and generalising to 
other populations. The observed relationships may be caused by an increased total 
hospitalisation rate in the LBW group. We are unable to exclude the possibility that the 
relationship observed may have been caused by an increased number of incidental events as a 
coexisting condition or other factors leading to a higher number of total hospital visits. 
Secondly, the use of hospitalisation records captures symptomatic and the most serious cases. 
Therefore, our findings may underestimate the association between birth weight and 
adulthood development of cardiovascular outcomes.  
Thirdly, the missing information of young people at the health screening examinations 
limited our ability to control for confounding factors in the entire sample. Sensitivity analysis 
in the adult subgroup of the population showed that age, gender, tobacco use, alcohol 
consumption, decade of birth and diabetes status only had a small influence over the 
association. Moreover, information on maternal risk factors such as maternal hypertension, 
alcohol consumption and tobacco use were unknown for our participants.  
Finally, this population-based observational study will understate the association between 
BW and CVD due to the limited duration of the follow-up period. Another limitation is the 
assumption that each participant is disease-free at the time of baseline examination; this was 
due to the fact we were unable to identify cases of CVD through hospital records prior to 
1992.  
Strengths of this study include, to our knowledge, these health screening examinations are the 
most complete for a remote Indigenous Australian community, with the largest sample size, 
highest community participation rate and the longest follow-up. This study is also the first 
Indigenous cohort to investigate the association between LBW and long-term CVD 
development.  
 
Conclusion 
Members of this remote Indigenous Australian community are at a significantly higher risk of 
developing cardiovascular diseases if they were born less than 2,500 g.  Furthermore, LBW 
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women have over 2.6 times higher risk of having a hospital admission in which hypertension 
was recorded. We recognise the vast improvements in mean BW in previous decades within 
Indigenous Australians, however birth weight continues to be an important risk factor to ill-
health outcomes within this community. The quantifiable association between BW and CVD 
in adult life suggests continued improvements in LBW rates are essential to continue the 
reduction in CVD morbidity of this community. We furthermore recommend further studies 
within Indigenous populations (urban and remote) throughout the world to investigate the 
potential gender influence on the LBW and hypertension relationship.  
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5.1.1 Supplementary Tables 
 
Supplementary Table 5.4. Characteristics of adult participants at health screening 
examinations between 1992 and 1999  
 
 Men    Women    
 <2,500g ≥2,500g  <2,500g ≥2,500g  
 n Mean (SD) n Mean (SD) p-value n Mean (SD) n Mean (SD) p-value 
Adults ≥ 18 years           
Age, years 67 26.7 (5.0) 155 26.8 (5.3) 0.975 70 28.1 (5.9) 116 26.4 (5.7) 0.045 
Birth weight, kg 67 2.19 (0.3) 155 2.93 (0.3) <0.001 70 2.23 (0.2) 116 3.02 (0.4) <0.001 
BMI, kg/m2 67 21.3 (3.8) 155 22.6 (4.5) 0.032 70 22.7 (5.2) 115 24.3 (6.5) 0.079 
Height, cm  67 171.2 (6.2) 155 171.7 (5.9) 0.549 70 158.9 (5.9) 115 161.0 (5.3) 0.013 
Weight, kg 67 62.4 (11.8) 155 67.0 (15.1) 0.026 70 57.3 (14.1) 116 63.2 (17.6) 0.019 
Waist circumference, cm 65 82.1 (11.2) 151 84.1 (12.8) 0.264 70 86.3 (13.0) 110 88.3 (16.2) 0.389 
Hips circumference, cm 65 84.1 (10.6) 151 86.1 (11.9) 0.245 70 94.3 (12.4) 110 95.7 (15.3) 0.507 
HDL Cholesterol, 
mmol/L 
58 1.15 (0.2) 139 1.16 (0.3) 0.868 62 1.10 (0.3) 93 1.07 (0.2) 0.473 
Total Cholesterol, 
mmol/L 
63 4.8 (1.2) 141 4.7 (1.0) 0.638 64 4.1 (0.8) 95 4.2 (0.9) 0.383 
Triglycerides, mmol/L 63 1.9 (1.5) 141 2.0 (1.4) 0.632 64 1.8 (1.1) 94 1.7 (1.1) 0.811 
Systolic blood pressure, 
mmHg 
67 119.8 (14) 154 123.6 (15) 0.078 70 110.9 (15) 111 110.2 (14) 0.741 
Diastolic blood pressure, 
mmHg  
67 72.9 (12) 154 75.3 (12) 0.173 70 68.8 (11) 111 66.7 (11) 0.211 
Smoking status, n (%) 66 55 (83%) 150 125 (83%) 1.000 69 37 (54%) 110 75 (68%) 0.050 
Alcohol consumption 
status, n (%) 
66 60 (90%) 150 123 (82%) 0.094 69 18 (26%) 110 29 (26%) 0.967 
           
95 
 
 
  
96 
 
Supplementary Table 5.5. Characteristics of boys (<18 years old) at health screening 
examinations between 1992 and 1999 
  <2,500g ≥2,500g   
  n Mean (95% CI) n Mean (95% CI) p-value 
 
     
Age, years a 49 11.6 (3.7) 196 10.6 (3.6) 0.077 
Birth weight, kg 49 2.16 (2.0-2.3) 196 3.09 (3.0-3.1) <0.001 
BMI, kg/m2 35 15.8 (14.9-16.8) 122 17.0 (16.5-17.5) 0.037 
Height, cm  35 145.7 (142.6-148.9) 122 148.6 (146.9-150.3) 0.122 
Weight, kg 35 34.8 (31.3-38.2) 122 39.0 (37.1-40.8) 0.0385 
Waist circumference, cm 4 62.1 (53.3-71.0) 16 69.0 (64.4-73.6) 0.1935 
Hips circumference, cm 4 69 (60-79) 16 75 (70-80) 0.3483 
HDL Cholesterol, mmol/L 28 1.03 (0.96-1.09) 89 0.98 (0.94-1.01) 0.2012 
Total Cholesterol, mmol/L 28 3.5 (3.2-3.7) 91 3.6 (3.4-3.7) 0.425 
Triglycerides, mmol/L 28 1.8 (1.4-2.1) 91 1.7 (1.5-1.8) 0.5894 
Systolic blood pressure, mmHg 33 111 (108-115) 114 111 (109-113) 0.9755 
Diastolic blood pressure, mmHg  33 66 (63-70) 114 65 (64-67) 0.6599 
Age-adjusted means (95% CI) shown unless otherwise stated; a Mean (SD); Tobacco use and 
alcohol consumption information was not requested from participants under the age of 18 
years 
 
Supplementary Table 5.6. Characteristics of girls (<18 years old) at health screening 
examinations between 1992 and 1999 
  <2,500g ≥2,500g   
  n Mean (95% CI) n Mean (95% CI) p-value 
 
     
Age, years a 50 10.1 (3.8) 149 9.4 (3.5) 0.228 
Birth weight, kg 50 2.18 (2.09-2.27) 149 3.07 (3.02-3.12) <0.001 
BMI, kg/m2 32 16.8 (15.6-18.0) 99 17.4 (16.7-18.1) 0.4651 
Height, cm  32 136.1 (133-139) 99 137.9 (136-140) 0.2877 
Weight, kg 32 33.2 (30.1-36.2) 100 35.1 (33.4-36.8) 0.2857 
Waist circumference, cm 10 61.8 (58.0-65.5) 17 62.2 (59.3-65.1 0.8531 
Hips circumference, cm 10 69.1 (64.4-73.8) 17 69.7 (66.0-73.4) 0.8473 
HDL Cholesterol, mmol/L 18 1.04 (0.93-1.15) 55 1.10 (1.04-1.16) 0.3796 
Total Cholesterol, mmol/L 18 3.4 (3.1-3.7) 58 3.7 (3.6-3.9) 0.0685 
Triglycerides, mmol/L 18 1.7 (1.3-2.2) 58 1.7 (1.5-2.0) 0.9784 
Systolic blood pressure, mmHg 26 105 (101-110) 77 107 (104-110) 0.5792 
Diastolic blood pressure, mmHg  26 61 (58-65) 77 58 (56-60) 0.1328 
Age-adjusted means (95% CI) shown unless otherwise stated; a Mean (SD); Tobacco use and 
alcohol consumption information was not requested from participants under the age of 18 
years 
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Chapter 6 – LBW, WC and CVD 
Once an association between BW and CVD had been established in the preceding 
publication, how adult body size affected this relationship was investigated. A meta-analysis 
debated the use of adult body size as a confounding variable in BW and BP analysis [228]. 
Adjusting for body size is suggested to unnecessarily accentuate the calculated risk for CVD 
by mathematically assuming an unrealistic observation. Put simply, this means that studies 
which adjust for adult body size, make the mathematical assumption that all participants 
(both the LBW and NBW groups) will grow to become the same size. In reality however, 
those who are born of LBW tend to be smaller in height and weight than their NBW 
counterparts later in life [235-237]. Therefore, this assumption exaggerates the phenomenon 
of catch up growth by suggesting all LBW participants become larger in adulthood than they 
actually do [238-240]. 
The following chapter details a study which examined how the adult body size of participants 
affected the BW and CVD relationship. The study also compared the risk for CVD based on 
waist circumference, BMI and BW. The study highlights the independent risk for 
cardiovascular disease associated with each of these anthropometric measurements and also 
how they can combine to increase the risk further.  
The following study was submitted to the International Journal of Cardiology. The Editor 
could not find sufficient priority to publish as an original research article; however it was 
invited for resubmission as a Letter to the Editor. Chapter 6.1 demonstrates the Letter to the 
Editor as published in the International Journal of Cardiology. To provide further detail, 
Chapter 6.2 is the full-text version of the original research manuscript which was originally 
submitted to the International Journal of Cardiology. The following chapter addresses 
Research Questions 6 and 7, as proposed in Chapter 1.2.2. 
 
6.1 Letter to the Editor article published in the International Journal of Cardiology 
Arnold, L.W., Hoy, W.E. and Wang, Z. Low birth weight and large adult waist circumference 
increases the risk of cardiovascular disease in remote Indigenous Australians - An 18 year 
cohort study. (2015). Int J Cardiol, 186(0): 273-275. doi: 10.1016/j.ijcard.2015.03.209 
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An association of cardiovascular disease (CVD) with early life risk factors has been evident 
since the first introduction of the Developmental Origins of Health and Disease (DOHaD) 
hypothesis by Barker et al [241], which gained further support over the next 2 decades [209]. 
Other researchers continued to compare anthropometric measurements in later life to find 
better predictors [258]. Some studies in the literature have shown the two cannot be 
investigated independently; suggesting birth weight (BW) and adult body size may interact to 
increase the risk of chronic disease [259]. This amplification phenomenon is yet to be 
confirmed for CVD in Indigenous Australians despite their significantly higher rates of low 
BW, diabetes and CVD morbidity and mortality than the general Australian population [2, 
25, 155]. Waist circumference (WC) was previously identified as a better predictor for CVD 
than other anthropometric measurements in this population [1], however the comparison and 
combination of WC with early life risk factors is yet to be investigated. The study in this 
report aimed to quantify and compare the risk for CVD associated with WC, body mass index 
(BMI) and birth through the use of a cohort in a remote Indigenous Australian community 
with up to 18 years follow-up. 
The data for this study were obtained from health screening examinations conducted between 
1992 and 1998 in a remote Northern Territory Indigenous Australian community and 
Northern Territory hospitalisation records. Participants volunteered for the screening exams 
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with written informed consent and ethics approval was gained for this study from the 
Behavioural and Social Sciences Ethical Review Committee on behalf of School of Medicine 
in The University of Queensland (2011001232; Appendix 1).  
BW information was obtained through hospital and community clinic records. WC was 
measured at the narrowest point below the ribs or halfway between the lowest ribs and the 
iliac crest in centimetres. BMI was calculated by the individual’s weight in kilograms divided 
by their height in metres-squared (kg/m2). Further details of the measurement of these 
anthropometric measurements and other cardiovascular risk factors such as age, sex, smoking 
status, diabetes, total cholesterol and blood pressure have been described previously 
(Appendix 2) [42].   
The first event of CVD in each participant was identified by hospital records utilising the 
English Revision International Classification of Diseases (ICD-9 code) and International 
Statistical Classification of Diseases, 10th Revision (ICD-10 code) codes. For those thus 
identified with CVD, their follow up time was calculated from the time of their baseline exam 
to the time of their first CVD hospitalisation. Those who had not reached a CVD endpoint 
were considered “censored” at the date of 31st December 2010. Participants who did not have 
a documented hospitalisation of the CVD endpoint, but died before the end of the follow up 
period from another cause were censored at the time of death. 
Age- and sex- z scores were calculated for each variable and analysed both continuous 
variables and separated into quartiles for analysis. Risk ratios (RR) and 95% confidence 
intervals were calculated using Cox proportion hazard models. Sensitivity analysis was 
conducted using only participants with complete information for BW, WC and BMI, due to 
difference in population samples for each variable analysed. 
Totals of 889, 870 and 375 participants were included in the analyses for BMI, WC and BW, 
respectively. A total of 263 cases of CVD were identified during the 10,984 person-years 
follow-up period and 98 participants died of other causes without having a CVD 
hospitalisation. 
The incidence rates of CVD increased by WC quartiles, in participants with WC information 
(15, 19, 24 and 36 CVD events per 1000 person-years for the 1st, 2nd, 3rd and 4th WC 
quartiles, respectively).  
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Table 6.1. Rate Ratios of cardiovascular disease for age and sex specific quartiles and per 
one standard deviation increase for anthropometric measurements. 
  Crude           Adjusted a     
  n Quartile RR 95%CI P-value 
 
n RR 95%CI P-value 
WC 877 1 1 
   
743 1 
  
  
2 1.21 0.81-1.81 
   
1.10 0.71-1.71 
 
  
3 1.65 1.14-2.40 
   
1.49 0.98-2.27 
 
  
4 2.28 1.59-3.27 <0.001 
  
1.82 1.20-2.75 <0.001 
           
BMI 897 1 1 
   
753 1 
  
  
2 1.14 0.78-1.67 
   
0.85 0.56-1.30 
 
  
3 1.40 0.98-2.01 
   
1.06 0.71-1.61 
 
  
4 1.95 1.38-2.76 <0.001 
  
1.45 0.97-2.15 <0.001 
           
BW  374 1 2.37 1.28-4.39 
  
330 2.05 1.07-3.94 
 
  
2 1.57 0.81-3.03 
   
1.41 0.71-2.82 
 
  
3 1.06 0.52-2.14 
   
0.74 0.34-1.62 
 
  
4 1 
 
<0.001 
  
1 
 
<0.001 
           
WC d 870 
 
1.45 1.29-1.62 <0.001 
 
743 1.35 1.18-1.56 <0.001 
BMI d 889 
 
1.33 1.18-1.50 <0.001 
 
753 1.25 1.08-1.44 0.002 
BW b 375 
 
1.29 1.04-1.60 0.021 
 
330 1.24 0.99-1.55 0.056 
           
WC c d 366 
 
1.59 1.30-1.95 <0.001 
 
326 1.47 1.15-1.88 0.002 
BMI c d 366 
 
1.56 1.28-1.89 <0.001 
 
326 1.43 1.13-1.82 0.002 
BW b c 366   1.29 1.04-1.61 0.021   326 1.24 0.99-1.55 0.056 
a Adjusted for age, sex, systolic blood pressure, cholesterol, smoking and diabetes. b Risk 
shown as per one standard deviation decrease in birth weight. c Analysis included only 
participants with complete waist circumference, BMI and birth weight information. d Rate 
ratio per one standard deviation increase  
 
Table 6.1 shows that BW displayed the greatest increase in RR by risk factor quartiles. The 
lowest BW quartile had double the CVD risk when compared to the highest quartile (RR = 
2.05, 95 % CI 1.07-3.94). The RR between the lowest and highest WC quartiles demonstrated 
an 82 % increase in CVD risk, while BMI showed a 45 % increase. (RR = 1.82, 95 % CI 
1.20-2.75; RR = 1.45, 95 % CI 0.97-2.15).  
Table 6.1 shows that WC had the largest risk of CVD per standard deviation (SD) increase 
using age and sex specific z scores as continuous variables (RR = 1.35, 95 % CI 1.18-1.56, p 
< 0.001). A SD increase in BMI exhibited a 25 % increased CVD risk, while each SD 
reduction in BW increased the risk of CVD by 24 % (RR = 1.25, 95 % CI 1.08-1.44, p = 
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0.002; RR = 1.24, 95 % CI 0.99-1.55, p=0.056). For sensitivity analysis, the adjusted model 
demonstrated a 47 % and 43 % increase in CVD risk per SD increase for WC and BMI, 
respectively (RR = 1.47, 95 % CI 1.15-1.88, p = 0.002; RR = 1.43, 95 % CI 1.13-1.82, p = 
0.002). BW displayed a 24 % increased risk of CVD per SD decrease (RR = 1.24, 95 % CI 
0.99-1.55, p = 0.056). 
Table 6.2. Rate ratios of cardiovascular disease for waist circumference age and sex specific 
quartiles grouped by birth weight 
    Crude Adjusted a 
BW 
WC 
quartile 
n 
(events) 
RR 95% CI 
P-
value 
n 
(events) 
RR 95% CI 
P-
value 
≥ 2,500 g 1 68 (3) 1 (reference) 
 
64 (3) 1 (reference) 
 
 
2 56 (4) 1.45 0.32-6.48 0.628 48 (4) 1.22 0.27-5.52 0.797 
 
3 52 (9) 3.95 1.07-14.60 0.040 44 (8) 2.98 0.78-11.37 0.111 
 
4 62 (23) 8.24 2.46-27.63 0.001 53 (20) 5.29 1.50-18.70 0.010 
< 2,500 g 1 41 (13) 6.49 1.83-22.99 0.004 34 (10) 4.73 1.27-17.66 0.021 
 
2 38 (11) 6.54 1.82-23.50 0.004 34 (10) 4.87 1.32-17.98 0.017 
 
3 24 (8) 8.73 2.31-32.93 0.001 24 (8) 6.57 1.71-25.28 0.006 
 
4 25 (11) 10.26 2.85-37.00 <0.001 25 (11) 7.22 1.96-26.64 0.003 
a Adjusted for age, sex, systolic blood pressure, cholesterol, smoking and diabetes. The group 
with the lowest WC quartile and ≥ 2,500g BW was used as the reference group for the entire 
model.  
 
Table 6.2 shows that participants in the highest WC quartiles had a significantly increased 
risk for CVD irrespective of BW, using participants in the lowest WC quartile and with 
normal birth weight (NBW; ≥ 2,500 grams) as the referent group (RR = 5.29, 95 % CI 1.650-
18.70, p = 0.010; RR = 7.22, 95 % CI 1.96-26.64, p = 0.003). Two of the groups which had 
the highest RRs were the LBW participants in the 3rd and 4th WC quartiles. Sensitivity 
analysis identified a similar trend, however 95 % confident intervals were large (results not 
shown). 
This study found that adult WC was a strong predictor of CVD, both as a continuous variable 
and by quartiles. The highest quartiles of WC exhibited the highest risk for CVD regardless 
of the individual’s BW. However, the group with the highest risk for CVD overall were those 
of both LBW and in the highest WC quartiles. CVD prevention in this community would 
benefit from a multidisciplinary approach which considers later in life risk factors and their 
predisposition from early life influences. 
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Abstract 
Background: The debate over whether birth weight or current weight better predicts risk to 
cardiovascular disease (CVD) is increasing in the literature. This study aims to quantify and 
compare the risk of CVD predicted by waist circumference (WC), body mass index (BMI) 
and birth weight (BW) in a remote Indigenous Australian community. Methods: A 
community-wide screening baseline examination was conducted in 1992-1998 and 
cardiovascular outcomes were identified using hospital records. The study included 889 
participants aged over 20 years with anthropometric measurement data, who were followed 
for up to 18 years and 375 participants within the sample who had birth weight information. 
Rate ratios (RR) and 95 % confidence intervals (CI) were calculated using Cox proportional 
regressions for risk to CVD. Results: The risk for CVD increased 35 % per standard 
deviation increase in WC (RR 1.35, 95 % CI 1.18-1.56) and 25% in BMI (RR 1.25, 95 % CI 
1.08-1.44). Each standard deviation reduction in BW increased the risk to CVD by 24 % (RR 
1.24, 95 % CI 0.99-1.55). Adults with high WC and low BW had a significantly higher risk 
for CVD than any other group (RR 7.22, 95 % CI 1.96-26.64, p = 0.003). WC showed the 
strongest association with CVD and the association was increased when combined with low 
BW. Conclusion: This study suggests adult WC is a better predictor of CVD in this 
Indigenous community than BMI or BW. Furthermore, adults with high WC and low BW are 
identified as a high priority risk group. 
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Background 
Indigenous Australians suffer from one of the largest health disparities between Indigenous 
and non-Indigenous populations worldwide, which is highlighted by the significant 11 year 
life expectancy difference from their non-Indigenous counterparts [12]. Furthermore, this 
Indigenous population suffers from some of the highest rates of cardiovascular disease 
(CVD) [25], type 2 diabetes [2] and renal disease [24]. This significant burden from chronic 
disease highlights the importance of finding solutions to prevent or decrease the effects of 
risk factors. These solutions are clearly high priorities in these communities; however, the 
mechanisms of how these risk factors interrelate in the Indigenous context are not completely 
understood.  
In addition to a burden of chronic disease, many Indigenous Australian communities also 
have low birth weight (LBW; < 2,500 grams) incidence comparable to, if not worse than, 
those identified in the least developed nations of the world [151, 152, 155]. Although 
significant improvements in health care services have been implemented leading to large 
reductions in these rates over the past 5 decades, the disparity between Indigenous and non-
Indigenous Australian populations are still clearly identifiable [152, 260]. In 2011, the LBW 
rate for Indigenous Australians (12.6%) was double the rate experienced by their non-
Indigenous counterparts (6.0%) [152]. The burden of chronic disease and birth weight 
deserves further investigation in these communities.  
In attempts to investigate prevention of cardiovascular diseases, a number of studies have 
pursued the developmental origins of health and disease originally hypothesized by Barker et 
al [241]. Within general populations, popular findings suggest LBW increases an individuals’ 
risk to CVD [209]. On the other hand, there is overwhelming literature pursuing lifestyle and 
genetic factors suggesting diabetes, obesity, high blood pressure, tobacco use, high 
cholesterol and physical inactivity are high predictors [261, 262]. Debates in the literature 
have questioned the comparisons of LBW and later in life cardiovascular risk factors[230]. 
The diverse literature investigating CVD risk factors also exists in Aboriginal populations. 
Birth weight (BW) has been associated with adult hypertension in females [154], while 
anthropometric measurements such as body mass index (BMI) and waist circumference (WC) 
in adult life have also been identified as excellent predictors of CVD morbidity [1].  
The variety and volume of studies surrounding CVD risk factors makes it difficult for health 
promotion initiatives to determine which factor may provide the greatest benefit to preventing 
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CVD within Indigenous Australian populations. Albeit important, there is yet to be a 
distinctive study undertaken to distinguish the differences in associations between CVD, BW 
and adult anthropometric measurements within these Aboriginal communities. Through the 
use of an Indigenous Australian cohort with up to 18 years follow-up, this study aims to 
quantify and compare the risk of cardiovascular disease between WC, BMI and BW in a 
remote Indigenous Australian community to provide further clarity into the prevention of 
CVD in this setting. 
  
Methods 
This study is a prospective cohort study using baseline examinations conducted between 1992 
and 1998, where health screening exams were obtained from individuals of a remote 
Northern Territory Indigenous Australian community. Participants volunteered with written 
informed consent for clinical examination, biological testing and use of their medical records 
under NHMRC grant 921134 and approval of the Human Research Ethics Committee, 
Menzies School of Health Research, Darwin, Northern Territory. The methods of the health 
screening exams are detailed elsewhere [246]. Participants were included in the analysis if 
they i) were over 20 years old at baseline, ii) were born to an aboriginal mother, iii) had birth 
weight or adult anthropometric data available and v) were a member of the remote Aboriginal 
community studied. 
Of the 1490 individuals who participated in a baseline examination 562 were younger than 20 
years old and hence excluded from this study. The analysis of each measurement (BW, BMI 
and WC) was treated separately, by only including participants with the suitable information 
needed. This method of participant inclusion maximised the number of participants within 
each analysis. BW was compared only with WC and BMI as these have been previously 
shown to better predict CVD morbidity than other anthropometric indicators of adult body 
size in this population [1].  
  
Measurements and Identification of Events 
Birth weight information was obtained through hospital records. Further details of obtaining 
and measuring birth weight information are described elsewhere [155]. Waist circumference 
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was measured at the narrowest point below the ribs or halfway between the lowest ribs and 
the iliac crest in centimetres. Body mass index was calculated by the individual’s weight in 
kilograms divided by their height in metres-squared (kg/m2). Further details of the 
measurement of these anthropometric measurements and other cardiovascular risk factors 
such as age, sex, smoking status, diabetes, total cholesterol and blood pressure have been 
described previously [42].   
The first case of cardiovascular disease was identified by hospital records utilising the 
English Revision International Classification of Diseases (ICD-9 code) and International 
Statistical Classification of Diseases, 10th Revision (ICD-10 code) codes. Table 6.3 
highlights the ICD codes used in this study.  
Table 6.3. ICD codes used to identify cardiovascular disease cases 
Disease ICD-9 code ICD- 10 code 
   
Hypertensive disease 401-405 I10-I15 
Coronary heart disease 410-414 I20-I25 
Heart Failure 428 I50 
Atherosclerosis 440 I70 
Stroke 430-438 G45, G46 and I60-I69 
Peripheral vascular disease 441-444 I71-I74 
 
For those identified with CVD, their follow up time was calculated from the time of their 
baseline exam to the time of their first CVD hospitalisation. Those who had not reached the 
endpoint were considered “censored” at the date of 31st December 2010. Participants who did 
not have a documented hospitalisation of the endpoint, but died before the end of the follow 
up period from another cause were censored at the time of death. 
 
Statistical Analysis 
Age- and sex- specific means and standard deviations were used to calculate standard 
deviation scores for use in the analysis. These standard deviation scores were used as 
continuous variables and separated into quartiles for analysis. Due to difference in population 
samples for each measurement analysed, sensitivity analysis was conducted using only 
participants with complete information for BW, WC and BMI. Due to the drastic changes in 
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mortality rates by birth weight cohorts and reducing incidence of LBW over the past 40-50 
years in this community the model adjusted for the decade the individual was born [155].  
  
Baseline characteristics were compared between the WC quartiles using linear regression or 
two-way ANOVA for continuous variables and logistic regression or chi-squared (χ2) tests 
for dichotomous and categorical variables. Risk ratios and 95% confidence intervals were 
calculated using Cox proportion hazard models. All analysis was conducted using STATA 
13.0 [144]. 
 
Ethics Approval 
Ethics for this study was approved by the Behavioural and Social Sciences Ethical Review 
Committee on behalf of School of Medicine in The University of Queensland (2011001232; 
Appendix 1).  
 
Results 
A total of 889, 870 and 375 participants were included in the analysis for BMI, WC and BW, 
respectively. There were a total of 263 cases of CVD identified during the 10,984 person-
years follow-up period and 98 participants died of other causes without having a CVD 
hospitalisation. The incidence rates of CVD within this population increased by WC quartile 
(15, 19, 24 and 36 CVD events per 1000 person-years for the 1st, 2nd, 3rd and 4th WC 
quartiles, respectively). Table 6.4 also highlights participants in the higher WC quartiles had 
higher levels of other cardiovascular risk factors.  
Table 6.4. Baseline characteristics corresponding to waist circumference quartiles 
 Quartiles  
 1st 2nd 3rd 4th p-
value 
n 221 220 225 225  
Age, years 34.5 (12.2) 35.1 (12.0) 38.1 (13.3) 35.4 (10.7) 0.121 
Systolic BP, mmHg 116.5 (17.3) 120.6 (19.1) 125.2 (18.6) 126.4 (18.4) <0.001 
Diastolic BP, mmHg 71.1 (13.7) 74.0 (13.3) 76.6 (12.3) 79.0 (14.3) <0.001 
BMI, kg/m2 19.2 (2.5) 22.1 (3.0) 25.0 (3.2) 30.2 (4.5) <0.001 
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Waist circumference, cm 73.7 (5.5) 84.2 (5.0) 93.4 (6.0) 106.6 (9.0) <0.001 
Birth weight, kg a 2.7 (0.5) 2.7 (0.5) 2.7 (0.4) 2.8 (0.5) 0.034 
HDL, mmol/L b 1.2 (0.3) 1.1 (0.2) 1.1 (0.3) 1.0 (0.2) <0.001 
Total cholesterol, mmol/Lb 4.4 (1.0) 4.6 (1.0) 4.9 (1.2) 5.0 (1.2) <0.001 
Male, n (%) 113 (51) 111 (50) 113 (50) 115 (51) 0.985 
Diabetes, n (%) 13 (6) 21 (10) 34 (15) 57 (25) <0.001 
Smoking, n (%) 174 (79) 166 (75) 154 (68) 154 (68) 0.004 
Drinking, n (%) 145 (66) 135 (61) 132 (59) 124 (55) 0.015 
CVD events (per 1000 
person-years) 
44 (15) 53 (19) 76 (24) 90 (36) <0.001 
Mean (SD) unless otherwise stated. a Data only available in subset of the sample 109, 94, 76 
and 88 for 1st, 2nd, 3rd and 4th quartiles, respectively.  b Data only available in subset of the 
sample 188, 186, 176 and 179 for 1st, 2nd, 3rd and 4th quartiles, respectively. 
 
Using age and sex specific standard deviation scores as continuous variables, Table 6.5 
identified WC with the largest risk of CVD per standard deviation increase (RR = 1.33, 95 % 
CI 1.15-1.53, p < 0.001). A standard deviation increase in BMI produced a 25 % increased 
CVD risk, while each standard deviation reduction in BW also increased the risk of CVD by 
25 % (RR = 1.25, 95 % CI 1.08-1.44, p = 0.003; RR = 1.25, 95 % CI 0.99-1.56, p=0.058).  
Table 6.5. Rate Ratios to cardiovascular disease per one standard deviation increase of 
anthropometric measurements 
 
Crude Adjusted a 
 
n RR 95% CI P-value n RR 95% CI P-value 
Waist circumference 
870 1.45 1.29-1.62 <0.001 743 1.33 1.15-1.53 <0.001 
BMI 
889 1.33 1.18-1.50 <0.001 753 1.25 1.08-1.44 0.003 
Birth weight b 
375 1.29 1.04-1.60 0.021 330 1.25 0.99-1.56 0.058 
         
Waist circumference c 
366 1.59 1.30-1.95 <0.001 326 1.52 1.19-1.95 0.001 
BMI c 
366 1.56 1.28-1.89 <0.001 326 1.48 1.16-1.88 0.001 
Birth weight b c 
366 1.29 1.04-1.61 0.021 326 1.25 0.99-1.56 0.058 
a Adjusted for age, sex, systolic blood pressure, cholesterol, smoking, diabetes and decade of 
birth. b Risk shown as per one standard deviation decrease in birth weight. c Analysis included 
only participants with complete waist circumference, BMI and birth weight information 
 
Sensitivity analysis was conducted on participants with complete data for BW, WC and BMI 
to reproduce the associations identified in Table 6.5. The crude model identified 366 eligible 
participants and 326 for the adjusted model. The adjusted model produced a 52 % and 48 % 
increase in CVD risk per standard deviation increase for WC and BMI, respectively (RR = 
1.52, 95 % CI 1.19-1.95, p = 0.001; RR = 1.48, 95 % CI 1.16-1.88, p = 0.001). BW produced 
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a 25 % increased risk of CVD per standard deviation decrease (RR = 1.24, 95 % CI 0.99-
1.56, p = 0.058). 
 
Table 6.6. Rate Ratios to cardiovascular disease between age and sex specific quartiles for 
anthropometric measurements 
 Crude Adjusted a 
  n Quartile RR 95%CI P-value  n RR 95%CI P-value 
WC 877 1 1 
 
<0.001 
 
743 1 
 
<0.001 
  2 1.21 0.81-1.81 
   
1.03 0.65-1.65 
   3 1.65 1.14-2.40 
   
1.49 0.96-2.31 
   4 2.28 1.59-3.27 
   
1.77 1.14-2.73 
    
        BMI 897 1 1 
 
<0.001 
 
753 1 
 
<0.001 
  2 1.14 0.78-1.67 
   
0.97 0.63-1.51 
   3 1.40 0.98-2.01 
   
1.14 0.74-1.75 
   4 1.95 1.38-2.76 
   
1.55 1.03-2.35 
    
        BW  374 1 2.37 1.28-4.39 0.0002 
 
330 2.04 1.03-4.04 <0.001 
  2 1.57 0.81-3.03 
   
1.45 0.70-2.98 
   3 1.06 0.52-2.14 
   
0.94 0.42-2.10 
   4 1 
    
1 
  a Adjusted for age, sex, systolic blood pressure, cholesterol, smoking and diabetes 
 
BW displayed the greatest increase in RR by risk factor quartiles (Table 6.6). The lowest BW 
quartile had double the CVD risk when compared to the highest quartile (RR = 2.04, 95 % CI 
1.03-4.04). The RR between the lowest and highest WC quartiles produced an 77 % increase 
in CVD risk, while BMI produced a significant, but less so, 55 % increase. (RR = 1.77, 95 % 
CI 1.14-2.73; RR = 1.55, 95 % CI 1.03-2.35).  
Table 6.7. Rate ratios to cardiovascular disease for waist circumference age and sex specific 
quartiles grouped by birth weight 
    Crude Adjusted a 
Birth 
weight 
Waist 
circumference 
quartile 
n 
(events) 
RR 95% CI P-value n (events) RR 95% CI P-value 
≥ 2,500 g 1 68 (3) 1 (reference) 
 
64 (3) 1 (reference) 
 
 
2 56 (4) 1.45 0.32-6.48 0.628 48 (4) 0.91 0.18-4.64 0.912 
 
3 52 (9) 3.95 1.07-14.60 0.040 44 (8) 3.32 0.87-12.74 0.080 
 
4 62 (23 8.24 2.46-27.63 0.001 53 (20) 5.08 1.43-18.05 0.012 
< 2,500 g 1 41 (13) 6.49 1.83-22.99 0.004 34 (10) 3.47 0.90-13.43 0.071 
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2 38 (11) 6.54 1.82-23.50 0.004 34 (10) 4.54 1.23-16.77 0.023 
 
3 24 (8) 8.73 2.31-32.93 0.001 24 (8) 6.97 1.74-26.44 0.006 
 
4 25 (11) 10.26 2.85-37.00 <0.001 25 (11) 9.02 2.44-33.42 0.001 
a Adjusted for age, sex, systolic blood pressure, cholesterol, smoking, diabetes and decade of 
birth. The group with the lowest WC quartile and ≥ 2,500g BW was used as the reference 
group for the entire model.  
 
Table 6.7 details the risk to CVD based on the individuals’ BW and highlights how the risk 
changes by adult WC quartiles. The risk to CVD increased by WC quartile irrespective of 
BW. Using the lowest WC quartile with normal birth weight (NBW; ≥ 2,500 grams) 
participants as the reference group, we identified participants in the highest WC quartiles had 
a significantly increased risk for CVD irrespective of BW (RR = 5.08, 95 % CI 1.43-18.05, p 
= 0.012; RR = 9.02, 95 % CI 2.44-33.42, p = 0.001). Two of the groups which experienced 
the highest RRs were the LBW participants in the 3rd and 4th WC quartiles. For sensitivity 
analysis conducted on results presented in Table 6.7, RRs were also calculated separately for 
BW between WC quartiles using the lowest WC quartile of the corresponding BW as the 
reference group. The similar trend was identified as in Table 6.7, however 95 % confident 
intervals were large (results not shown). 
 
Discussion 
This study found that adult WC is associated with CVD stronger than BMI and BW in this 
Indigenous Australian population. Association was strongest between WC and CVD in this 
study as a continuous variable and within quartiles analysis. The highest quartiles of WC 
exhibited the highest risk for CVD regardless of the individual’s BW, however this study 
found the group with the highest risk for CVD overall were those of both LBW and in the 
highest WC quartiles in adult life.  
These findings indicate WC is associated with CVD irrespective of BW, however further 
identify that individuals who are born of LBW which grow to have large WC in adult life are 
a high-risk group. This concept is consistent with the developmental origins hypothesis, 
suggesting intrauterine growth retardation, followed by catch-up growth later in life may 
cause the greatest risk to CVD [196, 263]. However, through the quantification and 
comparison of adult WC and BMI with BW in this study, we identify the later-in-life growth 
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has the strongest association with CVD, which may play the significant role in the BW and 
CVD relationship. Results by Frankel et al. also eluded to the phenomena identified in this 
study, where they found LBW participants who were obese in adulthood were at the greatest 
risk for coronary heart disease [196]. Despite discussion of potential explanations for these 
results the specific causal link of this association remains unclear. This study highlights the 
importance of an individual’s CVD risk factors in adult life and identifying BW as a potential 
predisposition for the risk, but not the sole predictor.  
Sensitivity analysis conducted in this study provides evidence for the occurrence of these 
observed associations within the identical sample of participants. In this analysis, WC and 
BMI exhibited high statistical significance and stronger associations with CVD whereas BW 
produced a lower and statistically insignificant association. Through a statistical scope, a 
sample size necessary to produce a statistically significant chance of detecting a difference 
between populations is dependent on the size of the difference expected [264]. The notion 
that a constant sample size produced highly statistically significant results for BMI and WC, 
but not BW, provides further evidence that adult anthropometric measurements in this 
population exhibit stronger associations with CVD than BW.  
This study recognises the dramatic improvements in health facilities and health services 
delivery as major contributors to the reduction in LBW rates, infant mortality rates and the 
steady increase in median BWs experienced within Indigenous Australian communities [152, 
155]. In the context of CVD risk, although the residual effects of generally better access to 
health care would have played a role in the decreasing rates of CVD mortality and morbidity, 
the findings of this study suggest risk factors later in life may have had the greatest influence 
on the CVD incidence. Future health promotion initiatives should continue with a 
multidisciplinary approach to tackle CVD risk factors later in life, while also considering the 
potential predisposition of LBW. 
The phenomena of adult life risk factors playing a significant role in predicting CVD with an 
additional BW predisposition has not been previously investigated in this population. This 
study’s findings highlight the lack of understanding on the mechanisms of CVD risk factor 
interaction and the direction of associations in the existing literature. It remains unclear if 
these are causal relationships or biomarkers of an unknown mechanism. Further research is 
needed to investigate these risk factor interactions within Indigenous Australian populations 
to effectively prevent CVD and consequently close the health disparity gap.  
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This study’s limitations  must be considered before generalising these findings. CVD 
outcomes were identified using hospitalisations representing the most extreme cases of CVD, 
which suggests these reported associations may be underestimated. Associations may be 
further understated due to the commencement date of the follow-up period. Lack of complete 
data for all participants may also be a limitation of this study. For this reason, sensitivity 
analysis was conducted on participants with all anthropometric information and observed 
similar associations as previously identified. There may be a limitation of potential random 
misclassification through a population-based study design. The use of this study design and 
outcome identification are justified as WC, BMI and BW relationships were calculated using 
the same methodology and each participant within each measured variable was subjected to 
the same potential for random misclassification. 
 
Conclusion 
This study identifies that WC has a stronger association with CVD in this remote Indigenous 
Australian population than BMI and BW. Future health promotion initiatives targeting the 
prevention of CVD should focus on risk factors later in life such as WC while using LBW as 
a potential predisposition factor to consider when determining high priority groups.  
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Chapter 7 – C-Reactive Protein (CRP) 
7.1 Literature Review 
In 1930, William Tillet and Thomas Francis from the Rockefeller University were the first to 
discover C-reactive protein (CRP) in patients infected with pneumococcus [265]. It was a 
decade later that researchers described CRP as an “acute-phase reactant” which was increased 
in serum of patients suffering from a spectrum of inflammatory stimuli [266-268]. The 
following five decades presented research that confirmed CRP as a marker of systemic 
inflammation and introduced the potential association between CRP and CVD. Studies until 
the 1990’s were case studies and cross-sectional analyses which were unable to determine if 
CRP was elevated due to the cardiovascular event or was a marker of the risk prior to the 
event [34]. In 1996 and 1997, the Multiple Risk Factor Intervention Study (MRFIT) and 
Physicians Health Study (PHS) were the first prospective cohort studies to find an association 
between CRP and CVD risk which led to significantly increased research activity into CRP as 
a risk marker [269, 270]. 
At the turn of the new millennium CRP research shifted from primarily exploring the 
association between CRP and CVD, to also investigating potential associations between CRP 
and diabetes, and CRP and renal disease. In 2001 and 2003, two studies from USA found 
positive associations between CRP and renal insufficiency, indicated by serum creatinine, in 
elderly adults of general populations [271, 272]. Data from the Third National Health and 
Nutrition Examination Survey (NHANES III) [271] and the Cardiovascular Health Study 
(CHS) [272] were analysed cross-sectionally using multivariate regression models to identify 
participants with higher CRP levels exhibited higher levels of serum creatinine and, hence 
lower eGFR. In 2003, a cross-sectional study of a large non-diabetic cohort in the 
Netherlands found that elevated CRP was significantly associated with low eGFR. This study 
included a sample of a non-hispanic white population and highlighted that the CRP 
association with renal dysfunction was independent of diabetes [273]. These studies were the 
first investigations testing the CRP and renal disease association in samples from general 
populations. 
In 2004, Fried et al analysed longitudinal data from the CHS which had previously been 
studied cross-sectional by Shlipak et al [272] one year earlier. Fried et al tested the 
association between numerous inflammatory indicators and renal disease in this elderly 
population. The participants were followed for up to 7 years (4 years for the later recruited 
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African American cohort) and Fried et al found a positive association between almost all 
indicators of inflammation, including high CRP, with low eGFR [274]. This was the first 
longitudinal study to find an association between CRP and renal disease. Prior to 2004, 
studies investigating CRP and renal disease were cross-sectional analysis, so similarly to the 
MRFIT [269] and PHS [270] studies highlighting the pathway of long term CRP and CVD 
association, the study by Fried et al produced significant evidence that systemic 
inflammation, as indicated by CRP, was associated with long term renal dysfunction. Fried et 
al were also the first to show that the CRP was not a result from renal disease, but may be a 
marker for the development of the disease. Using data from a randomised control trial (the 
CARE study), Tonelli et al found that higher CRP was independently associated with faster 
rates of kidney function loss in CKD. This study concluded that inflammation may mediate 
the loss of kidney function among people with CKD and concomitant coronary disease [275]. 
The findings of Tonelli et al were confirmed in a study by Weiner et al in 2008. A 
longitudinal analysis of data from the CHS and the Atherosclerosis Risk in Communities 
(ARIC) study by Weiner et al investigated the association between non-traditional CVD risk 
factors and myocardial infarction, stroke and all-cause mortality in participants with stage 3 
and 4 CKD. This study highlighted that CKD patients from the CHS with higher CRP had a 
significantly higher risk of progression to myocardial infarction, stroke and all-cause 
mortality, independently [276]. The studies by Weiner et al and Tonelli et al examined the 
long term progression of CKD associated with systemic inflammation and both concluded 
elevated CRP is not only a risk marker for renal dysfunction and development of CKD, but 
also increases the progression of CKD [275, 276]. 
In addition to the study by Fried et al, Fox et al (2010) found CRP was higher in participants 
with CKD (eGFR <60 mL/min/1.73m2) compared to participants without CKD in a study of 
African American participants from the Jackson Heart Study [277]. This cross-section 
analysis provided further evidence that elevated CRP was associated with CKD in different 
ethnic populations. A review of biomarkers in CKD conducted in 2011 identified CRP and 
other markers of inflammation as important research fields where more information is 
needed. The review suggested some biomarkers showed promise, however further validation 
was required in larger, more diverse populations before translation into clinical practice 
[278]. The association between CRP and renal disease has been primarily limited to elderly 
participants of the general US population, non-hispanic white non-diabetic residents of the 
Netherlands, elderly Iranian adults and African American adults. The CRP and CKD 
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association is of particular interest in Indigenous Australian communities due to the 
significantly high rates of renal disease and renal death [24, 52, 279]. 
Studies that have reported no causal association between CRP and cardio metabolic outcomes 
using the Mendelian randomisation framework [280-283]. The basic principle utilised in 
Mendelian randomisation is that genetic variants, that either alter the level of, or mirror the 
biological effects of, a modifiable environmental exposure, itself alters disease risk should be 
related to disease risk to the extent predicted by their influence on exposure to the 
environmental risk factor [284]. In this context, studies in general populations of the world 
have suggested that polymorphisms in the CRP gene are associated with increases in CRP 
levels and thus would theoretically predict an increased risk of cardio metabolic outcomes 
[283]. Zacho et al has identified however, that these polymorphisms are not in themselves 
associated with an increased risk of ischemic vascular disease [283]. The CRP association 
with cardio metabolic outcomes using the Mendelian randomisation framework has not been 
investigated in Indigenous populations.  
 
7.1.1 CRP and CKD in Indigenous Australians 
The association between CRP and albuminuria, eGFR and other traditional CVD risk factors 
was investigated for the first time in a remote Aboriginal Australian community in 2004. 
McDonald et al conducted a cross-sectional study of a small sample of Aboriginal 
Australians and found a positive and significant association between CRP and albuminuria, 
as indicated by ACR. CRP was also positively associated with many other CVD risk factors 
such as BMI, blood pressure, HDL cholesterol and carotid intima-media thickness. The crude 
regression model showed a positive and significant association between CRP and CKD as 
indicated by eGFR, however failed statistical significance after adjustment for age and sex 
[285]. This finding was likely due to the small sample size, however it was able to show the 
concept that CRP may play a role in CKD in the remote Indigenous Australian population.  
Three studies by Wang and Hoy followed the investigation by McDonald et al in a different 
remote Indigenous Australian community. The first was a cross-sectional study exploring the 
distribution of CRP in the community and compared to published distribution data in 
international populations. This study highlighted that CRP values were significantly higher in 
Aboriginal people than populations in USA, Germany, Japan, Thailand and UK and that CRP 
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changes with age [286]. Consistent with this study, Claes et al (2014) also found that median 
CRP levels were higher in Indigenous Australian CKD patients than non-Indigenous 
Australian CKD patients [287]. Secondly, Wang and Hoy used a cohort study design which 
followed participants for up to 13 years and found a positive and significant association 
between CRP and risk for type 2 diabetes [44]. The third study by Wang and Hoy conducted 
in 2010, also found a positive and significant association between CRP and CVD incidence in 
a prospective cohort following participants for up to 13 years [288]. The studies by Wang and 
Hoy provide significant evidence suggesting high CRP levels dramatically increase the risk 
for CVD and type 2 diabetes in a remote Indigenous Australian community. To date, these 
were the only longitudinal investigations of CRP and chronic disease in Indigenous 
Australians and provided the most comprehensive information regarding the potential role 
CRP may play in the development of chronic disease in this minority population. Although 
CRP has been investigated in association with diabetes and CVD in this population, the long 
term association between CRP and renal disease is yet to be explored.  
McDonald et al provided evidence that there may be an association between CRP and eGFR 
and Wang and Hoy found associations between CRP and other chronic diseases. The 
significantly high rates of CKD in Indigenous Australian communities suggest that the role of 
CRP as a potential risk marker of the long term development of renal disease in this 
population must be explored.   
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Chapter 8 - CRP and CKD 
 
This chapter investigates CRP, as a marker of systemic inflammation, and its association with 
chronic kidney disease hospitalisations. As outlined in Chapter 8, there is a large gap in the 
literature regarding kidney disease and CRP. There is yet to be any long term investigation 
between CRP and the development of CKD in any Indigenous population worldwide. Our 
study community experiences high rates of kidney disease [24], so identifying the role CRP 
may play in the association may significantly benefit the community and assist in the 
understanding of the mechanism for early clinical intervention.  
The following chapter details a study published in Nephrology. The study investigated 
systemic inflammation as a marker of, or may play a role in, the development of chronic 
kidney disease in the Indigenous Australian community. The following chapter addresses 
Research Question 8, as proposed in Chapter 1.2.2.  
 
8.1 Original Research article published in Nephrology 
Arnold, L.W., Hoy, W.E. and Wang, Z. High C-reactive protein levels increase risk for 
chronic kidney disease hospitalisations in adults of a remote Indigenous Australian 
community - A prospective cohort study. 2016. Nephrology, doi: 10.1002/NEP.12841 
 
The association between C-reactive protein levels and the risk for chronic kidney 
disease hospitalisations in adults of a remote Indigenous Australian community - A 
prospective cohort study 
Luke W Arnold1, Wendy E Hoy1 and Zhiqiang Wang1 
1Centre for Chronic Disease, The University of Queensland School of Medicine 
Keywords: C-reactive protein, chronic kidney disease, Indigenous Australians, epidemiology 
 
Abstract 
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Background: Indigenous Australians are significantly burdened by chronic kidney disease 
(CKD). Elevated levels of C-reactive protein (CRP) have been associated with diabetes and 
cardiovascular incidence in previous studies. Elevated CRP has been associated with 
albuminuria and reduced eGFR in cross-sectional studies. This study investigated the long 
term predictive association between CRP measured at a baseline exam and the incidence of a 
subsequent CKD-related hospitalisation. 
Methods: Health screening examinations were conducted in individuals of a remote 
Indigenous Australian community between 1992 and 1998. The risk of subsequent CKD 
hospitalisations, documented through Northern Territory hospital records up to 2010, was 
estimated with Cox proportional hazard models in people aged over 18 years at the baseline 
screen and who had albumin creatinine ratios (ACRs) less than 34g/mol.  
Results: 546 participants were eligible for our study. Individuals in the highest CRP tertile at 
baseline had increased levels of traditional cardiovascular risk factors. They also had almost 4 
times the risk of a CKD-related hospitalisation compared with participants in the lowest CRP 
tertile (HR=3.91, 95%CI 1.01-15.20, p=0.049) after adjustment for potential confounding 
factors. Participants with CRP concentrations greater than 3mg/L had almost 3 times the risk 
of CKD hospitalisations than those ≤3mg/L (HR=2.84, 95%CI 1.00-8.00, p=0.049). 
Furthermore, risk of CKD hospitalisations increased 34% per doubling of baseline CRP 
(HR=1.34, 95%CI 1.04-1.74, p=0.024). 
Conclusions: In individuals in this remote indigenous community without overt albuminuria 
at baseline the risk for incident CKD related hospitalisations was predicted by elevated C-
reactive protein levels almost a decade earlier. Further research is needed to understand the 
roles that CRP and systemic inflammation play in CKD risk. 
 
What this study adds 
• Elevated CRP levels can predict the risk for incident CKD hospitalisations almost a 
decade later in life 
• Elevated CRP, a marker of systemic inflammation, has a high prevalence in this 
remote Indigenous Australian community which also has high levels of CKD 
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Background 
Renal disease is one of the most significant contributors to hospitalisations in Australia. 
Chronic kidney disease (CKD) accounted for more than 14% of all hospitalisations in 
Australia in 2012-13 [52]. Remote regions have double the CKD hospitalisation rates of 
major cities [52], which is largely due to the higher rates observed in  Indigenous 
communities. Remote Indigenous Australians accounted for 54% of CKD hospitalisations 
despite only making up 15% of the remote population between 2006/07 and 2008/09 [279]. 
Aboriginal communities have some of the highest rates of CKD, end stage renal disease 
(ESRD) and renal deaths in Australia [24]. The progression from CKD towards ESRD and 
the increased incidence of CKD is a significant public health problem for these communities 
and health systems and requires urgent intervention [285].  
C-reactive protein (CRP) concentration is a marker of low grade systemic inflammation. 
Typically associated with inflammation caused by infection, high CRP levels have been 
found as a marker of renal insufficiency in elderly general populations [271, 272]. Although 
there is yet to be an investigation of CRP predicting CKD hospitalisations, a study reviewing 
evidence of biomarkers for CKD in general populations suggested that high CRP may be 
associated with CKD [278]. The Jackson Heart Study found that high CRP levels in African 
Americans were associated with a greater risk of renal dysfunction compared to those with 
lower CRP levels [277]. A longitudinal study by Fried et al, assessed the long term 
association between elevated CRP and renal disease [274]. Their study showed that high CRP 
was associated with long term renal dysfunction and suggested that high CRP was not a result 
of the renal disease, but may be a marker for its development. These studies in international 
populations suggest a better understanding of the association between CRP and CKD may 
provide opportunities for preventing or reducing the progression of CKD. 
Studies in Indigenous Australians have found associations of elevated CRP with chronic 
diseases such as diabetes and cardiovascular disease (CVD) hospitalisations [44, 288]. A 
study in a remote Northern Territory community found high CRP was associated with 
numerous renal disease and CVD risk factors [285]. Although CRP has been associated with 
many risk factors and markers of renal disease, an association between CRP and an incidence 
of a CKD-related hospitalisation is yet to be determined in Indigenous Australians. A 
predictive association between CRP and CKD may provide opportunities for early detection, 
prevention or delayed progression of CKD, in a community which has high rates of renal 
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disease and renal death [24]. Reducing the burden of CKD in Indigenous communities may 
also help reduce the life expectancy gap between Indigenous and non-Indigenous Australians. 
The aim of our study was to investigate, in a remote Indigenous Australian community, the 
association between CRP at baseline examination and the first CKD-related hospitalisation,  
in adults with ACR <34g/mol at baseline, using cohort data following participants for up to 
18 years.  
 
Methods 
A community-wide health screening examination was conducted in a remote indigenous 
Australian community in the Northern Territory between 1992 and 1998. Participation was 
voluntary and written informed consent was obtained from the individual. Participants were 
included in this current report if they were: born to an Aboriginal mother, older than 18 years, 
a member of the community studied, had an eGFR ≥ 60 mL/min/1.73m2 and had a urinary 
albumin to creatinine ratio (ACR) < 34 g/mol at baseline. 
 
Measurements and Identification of Events 
Methods for baseline examinations have been described in detail elsewhere [246]. Briefly, 
blood and urine samples and anthropometric measurements were taken during health 
screening examinations (Appendix 2). The participants were also interviewed to obtain 
lifestyle information such as tobacco use and alcohol consumption. Estimated glomerular 
filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) method. High sensitivity CRP was analysed using 
immunoturbidimetric CRP assay on a Hitachi 917 analyzer (Roche Diagnostics Australia) 
with a detection limit of 0.03 mg/L. The assay’s analytical range was from 0.1 to 20 mg/L. 
CRP concentrations greater than 20 mg/L were measured using diluted samples. The 
imprecision of the assay is less than 5% [44]. Microalbuminuria was defined by an ACR 
between 3.4 and 33.9 g/mol. 
The first case of a CKD-related hospitalisation was defined as the first occurrence of ICD-9 
and ICD-10 codes detailed in Table 8.1. The selected ICD codes used to identify chronic 
kidney disease have been validated previously [289-291]. These hospitalisation records 
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included any admissions and emergency department visits for all patients who presented to a 
public hospital in the Northern Territory between 1992 and 2010. ICD-9 codes were mapped 
retrospectively according to ICD-10 codes. For example, those originally classified as 585.9 
unspecified chronic renal failure by ICD-9 codes were reclassified as 585.9 unspecified 
chronic kidney disease by ICD-10 codes. The identified ICD code was not necessarily the 
principal diagnosis for the hospitalisation, however it was the first hospitalisation where a 
CKD-related ICD code was recorded. This means many of the identified hospitalisations 
recorded CKD as an additional diagnosis. No cases of CKD identified were dialysis-related. 
For those identified as a case of CKD, their follow up time was calculated from the time of 
their baseline exam to the time of their first CKD-related hospitalisation. Those who had not 
reached the endpoint were considered “censored” at the date of 31st December 2010. 
Participants who did not have a documented hospitalisation of the endpoint, but died before 
the end of the follow up period from another cause were censored at the time of death. 
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Figure 7.1. Biomarkers of chronic kidney disease (CKD) progression and renal 
cardiovascular disease (CVD) [278] 
 
Statistical Analysis 
Means of baseline characteristics were calculated for normally distributed continuous 
variables and compared using ANOVA, while geometric means were calculated for CRP, 
triglycerides, urinary ACR and eGFR and compared using Kruskal-Wallis tests. Proportions 
of categorical variables were calculated and compared using chi-squared (χ2) tests. Hazard 
ratios and 95% confidence intervals (95% CI) were calculated using Cox proportional hazard 
models. Potential confounding variables such as age, sex, BMI, HDL cholesterol, ACR, 
triglycerides, systolic blood pressure, diabetes, alcohol use and tobacco use were adjusted for 
in Cox proportional hazard models. The adjustment of these potential confounding variables 
is consistent with other studies testing the CRP and CKD association [273, 275, 292] and the 
variables highly correlated with CRP in Indigenous Australian people [285]. Participants 
were categorised according to CRP tertiles and dichotomous groups (defined as CRP greater 
than 3mg/L and less than or equal to 3mg/L of CRP concentration) for analysis. CRP values 
were log-transformed by the base of 2 for analysis as a continuous variable. A total of four 
Cox proportional hazard models were conducted for continuous variable analysis in a step-
wise sequence. Model 1 adjusted for age and sex. Model 2 adjusted for variables in Model 1, 
BMI, systolic blood pressure, HDL cholesterol and triglycerides. Model 3 adjusted for 
variables in Model 2, diabetes, alcohol use and tobacco use. Model 4 adjusted for variables in 
Model 3 and ACR. The conceptual model presented in Figure 7.1 highlights the intricate 
interrelationships of biomarkers of CKD and CVD. The step-wise analysis enabled 
differentiation and transparency to what affects and potential confounding the risk factors 
may have on the effect estimates in the Cox proportional hazards models. 
 
Ethics Approval 
Ethical approval was provided for this study by the Behavioural and Social Sciences Ethical 
Review Committee on behalf of School of Medicine in The University of Queensland 
(2011001232; Appendix 1).  
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Table 8.1. ICD-10 codes and corresponding ICD-9 codes used to identify chronic kidney 
disease hospitalisations. 
Code description ICD 10 Codes 
Corresponding 
ICD 9 Codes 
N † 
Type 1 diabetes mellitus with incipient diabetes 
nephropathy adequately or inadequately controlled by 
insulin, diet, or oral agents 
E10.2 250.43, 250.41  
Type 2 diabetes mellitus with incipient diabetes 
nephropathy adequately or inadequately controlled by 
insulin, diet, or oral agents 
E11.2 250.40, 250.42 3 
Other specified diabetes mellitus with incipient 
diabetes nephropathy adequately or inadequately 
controlled by insulin, diet, or oral agents 
E13.2 249.41  
Unspecified diabetes mellitus with incipient diabetes 
nephropathy adequately or inadequately controlled by 
insulin, diet, or oral agents 
E14.2 249.40  
Hypertensive renal disease I12 403 1 
Hypertensive renal and heart disease I13 404  
Glomerular disorders in diseases classified elsewhere N08 582 1 
Renal tubulo-interstitial disorders in transplant 
rejection 
N16.5 588  
Chronic Kidney Disease N18 585 28 
Unspecified renal failure N19 586 1 
Kidney Transplant Failure and rejection T86.1 996.81  
Kidney Transplant Status Z94.0 V42.0 2 
† The number of first case of chronic kidney disease hospitalisations identified during the 
follow up period 
 
Results 
Our study included 546 participants, who represented 80 % of the age-eligible population of 
this remote indigenous Australian community, based on the 1996 Census. Fifty-four percent 
of this sample were men, however a higher proportion of women were present in the higher 
CRP tertiles (Table 8.2). The age of the study population ranged from 18 to 73 years. The 
median and total follow-up time of the study population was 16.8 and 8406.9 person-years, 
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respectively. A total of 36 people had an incident CKD-related hospitalisation during the 
follow-up period (Table 8.1). Of these participants, the median time between their CRP 
measurement and the date of their first CKD-related hospitalisation was 9.16 years.  
Table 8.2. Baseline characteristics of adults in a remote indigenous Australian community 
stratified by CRP tertiles 
 Tertiles  
 1st 2nd 3rd p 
 n Mean (SD) n Mean (SD) n Mean (SD)  
Age, years 179 29.6 (8.8) 183 32.6 (11.7) 184 35.0 (11.6) <0.001 
Men, n (%) 179 119 (66%) 183 108 (59%) 184 69 (38%) <0.001 
Diabetes, n (%) 178 2 (1.1%) 182 5 (2.8%) 184 8 (4.4%) 0.173 
Tobacco use, n (%) 176 131 (74%) 181 141 (78%) 183 125 (68%) 0.110 
Alcohol use, n (%) 176 136 (77%) 181 111 (61%) 183 104 (57%) <0.001 
Systolic BP, mmHg 177 120.4 (17.2) 179 118.4 (16.2) 182 118.6 (16.0) 0.458 
Diastolic BP, mmHg 177 72.1 (12.6) 179 72.5 (12.3) 182 72.6 (12.2) 0.942 
BMI, kg/m2 177 21.9 (3.8) 182 23.1 (4.5) 184 24.7 (5.7) <0.001 
Waist circumference, cm 175 79.7 (9.5) 181 86.3 (11.3) 181 91.7 (13.9) <0.001 
Total cholesterol, mmol/L 174 4.45 (0.95) 177 4.67 (1.11) 176 4.53 (1.03) 0.147 
HDL cholesterol, mmol/L 171 1.23 (0.32) 172 1.13 (0.29) 171 1.04 (0.23) <0.001 
ACR, g/mol † 177 0.98 (0.81-1.18) 182 1.67 (1.35-2.08) 183 2.79 (2.27-3.43) <0.001 
Microalbuminuria, n (%) 179 37 (21%) 183 57 (31%) 184 85 (46%) <0.001 
Triglycerides, mmol/L † 173 1.40 (1.29-1.52) 177 1.69 (1.55-1.84) 176 1.73 (1.61-1.87) 0.056 
CRP, mg/L † 179 1.28 (1.19-1.38) 183 4.25 (4.06-4.44) 184 15.14 (13.86-16.54) <0.001 
eGFR, mL/min/1.73m2 † 107 101.0 (98.1-104.0) 114 99.5 (96.5-102.6) 134 99.5 (96.9-102.1) 0.588 
Results are presented as mean (SD) unless otherwise stated. † Geometric mean (95% CI).  
BP, blood pressure; BMI, body mass index; HDL, high density lipoproteins; ACR, 
albumin/creatinine ratio; CRP, C-reactive protein; eGFR, estimated glomerular filtration rate. 
Microalbuminuria was defined as an ACR between 3.4 and 33.9 g/mol.    
 
The baseline characteristics of participants divided into CRP tertiles are detailed in Table 8.2. 
They highlight the increased level of other chronic disease risk markers in the higher CRP 
tertiles. Mean waist circumference, BMI, HDL cholesterol, ACR and triglycerides values in 
the higher CRP tertile suggested a particularly increased risk for CVD, diabetes and CKD. 
The prevalence of microalbuminuria increased dramatically from 21% in the lowest CRP 
tertile to 31% and 46% in the middle and highest tertiles, respectively. 
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Figure 8.0.2. Crude incidence rates of CKD hospitalisations for participants in each CRP 
tertile with and without microalbuminuria.  
 
The incidence rates of people with CKD-related hospitalisations increased from 1.1 per 1000 
person-years (95%CI 0.34-3.26) in the first tertile to 4.6 (95%CI 2.69-7.99) and 7.3 (95%CI 
4.69-11.27) in the second and third, respectively. Figure 8.1 shows that participants with 
microalbuminuria had higher incidence rates of CKD hospitalisations compared with 
participants without microalbuminuria. CKD-related hospitalisation incidence for participants 
with microalbuminuria increased from 4.6 per 1000 person-years (95%CI 1.48-14.22) in the 
lowest CRP tertile to 10.8 (95%CI 5.61-20.74) and 15.6 (95%CI 9.68-25.05) in the second 
and third CRP tertiles, respectively. Survival analysis in Table 8.3 highlighted that 
participants in the highest CRP tertile had 7 times the risk of a CKD-related hospitalisation 
than the lowest CRP tertile (HR = 7.01, 95% CI 2.08-23.59, p=0.002). This association 
remained significant after adjustment for age, sex, BMI, HDL, ACR, triglycerides, systolic 
blood pressure, diabetes, alcohol use and tobacco use. The adjusted model showed almost 4 
times the risk of CKD between participants in the highest and lowest tertiles of CRP at 
baseline (HR = 3.91, 95% CI 1.01-15.20, p=0.049). Dichotomous group analysis showed that 
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participants with CRP levels greater than 3 mg/L had almost 3 times the risk of CKD 
hospitalisation incidence than those with CRP ≤ 3 mg/L (HR = 2.84, 95% CI 1.00-8.00, 
p=0.049), after adjustment for potential confounding.  
Table 8.3. Risk for chronic kidney disease hospitalisations by CRP stratification. 
   Crude  Adjusted † 
  n 
(events) 
HR 95% CI p n (events) HR 95% CI p 
  546 (36) 
   
501 (31) 
   
Tertiles 
         
 
1st 179 1 
  
165 1 
  
 
2nd 183 4.46 1.27-15.66 0.020 168 3.42 0.91-12.90 0.069 
 
3rd 184 7.01 2.08-23.59 0.002 168 3.91 1.01-15.20 0.049 
Groups          
 ≤ 3 mg/L 218 1   201 1   
 > 3 mg/L 328 4.46 1.73-11.46 0.002 300 2.84 1.00-8.00 0.049 
† Adjusted for age, sex, BMI, HDL, ACR, triglycerides, systolic blood pressure, diabetes, 
alcohol use and tobacco use. 
 
Table 8.4. Risk for chronic kidney disease hospitalisations per doubled increase in CRP †. 
 n events, n HR 95%CI p 
Crude 
546 36 1.38 1.13-1.68 0.001 
Model 1 
546 36 1.35 1.10-1.65 0.004 
Model 2 
505 31 1.37 1.07-1.75 0.013 
Model 3 
501 31 1.34 1.04-1.74 0.024 
Model 4 
501 31 1.26 0.97-1.66 0.088 
Crude b 
501 31 1.31 1.06-1.62 0.014 
† CRP was log transformed by the base of 2, which is the equivalent of each doubling 
increase of CRP 
‡ Crude hazard ratio calculated for participants who had complete information for all 
variables in Model 4. Model 1 adjusted for age and sex. Model 2 adjusted for variables in 
Model 1, BMI, systolic blood pressure, HDL cholesterol and triglycerides. Model 3 adjusted 
for variables in Model 2, diabetes, alcohol use and tobacco use. Model 4 adjusted for 
variables in Model 3 and ACR. 
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Table 8.4 demonstrates the risk for chronic kidney disease hospitalisations per log increase in 
CRP. These hazard ratios represent the increased risk for CKD per doubled increase in CRP 
concentration. The unadjusted model showed a 34% increased risk of CKD as CRP levels 
doubled (HR = 1.38, 95% CI 1.13-1.68, p=0.001). The following models adjusted for various 
confounding factors continued to show this strong and statistically significant association. 
The models showed a 35%, 37%, 34% and 24% increased risk of CKD as CRP levels 
doubled for adjusted models 1, 2 and 3, respectively (HR = 1.35, 95% CI 1.10-1.65, p=0.004; 
HR = 1.37, 95% CI 1.07-1.75, p=0.013; HR = 1.34, 95% CI 1.04-1.74, p=0.024). Including 
ACR in model 4 decreased the estimated risk to 26%, however this model did not achieve 
statistical significance (HR = 1.26, 95% CI 0.97-1.66, p=0.088). Unadjusted subgroup 
analysis of the participants with complete information for all variables in Model 4 (Table 
8.4), highlighted a similar risk as observed in the unadjusted model including all study 
participants (HR = 1.31, 95% CI 1.06-1.62, p=0.014). 
 
Discussion 
This is the first study to show an association between CRP at baseline examination and 
incident CKD-related hospitalisations almost a decade later in Indigenous Australians who 
had ACR <34 at baseline. Our findings show that higher CRP values are associated with 
increased risk for future CKD-related hospitalisations in adults of this remote Indigenous 
Australian community. Participants in the highest CRP tertile had almost four times the risk 
for incident CKD-related hospitalisations compared with the lowest tertile after adjustment 
for potential confounding variables. The risk for incident CKD-related hospitalisations 
increased as CRP doubled.  
This study provided further evidence to previous studies investigating CRP and CKD risk 
markers in a remote Australian Aboriginal community. A study by McDonald et al in found 
that increased CRP levels were associated with increased ACR and albuminuria in another 
remote Aboriginal group [285]. In that study, an association between CRP and eGFR was 
investigated, however only the crude association per standard deviation increase was 
statistically significant. Once the regression models testing the CRP and eGFR association 
were adjusted for age and sex, it was not statistically significant, likely due to a small sample 
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size [285]. In the current study we found that after adjustment for common CVD risk factors, 
high CRP levels at baseline predicted an increased risk for a future incident CKD-related 
hospitalisation with statistical significance, suggesting that the CRP-CKD association was 
independent of other CVD risk factors. The study by McDonald et al was a cross-sectional 
study of 237 participants, while our study had a larger sample population and the longitudinal 
cohort design enabled us to observe that elevated CRP at baseline predicted CKD-related 
hospitalisations later in life.  
Our findings of an association between CRP and future CKD-related hospitalisation are also 
consistent with a cross-sectional study of African American participants in the Jackson Heart 
Study. In that study, CRP was significantly higher in participants with existing CKD (< 60 
mL/min/1.73m2 eGFR) than in participants without CKD [277]. Other international studies in 
general populations show a similar association, suggesting higher CRP levels are associated 
with CKD [273, 274]. This suggests the CRP and CKD association observed in our study is 
not exclusive to remote indigenous Australian communities. A study by Wang and Hoy in 
this same Indigenous community showed median CRP levels were higher than in several 
other international populations [286]. More recently Claes et al, in a sample of over 23,000 
CKD patients including almost 2,700 Indigenous Australians, showed Indigenous Australian 
CKD patients had significantly higher median CRP levels than their non-Indigenous 
counterparts [287].   
It is not sufficiently clear, the role albumin-creatine ratio may play in the CRP and CKD 
relationship observed in our study. CRP remained a risk marker of CKD-related 
hospitalizations independent of ACR in categorical analysis in this study. The incidence rates 
for CKD-related hospitalisations were higher in participants with microalbuminuria in all 
CRP tertiles than in those without microalbuminuria. These findings are consistent with a 
recent study in this population which showed higher ACR predicts natural and renal deaths 
[3]. We expected that participants microalbuminuria would likely progress to renal disease, 
thus accounting for much of the incidence of observed CKD hospitalisations. Our categorical 
analysis showed a positive and significant association between the lowest and highest CRP 
tertiles (p=0.049) and also in the group of participants with CRP levels greater than 3mg/L 
compared to the ≤3mg/L CRP group (p=0.049), after adjustment for ACR at baseline. 
However, continuous variable analysis showed positive and significant associations between 
doubling increase CRP and CKD hospitalisations for all models except where ACR was 
included as a potential confounding variable (p=0.088). This study was unable to identify if 
130 
 
this statistically insignificant association was in continuous variable analysis was due to a 
small sample size. CRP remained an independent risk predictor of CKD hospitalisations in 
later life for participants with ACR <34g/mol at baseline in categorical analyses. 
Our study provides evidence that CRP is a significant chronic disease risk marker in this 
remote indigenous Australian community. The relatively short 19 hour half-life of CRP [293] 
and the fast catabolism of CRP by liver cells suggests that the elevated concentrations are 
caused by consistent stimuli associated with systemic inflammation. These may increase their 
risk for chronic disease. Previous studies in this community had found associations between 
CRP and other chronic diseases such as diabetes and cardiovascular disease [44, 288]. In 
conjunction with these previous studies, it appears that individuals with elevated CRP levels 
are more likely to develop diabetes, CVD and CKD, independently. The significant chronic 
disease burden in this remote indigenous community is highlighted by the elevated incidence 
rates of diabetes, CVD and CKD identified in participants with high CRP levels. 
Investigations into stimuli causing chronic systemic inflammation and elevated CRP 
concentrations are necessary to determine the underlying cause of this increased chronic 
disease risk. Studies in other Indigenous Australian communities are necessary to allow 
researchers to assess the generalisability of these CRP and CKD associations.  
Evidence from our study supports the use of CRP as a risk marker of kidney disease in 
Indigenous Australians and an area of research which warrants further investigation. A 
review of biomarkers for CKD identifies that the limit of implementing many emerging CKD 
biomarkers into clinical practice is the lack of large studies conducted in diverse populations 
[278]. Our study population was over 80% representative of the age-eligible community and 
were followed for up to 18 years using hospitalisation records. To our knowledge, this is the 
largest community sample with the highest level of community participation and longest 
follow-up in Indigenous Australian community-based CKD research.  
There are limitations in this study. Our findings may underestimate the association between 
CRP and CKD, because hospitalisations represent the most severe cases of CKD. 
Furthermore, by using ICD codes there may have been coders’ bias. The direction of the 
association between CRP and CKD is complicated due to diabetes and CVD sharing many 
risk factors, and also playing a role in the development of CKD, however, our observed 
associations remained positive and significant after adjustment for CVD risk factors and 
diabetes. The underlying mechanism of how CRP and inflammation increases the risk of 
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CKD remains unknown. It is unknown if CRP is the risk factor of CKD or whether CRP is a 
marker of other unknown factors causing CKD. Nevertheless, CRP is a novel indicator of 
CKD in Indigenous Australians which should be utilised whilst further research is conducted 
to investigate other potential causes of the increased CRP levels. Incomplete data for all 
confounding factors may have limited our ability to detect the true association between CRP 
and CKD-related hospitalisations in this community. Sensitivity analysis showed the crude 
HR of the subgroup with complete information of the final Cox proportional hazard model 
was similar to the crude HR for the total study population in the log-transformed CRP 
analysis. Sensitivity analysis suggests that incomplete data unlikely affected our ability to 
observe the true association. 
 
Conclusion 
This study found that systemic inflammation, as indicated by C-reactive protein, 
independently predicts risk for hospitalisations where chronic kidney disease was first 
recorded in adults with ACR less than 34g/mol at baseline. Our findings suggest 
understanding the mechanisms of elevated CRP may help identify opportunities to reduce the 
CKD burden in this community. Future investigations are needed to better understand how 
the association between CRP and albuminuria affects the long term relationship between CRP 
and future CKD-related hospitalisations.  
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Chapter 9 – Discussion 
The success of research may be evaluated on a number of criteria. Successful research should 
have an explicit and measurable research agenda, appropriate data and methodology to 
address the research question, be presented in an objective manner, suitably report on 
findings and draw appropriate conclusions based on the generalisability of the results, all 
while being conducted in an ethical manner. Using these criteria, the research detailed in this 
thesis may be considered successful. 
An explicit research agenda was provided in Chapter 1.2. Chapter 1.2.1 detailed four key 
objectives which this thesis aimed to achieve. To ensure these objectives were achievable 
Chapter 1.2.2 proposed eight research questions, each aimed to address a key objective in 
Chapter 1.2.1.  Furthermore, each of the manuscript chapters included in this thesis was 
designed to address particular research questions of Chapter 1.2.2.   
Chapter 2.2.1 provided evidence of a non-linear association between HbA1c and all-cause 
mortality as proposed in Research Question 1 to address Objective 1 of this thesis. Chapter 
3.1 provided detailed solutions for Research Questions 2 and 3 as proposed in Chapter 1.2.2 
to satisfy Objective 2 as identified in Chapter 1.2.1. Chapter 3.1 presented the health profile 
of the community who did not have a diagnosis of diabetes, but may have been at high risk 
according to their HbA1c level. This chapter highlighted that participants with higher HbA1c, 
and subsequent higher risk of diabetes, also had higher numbers of cardiovascular disease 
risk factors. Chapter 3.1 further provided clarity surrounding the potential for particular 
HbA1c cut-off value to be utilised to highlight an individuals’ high risk of chronic disease. In 
this remote community, 5.7-6.4% HbA1c categories encompassed a significant proportion of 
the population who also had a high number of chronic disease risk markers, which suggests 
HbA1c screening, as a marker of diabetes risk, may play a role in identifying individuals at 
high risk of other chronic diseases. 
The information presented in Chapter 5.1 provided solutions for Research Questions 4 and 5 
in Chapter 1.2.2 which satisfies Objective 3 in Chapter 1.2.1. Chapter 5.1 details that resident 
adults of this community were 43% more likely to be hospitalised for any CVD outcome if 
they were born of LBW, compared to their normal birth weight counterparts. Chapter 5.1 
further identified that women born of LBW were more than 2.6 times at risk than their 
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normal birth weight counterparts of CVD hospitalisations, whereas there was no significant 
difference of risk for men.  
Chapters 6.1 and 6.2 presented detailed solutions for research questions 6 and 7 as proposed 
in Chapter 1.2.2 to satisfy Objective 4 in Chapter 1.2.1. Increased adult body size, as 
indicated by waist circumference (WC), showed a higher risk for CVD than BMI and BW. 
Additionally, Chapters 6.1 and 6.2 showed that risk for CVD was amplified if an individual 
was born of low weight and had a large WC in adult life. 
Chapter 8.1 provided solutions for Research Question 8 proposed in Chapter 1.2.2 to satisfy 
Objective 5 in Chapter 1.2.1. Chapter 8.1 provided evidence that elevated CRP levels 
increase the risk for CKD-related hospitalisations independent of other potential confounding 
factors. The findings presented in Chapter 8.1 also showed that systemic inflammation, as 
indicated by elevated CRP levels, predicted the risk for CKD-related hospitalisations almost a 
decade later in life.    
The strengths and limitations of this thesis are discussed in detail in the relevant chapters 
(Chapters 2.2.1, 3.1, 5.1, 6.2 and 8.1), but briefly, the use of hospitalisation records may have 
underestimated the reported associations between exposure and outcome in this thesis, as 
hospitalisations represent the most severe cases of chronic diseases. Additionally, the sample 
size of participants in this thesis may be smaller than other general population-based 
observation studies, however it should be recognised that, to our best knowledge, the sample 
included in this thesis is one of the largest and most representative Indigenous Australian 
cohort studies.  
The studies included in this thesis may be limited by potential sources of bias, such as 
regression dilution. Regression dilution bias is a key source of measurement error in 
longitudinal studies where single measures of biological exposures as used, such as CRP 
[294-296]. It cannot be excluded that measurement errors in the health screening 
examinations may have an impact on the observed associations reported. The findings of the 
thesis are limited by the inherent limitations of observational studies and routinely collected 
data such as residual confounding [297] and potential misclassification bias [298].  
Measurement error in confounding variables will lead to residual confounding, however the 
direction of the bias is unclear. Additionally, there may be unmeasured confounding variables 
not included in the adjustment models, which may have otherwise contributed to the observed 
association.   
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Each of these potential biases are recognised as random in this thesis, as opposed to 
systematic. The data collection methodology is detailed in Appendix 2, with strict clinical 
processes. The findings cannot exclude random measurement error, potentially leading to 
residual confounding, regression dilution bias or misclassification. 
Another limitation of this thesis was the incomplete data for some variables in the health 
screening examinations. These missing data was inconsistent across participants which made 
analysis and interpretations of findings difficult and may have caused a selection bias. This 
limitation was overcome by a variety of statistical methodologies. Sensitivity analysis, 
numerous adjustment models and subgroup analysis were utilised, where appropriate, to 
ensure the data was adjusted by appropriate confounding variables without the magnitude or 
direction of the association inadvertently changing due to missing data. The potential effect 
of missing data was monitored in all analyses in this thesis. Other methods such as 
categorical analysis and adjusted z-scores also ensured associations between exposure and 
outcome variables were tested appropriately.     
There were also a number of strengths of this thesis. One of the most significant strengths is 
described in Chapter 1.1, the strength of the relationship between the research group and the 
community who partnered to make this thesis possible. The established relationship of trust, 
respect and honesty between Professor Hoy’s group and the Tiwi community is unique to the 
research associated with the data used in this thesis. This thesis must attribute much of the 
success of this research to the collaboration of the stakeholders involved in the data 
collection.  
The significant age-eligible representation in health screening examinations [2] is reflected 
by the strong community engagement, which provides substantial confidence when 
generalising the research of this thesis across the Tiwi community. The findings of this thesis 
provide evidence of long term associations for risk factors with chronic disease outcomes 
which, due to the significant population representation in the studies, enables direct feedback 
for health services direction and improvements.  
The thesis has exposed potential opportunities for post-doctoral research. The potential 
mechanisms of the associations identified in this thesis are largely unknown. For example, 
investigation of the underlying mechanism of the association between HbA1c and other 
cardiovascular risk factors was not in the scope of this thesis, however further knowledge of 
this mechanism would significantly contribute to the current literature. Additionally, 
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investigating how the mechanism compares between Indigenous and non Indigenous people 
would be of significant interest. A further opportunity for post-doctoral research would be to 
investigate the observed associations in this thesis using the Mendelian randomisation 
framework [284]. This would enable measurement of genetic variation and strengthen the 
causal inference of associations reported in the thesis. 
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Chapter 10 – Conclusion 
This thesis provides significant evidence of the long term associations between chronic 
disease risk factors and the development of cardiovascular disease, diabetes and chronic 
kidney disease in adult life. This thesis presents the first investigations for these long term 
associations in Indigenous Australian populations. The use of observational studies at a 
population level highlights the significant disadvantage of this community. Optimistically, 
these risk factors which play such a large role in the chronic disease burden, are largely 
preventable, or at the very least, manageable if detected early.  
Early life risk factors such as LBW, are easily identifiable, and allow health care services to 
tailor health promotion initiatives for these people and address the associated predisposition 
for chronic diseases later in life. More specifically, this community would significantly 
benefit from continued initiatives aimed at improving maternal and antenatal health, which 
would subsequently lead to improved birth weights.  
This thesis also found that a large proportion of this community are at high risk of developing 
diabetes. Systematic HbA1c screening could be adopted in high risk Indigenous communities 
in the future, which would allow early identification of people, not only at high risk for 
diabetes, but whom also have numerous cardiovascular risk factors. This thesis also identified 
that there is a high prevalence of diabetes-related complications in this community. This 
reinforces the increased need to prevent or slow the progression of diabetes for the people of 
this remote community. 
CRP was highlighted by this thesis as a risk marker of CKD and provides significant 
opportunities for prevention or delayed progression of chronic disease in this remote 
Indigenous Australian community. The role of systemic inflammation in chronic disease 
development still remains unknown, however findings of this thesis suggests elevated CRP 
levels significantly contribute to the high rates of CKD in this community. Combined with 
findings from other studies, this thesis suggests interventions addressing high CRP levels 
may reduce the burden of CVD, diabetes and CKD in this remote community.  
This thesis addressed the increasing burden of CVD, CKD and diabetes in a remote 
Indigenous community by investigating the association of BW, HbA1c and CRP as risk 
markers. This thesis has identified that it is significantly beneficial to include the 
predisposition of early life risk factors such as LBW when implementing CVD prevention 
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initiatives. Furthermore, this thesis has identified the significant comorbid status of this 
community. A high proportion of individuals at high risk for diabetes also have numerous 
CVD risk markers. In addition to CVD and diabetes sharing risk markers, this thesis has also 
identified CRP as a common risk marker of CVD, diabetes and CKD. A collaborative effort 
is needed to target prevention interventions for these chronic diseases in this remote 
Indigenous Australian community. An interdisciplinary team is necessary which addresses 
intrauterine health, systemic inflammation, and long term glycaemia of patients to combat 
this ever increasing chronic disease burden in the Indigenous Australian population. The 
studies conducted in this thesis give an optimistic outlook on the future health of Indigenous 
Australians. By identifying opportunities for improvements in Indigenous health outcomes, in 
time, with further direction of resources and continued efforts by dedicated and passionate 
personnel, the health disparity between Indigenous and non-Indigenous Australians will 
narrow.  
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Appendix 2. Measurements 
Anthropometric 
Blood pressure  
Blood pressure measurement was performed in a seated position after participants had rested 
for at least 5 minutes. Blood pressure was measured on the right arm in the seated position 
using an automated BP device (Dinamap; Critikon,Tampa, FL) using appropriate cuffs for 
size.  
 
Body mass index  
Body mass index (BMI) was calculated:  
BMI = weight (kg)/height (m)2  
 
Height  
Height was measured using a portable stadiometer. The stadiometer was placed flat against a 
wall that met the floor at right angles. Participants stood barefoot on a firm, flat surface 
facing forward with feet planted flat and evenly on the floor as close to possible to each other. 
Participants stood erect with heels, buttocks and shoulders resting as lightly as possible 
against the wall. The headboard was lowered until it rested lightly but firmly on the head and 
the closest 0.1cm reading was taken.  
 
Waist circumference  
Waist was measured halfway between the lower border of the ribs and the iliac crest in a 
horizontal plane. Participants were relaxed with measurements taken between exhalation and 
inhalation.  
 
Weight  
Weight was measured to the nearest 0.1 kilogram using digital scales (Tanita model TBF-
521). Participants were dressed in light clothing with footwear removed.  
 
Biochemistry  
Urine and blood samples collected from participants were sent to the Royal Darwin Hospital 
for analysis at first screen and Westerns Pathology in Darwin at second screen. All assays at 
second screen were performed using the Roche Integra I800.  
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C-Reactive protein 
High Sensitivity C-Reactive protein (CRP) was analysed using immunoturbidimetrric CRP 
assay 
 
Lipids  
At first screen, total cholesterol and triglyceride concentrations were measured using Kodak 
(now Ortho Diagnostics Vitros) enzymatic dry-slide tests. HDL was measured using the same 
cholesterol slides, after precipitation of non- HDL with a Magnesium/Phosphotungstate 
solution. At second screen, total cholesterol concentration was measured using cholesterol 
oxidase/peroxidase reagents. Triglyceride (Trig) was measured using lipsae/glycerol kinase/ 
GPO-PAP assays. HDL was measured using cyclodextrin sulphate/PEG modified enzymes. 
LDL was only calculated at second screen using the equation: LDL = Total Cholesterol – 
HDL – (Trig/2.2).  
 
Urinary albumin  
Random urine samples were measured by immunonephelometry using the Beckmann Array 
(Beckman Instruments, Brea, CA) at first screen and immunoturbidimetric at second screen. 
Samples were analysed within 48 hours of collection, with interim storage at 40C.  
  
Urinary creatinine  
At first screen, urine creatinine concentration was measured by enzymatic assay using the 
Ektachem 400 (Eastman Kodak Co., Rochester NY 14600). At second screen, urinary 
creatinine was measured using the kinetic method with an alkaline picrate reagent.  
 
Urinary ACR 
Urinary Albumin-creatinine ratio (ACR) testing is a relatively convenient way to test for 
urinary albumin, correlates well with the gold standard 24 hour urinary excretion of albumin 
[391] and may be better than urinary albumin concentrations alone in screening for 
albuminuria [392].  
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Birth weights  
Birth weight is defined as the first weight of the fetus or newborn obtained after birth, usually 
within the first hour of birth. Birth weight is easy to measure, does not require sophisticated 
equipment or expertise, is reliable and reproducible. 
